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Abstract: Liver metastases cause the majority of deaths from colorectal cancer, and 
response to chemotherapy and external radiotherapy is poor. An alternative is internal 
radionuclide therapy using 90Y labeled microspheres. These microspheres are very 
stable and have a proven efficacy in the field of treatment of primary or metastatic 
hepatic cancer. Whilst these spheres showed encouraging results in patients, their high 
density is a serious drawback. Currently, other materials with lower densities and 
other radioisotopes are being investigated in order to optimize this promising new 
therapy. Three major radiolabeled microsphere materials, viz. glass, resin-based and 
polymer-based, are now available for therapy or are being tested in animals. In this 
review the preparation, stability and degradation of these spheres are highlighted. 
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1.1 Introduction 
In western countries malignant tumours originating from colorectal carcinoma are 
frequently seen in the liver. Surgical resection is presently the treatment of choice in 
patients with liver metastases. After this procedure the 5-year survival is around 35% 
[1]. However, most tumours are inoperable by the time of diagnosis. Other treatment 
options for these tumours include conventional chemotherapy and external 
radiotherapy [2,3]. Unfortunately, neither of the latter regimens have shown an 
obvious improvement in patient survival. The regional administration of therapeutic 
agents [4] via the hepatic artery is one strategy that has been developed to improve 
tumour response, since both primary and metastatic liver tumours are well 
vascularized and receive the bulk of their blood supply from the hepatic artery [5]. 
These therapies must satisfy two requirements in order to be successful: (a) the 
relevant agent must be effective in the in-vivo orthotopic microenvironment of 
tumours, and (b) this agent must reach the target cells in-vivo in optimal quantities 
[6]. All conventional and novel therapeutic agents for regional administration may be 
divided into three categories: molecules, particles and cells. In this review we focus on 
the injection of particles into the hepatic artery in order to obtain selective delivery of 
radioisotopes to the tumour, thus maximizing the irradiation effect while sparing 
toxicity to the surrounding healthy liver [2]. Among the more promising of these 
radiotherapeuticals are beta-emitting microspheres. These microspheres can be based 
on polymers, polymeric resins, albumin or inorganic materials e.g. glass. 
Radioisotopes used for labeling are yttrium-90 (90Y), rhenium-186/rhenium-188 
(186Re/188Re) and holmium-166 (166Ho).  
This chapter reviews the current literature on radioactive microspheres used for the 
treatment of liver malignancies and concludes with the aims and outline of the thesis. 
 
1.2 Microspheres: materials and preparation 
The ideal properties for radiolabeled microspheres or particles for intra-arterial 
therapy are summarised in Table 1. Müller and Rossier [8] first described the use of 
particles radiolabeled with gold-198 (198Au), which were used in the treatment of lung 
cancer. Early studies used angular fragments that were made by crushing the bulk 
material and sieving the particles to grade in the desired diameter [9]. The first plastic 
microspheres were labeled with 90Y and showed an unpredictable and catastrophic 
leaching of yttrium, which brought them into question [10]. This problem was solved 
later by the use of glass beads. As well as these glass beads, resin-based and other 
polymeric microspheres are currently being used. An overview is given in Table 2. 
 
 
 
Chapter 1  
 
10 
Table 1. Ideal properties of radiolabeled microspheres for intra-arterial therapy  [7] 
 
1. High mechanical stability to resist breakdown and passage through the capillary 
 network 
2. High chemical stability to resist elution of radioactive label, macrophage 
 removal, or radiolysis 
3. Uniform size 
4. Unit density to prevent settling or streaming 
5. Relative ease of label 
6. Radionuclide label with high-energy beta particle, low photofraction, 
  and intermediate  (days) half-life 
 
 
 
Table 2. Radiolabeled microspheres currently in use 
 
Radionuclide Microsphere Labeling Ref. 
 
166Ho 
 
PLLA 
 
N 
 
[13,29] 
 Resin (Aminex A-5) Lr [14] 
 
90Y 
 
Glass (TheraSpheres®) 
 
N 
 
[10] 
 Resin (Bio-Rex-70) 
Resin 
PLLA 
Albumin 
Lr 
Lr 
Lr/Lp 
Lr 
[19] 
[22] 
[33] 
[27] 
 
186Re/188Re 
 
Glass 
Resin (Aminex A-27) 
PLLA 
Albumin 
 
N 
Lr 
Lr/Lp 
Lr 
 
[16] 
[21] 
[2] 
[25] 
 
32P 
 
 
Glass 
 
N 
 
[18] 
N= activated by neutron bombardment; Lr= labeled with radioactive compound, 
retrospectively; Lp= labeled with radioactive compound, preceding production of 
microspheres.  
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1.2.1.1 Glass 
Glass is relatively resistant to radiation-damage, highly insoluble, and non-toxic. 
Glass can be easily spheridized in uniform sizes and has minimal radionuclidic 
impurities. The manufacturing process is described comprehensively by Ehrhardt and 
Day [10]. The yield of microspheres with the desired diameter, 20-30 µm (see below), 
is around 15%. Advances in this technology have led to the production of glass 
microspheres with practically no leaching [11]. Although the glass spheres have 
several advantages, their high density (3.29 g/ml [12]) and their non-biodegradability 
are major drawbacks [13,14]. The relatively high density increases the chance of 
intravascular settling [15]. These glass microspheres produced under the name 
TheraSpheres are the first registered microsphere product for internal radionuclide 
therapy, and are used in patients with primary or metastatic tumours. Because of the 
lack of γ-emission of 90Y, radioactive rhenium (186Re/188Re) microspheres were also 
produced. The general method of manufacture of these spheres was the same as for 
the 90Y spheres [2,16]. 
Brown et al. [17] prepared 166Ho-loaded glass particles (2-5 µm) for direct injection 
into tumours of mice, which resulted in an effective modality for deposition of intense 
γ-radiation for use in localised internal radionuclide therapy. However, no further 
studies were done. 
Kawashita et al. [18] suggested the use of phosphorus-rich Y2O3-Al2O3-SiO2-glass 
microspheres containing phosphorus ions, which were produced by thermoelectron 
bombardment of red phosphorus vapour and implanted into glass, thus resulting in a 
high phosphorus content and high chemical durability. After activation by neutron 
bombardment the glass contains phosphorus-32 (32P). 
 
1.2.1.2 Resins 
Resin-based microspheres are much favoured for radio-embolization. Chloride salts of 
holmium and yttrium were added to cation exchange resins. Different resins were 
investigated by Schubiger et al. [19], amongst which were Bio-Rex 70, Cellex-P, 
Chelex 100, Sephadex SP and AG 50W-X8. The resins with 90Y bound to the 
carboxylic acid exchange groups of the acrylic polymer were sterilised and used for 
renal embolization of pigs. Only the pre-treated Bio-Rex 70 resulted in applicable 
particles, with a retention of beta activity in the target organ of >95% of injected dose, 
and no histologically detectable particles in lung tissue samples [20]. 
As well as Bio-Rex 70, Aminex resins (Bio-Rad Inc. Hercules CA, USA) loaded 
with 166Ho or 188Re, also resulted in applicable preparations. Turner et al. [14] 
prepared microspheres by addition of 166Ho-chloride to the cation exchange resin 
Aminex A-5, which has sulphonic acid functional groups attached to styrene 
divinylbenzene copolymer lattices. Reproducible, non-uniform distributions of the 
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166Ho-microspheres throughout the liver were observed on scintigraphic images, 
following intrahepatic arterial administration in pigs. This predictable distribution 
allowed these investigators to determine the radiation absorbed dose from a tracer 
activity of 166Ho-microspheres, and to define the administered activity required to 
provide a therapeutic dose. 
Aminex A-27 was labelled with 188Re by adding 188Re-perrhenate and SnCl2 to 
vacuum-dried resin particles [21]. The mixture was boiled and centrifuged and 
microspheres were separated and resuspended in saline. Spheres were tested by direct 
intratumoural injection into rats with hepatoma. Survival over 60 days was 
significantly better in the treated vs. the control group (80% vs. 27%). 
Investigators from Australia and Hong Kong have used unspecified resin-based 
particles labeled with 90Y for treatment of patients with primary or secondary liver 
cancer [22,23]. The spheres had a diameter of 29-35 µm, a density of 1.6 g/ml and a 
specific activity of approximately 30-50 Bq per sphere. Treatment was well tolerated 
with no bone-marrow or pulmonary toxicity. The median survival was 9.4 months 
(range 1.8-46.4) in 71 patients, and the objective response rate in terms of drop in 
tumour marker levels was higher than that based on reduction in tumour volume 
shown by computed tomography [15,24]. 
 
1.2.1.3 Albumin 
Technetium-99m-microspheres (99mTc-microspheres) of human serum albumin (HSA) 
have been widely used for clinical nuclear medicine, particularly for lung scanning, 
since 1969 (25,26). 188Re labeled HSA microspheres used by Wunderlich et al. [25] 
are uniform in size, with a mean diameter of 25 µm, and are biocompatible and 
biodegradable. However, the labeling process is time-consuming and depends on 
SnCl2.2H2O and gentisic acid concentration. On the surface of the microspheres a 
shell of about 1 µm thickness was seen, probably consisting of precipitated tin 
hydroxide. The particle labeling (coating) may be achieved by a combination of the 
reduction reaction of Re(VII) with Sn(II) and a particle surface-related coprecipitation 
effect of tin hydroxide colloid with high adsorption capacity and reduced, hydrolysed 
rhenium. The labeling yield under optimal reaction conditions is more than 70%. 
Biodistribution experiments in rats, using the lungs as a model for a well-perfused 
tumour, resulted in excellent in vivo stability. 
As well as rhenium, yttrium was bound to HSA for internal radiotherapy [27]. 90Y-
acetate and macroaggregates of HSA (MAA) (Macrokit®, Dainabot, Tokyo, Japan) 
were suspended in sodium acetate buffer and incubated at room temperature. 
Experiments in mice were carried out in order to investigate the possibility of using 
90Y-MAA as an internal radiotherapeutic agent for whole-lung irradiation. Yttrium-
activity in the lung was cleared within 72h post injection and activity was 
General introduction: Advances in nuclear oncology 
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redistributed in other organs, especially in the bone, but this could be prevented by the 
combined use of CaNa3DTPA. Based on its rapid clearance 90Y-MAA was suggested 
as being useful for fractionated internal radiotherapy of the lung. 
 
1.2.1.4 Polymers  
Polymer-based microspheres have many advantages over other materials, in particular 
their near-plasma density, biodegradability and biocompatibility. However, their 
major disadvantage is their inability to withstand high thermal neutron fluxes [16]. 
Additives [13,28] and adjustment of irradiation-parameters [29] can overcome this 
problem. 
Polymer-based microspheres used for internal radionuclide therapy are mainly 
prepared by a solvent evaporation technique. In the solvent evaporation process, the 
polymer is dissolved in a suitable water immiscible volatile solvent, and the 
medicament is dispersed or dissolved in this polymeric solution. The resulting 
solution or dispersion is then emulsified by stirring in an aqueous continuous phase, 
thereby forming discrete droplets. In order that the microspheres should form, the 
organic solvent must first diffuse into the aqueous phase and then evaporate at the 
water/air interface. As solvent evaporation occurs the microspheres harden, and free 
flowing microspheres can be obtained after suitable filtration and drying [30]. The 
solvent evaporation method has been used for preparation of poly(L-lactic acid) 
(PLLA) microspheres containing 166Ho, 90Y and 186Re/188Re. 
Mumper et al. [13,28,31] and also our group [29] prepared PLLA microspheres 
with holmium-165-acetylacetonate (HoAcAc) [32]. HoAcAc complex and PLLA 
were dissolved in chloroform and the solution was added to a polyvinyl alcohol 
(PVA) solution and stirred until the solvent had evaporated. Microspheres were 
graded and collected according to size, on stainless steel sieves of 20-50 µm. These 
microspheres can be dispensed in patient-ready doses, that only need to be activated 
by neutron bombardment to a therapeutic amount of radioactivity in a nuclear reactor 
[29]. These holmium loaded microspheres are currently being tested by intrahepatic 
arterial administration to rat liver tumours (Fig. 1a). A seven-fold increase of the 
166Ho-microspheres in and around the tumour compared with normal liver is found 
(Fig. 1b), based on distribution of radioactivity. 
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Fig. 1. Scanning electron micrograph of holmium loaded PLLA microspheres (a). 
Radioactive holmium loaded microspheres in an artery of tumour-tissue in rat liver (white 
arrow). Artificial black line shows the border between tumour tissue (left) and liver tissue 
(right) (b). 
 
 
Magnetic PLLA microspheres loaded with yttrium were made by Häfeli et al. 
[33,34], in order to direct them to the tumour. Their method resulted in stably loaded 
spheres, with the possibility of pre- or afterloading. To produce preloaded 
microspheres PLLA was dissolved with L-α-phosphatidylcholine in methylene 
chloride. Commercially available 90YCl3 and magnetite Fe3O4 were added to the 
solution, vortexed, and sonicated. The suspension was injected into PBS with PVA, 
and microspheres were prepared following a solvent evaporation technique. 
Afterloaded spheres were prepared by suspending dried microspheres in a solution of 
PBS, after which 90YCl3 in HCl was added. Spheres were subsequently vortexed, 
incubated, and washed, resulting in labeled microspheres. Leaching of 90Y was around 
4% after 1 day in PBS at 37°C. Specific activity was 1.85 MBq/mg in both methods. 
90Y was bound to the carboxylic endgroups of the PLLA. Experiments in mice 
showed a 12-fold increase in activity in the tumour with a directional magnet fixed 
above it [34]. Rhenium loaded PLLA microspheres were also developed, but these 
microspheres were unable to withstand the high neutron fluxes in a nuclear reactor 
which are necessary to achieve the high specific activity required in the treatment of 
liver tumours [2]. 
 
1.2.2.1 Size of microspheres for treatment of hepatic malignancies 
The size of the microsphere is an important factor for the distribution in the liver and 
tumour. The production parameters of microspheres can be modified to result in high 
yields of spheres with the desired diameter. For example, lowering the stirring rate 
during production and a higher viscosity of the aqueous phase, result in increasing 
diameters of the polymeric microspheres. Although the size of the microspheres can 
a) b) ) 
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be regulated by production methods, a sifting step is necessary after production of 
cold or radioactive spheres. 
A range of sizes has been reported in the literature with microsphere diameters 
varying from 13 to 75 µm [14,22,23,35,36]. The widely used 90Y glass microspheres 
have a mean diameter of 22 µm with a range of 15 to 30 µm [10,12,37]. 
Larger microspheres, 40-50 µm, are distributed more homogeneously in the liver 
and with fewer spills to other organs such as lungs and spleen than smaller particles. 
However, with larger particles the tumour/liver ratio decreases. Microspheres of 
around 30 µm are the optimum size for hepatic radionuclide therapy, as they are most 
evenly distributed within the normal liver tissue, yet still provide a concentrated dose 
of radiation to tumour tissue [8,38,39]. Distribution of intra-arterial microspheres with 
a diameter of 32 µm was extensively investigated in the microvasculature of tumour 
in human liver by Campbell et al. [40]. Microspheres were found to deposit 
preferentially in the richly vascularized periphery of the tumour. 
 
1.2.2.2 Choice of radionuclide 
The ultimate radionuclide suitable for internal radionuclide therapy of primary and 
metastatic malignancies requires the following properties: 1) The radioisotope must 
have an appropriate radiation spectrum for treating small to large multiple tumours. 
Large tumours with a vascular periphery but a necrotic centre take up less 
microspheres per volume, therefore a high energy β-emitter with a subsequently high 
tissue range is needed to reach the interior of the tumour. 2) A high dose rate is 
advantageous for the radiobiological effect [41,42]. Consequently, a short half-life is 
preferable. 3) For external imaging of the biodistribution of the radioisotope with a 
gamma camera, a γ-emitter is necessary. However, the energy should be low to 
prevent unnecessary radiation burden to the patient and environment [13]. 4) The 
labeling of particles has to be simple without any leakage of the isotope. 5) A large 
thermal neutron cross section is needed to enable high specific activities to be 
achieved within short neutron activation times [16]. 
Only a few radioisotopes have characteristics, which make them potentially 
suitable for the treatment of tumours (see Table 3). Taking into account the 
aforementioned properties three radioisotopes are the most likely candidates, yttrium-
90, rhenium-188 and holmium-166. Yttrium-90 has two major disadvantages as a 
radioisotope for therapy. First, long neutron activation times (>2 weeks) are needed to 
achieve therapeutic activities of yttrium because 90Y’s precursor has a small thermal 
neutron cross section of 1.28 barn. Secondly, the biodistribution of microspheres 
loaded with 90Y cannot be directly determined in clinical trials, since 90Y is a pure β-
emitter and does not produce imageable γ-rays. 
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 Table 3. Characteristics of radionuclides suitable for therapeutical application [43-46]  
 
Radio-
nuclide 
Production 
Half-life 
(h) βmax (MeV) γ (MeV) 
Max. tissue 
range (mm) 
Cross 
section 
(barn) 
 
32P 
 
31P(n, γ) 
34S(d, α) 
32S(n, p) 
 
 
343.2 
 
1.71 
 
 
 
 
 
 
 
7.9 
 
0.19 
90Y 89Y(n, γ) 
90Sr/90Y 
64.1 2.27  11 1.3 
109Pd 108Pd(n, γ) 13.4 1.03 0.088 4.2 8.8 
140La 139La(n, γ) 
140Ba/140La 
40 1.31 (79%) 
2.18 (6%) 
 
0.487 
0.329 
0.815 
 
10 8.9 
153Sm 152Sm(n, γ) 
150Nd (α, n) 
46.8 0.80 
 
 
0.070 
0.103 
 
3.0 220 
165Dy 164Dy(n, γ) 2.4 1.29 
 
0.095 
 
5.7 800 
166Ho 165Ho(n, γ) 26.8 1.84 (51%) 
1.78 (48%) 
 
0.081 
 
8.6 64 
169Er 168Er(n, γ) 230.4 0.34 
 
0.008 
 
0.9 2 
186Re 185Re(n, γ) 90.6 1.07 
 
0.137 
 
4.5 110 
188Re 187Re(n, γ) 
188W/188Re 
17 2.11 
 
0.155 
 
10 70 
 
198Au 
 
197Au(n, γ) 
198Pt(p, n) 
 
 
64.8 
 
0.96 
 
 
0.412 
 
 
3.9 
 
99 
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Natural rhenium is composed of two isotopes (185Re and 187Re) that form β-emitting 
186Re and 188Re radioisotopes respectively, upon neutron activation. The nuclear and 
dosimetric properties of the rhenium radioisotopes are comparable to those of 90Y, but 
they have imageable γ-photons and 188Re is easily available from a 188W/188Re-
generator system. 
Like the rhenium radioisotopes, 166Ho emits β-particles and photons. It has a 
physical half-life of 26.8h resulting in a high dose rate. Its cross section is comparable 
with rhenium, but 165Ho has a natural abundance of 100% and thus only one 
radioisotope, 166Ho, is formed by neutron bombardment. Taking these characteristics 
into consideration, 166Ho is therefore an attractive candidate for use in future 
treatments. 
 
1.3 Characteristics in-vitro and in-vivo 
1.3.1 Irradiation damage of neutron activated microspheres 
Glass is relatively resistant to irradiation damage, as is shown by the long irradiations 
that are necessary to produce rhenium loaded glass microspheres [16]. The γ-heating, 
neutrons and other radiation conditions in a nuclear reactor result in considerable 
irradiation damage to polymers. Literature concerning γ-irradiations for sterilisation of 
the product can be found to gain an impression of the damage caused by irradiation of 
polymeric microspheres, which must be irradiated in a nuclear reactor to produce 
radioactive pharmaceuticals. We investigated the changes in morphology of the 
surface of holmium loaded microspheres after irradiation [29]. Non-irradiated 165Ho-
PLLA-microspheres show a smooth, spherical appearance, whilst irradiated spheres 
show minor surface changes of small free PLLA fragments. These fragments 
represent, under the irradiation conditions used, a negligible part of total particle 
volume. However, changes in molecular weight of PLLA were substantial [29] and 
this was also confirmed in other studies using γ-sterilisation [47,48]. Two major 
mechanisms of degradation (Fig. 2) take place in a polymer as it is subjected to 
radiation: (1) chain scission occurs as a random rupturing of bonds, resulting in 
reduction of the molecular weight or, (2) cross-linking which results in the formation 
of three-dimensional networks. These mechanisms usually occur simultaneously. The 
cause of the decrease in molecular weight of polymers is mainly radiation chain 
scission owing to radical formation [49]. In γ-irradiation of PLLA chain scission 
occurs predominantly in the amorphous phase of the polymer [31,47]. High crystalline 
polymers are more radiation resistant. The reduction in molecular weight is also 
dependent on the environment. Oxygen, water, additives and device dimensions are 
major factors influencing the degradation [29,49,50]. In most polymers such as PLLA, 
dl-PLA [51], poly(lactic-co-glycolic acid) (PLGA) [52,53,54] or polyglycolic acid 
(PGA) [55] the mechanisms of degradation are comparable. 
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Fig. 2. Hypothetical degradation mechanisms of PLLA upon-irradiation [49]. 
 
 
1.3.2 Degradation, biodegradability, biocompatibility 
Glass and resin particles do not undergo degradation in vivo. Unlike resin or glass 
microspheres, polymers such as PLLA and PLGA do degrade [10,56]. Polymeric 
microspheres <300 µm in diameter undergo a homogeneous hydrolytic degradation, 
the extent of degradation of the core being equivalent to the degradation at the surface 
[57]. Factors affecting the hydrolytic degradation of biodegradable polyesters are 
indicated in Table 4. The porosity of microspheres may play a major role in enhancing 
the rate of biodegradation. Micropores in the spheres permit the release of low 
molecular weight degradation products, whose carboxylic end groups may facilitate 
the autocatalytic degradation of the polymer. During the degradation process, the 
crystallinity of the polymer gradually increases, resulting in a relatively stable product 
[57]. 
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Table 4. Factors affecting the hydrolytic degradation behaviour of biodegradable 
polyesters [57] 
 
- Water permeability and solubility (hydrophilicity/hydrophobicity) 
- Chemical composition 
- Mechanism of hydrolysis (noncatalytic, autocatalytic, enzymatic) 
- Additives (acidic, basic, monomers, solvents, drug) 
- Morphology (crystalline, amorphous) 
- Device dimensions (size, shape, surface to volume ratio) 
- Porosity 
- Glass transition temperature (glassy, rubbery) 
- Molecular weight and molecular weight distribution 
- Physico-chemical factors (ion exchange, ionic strength, pH) 
- Sterilization 
- Site of implantation 
 
 
Anderson and Shive reported in detail the biocompatibility and tissue/material 
interactions of biodegradable microspheres [57]. Injection of microspheres, either 
subcutaneously or intramuscularly, results in the implantation of a high surface 
area/low volume of material into a given tissue volume. Depending upon the packing 
and volume of microspheres within an implant site, days to weeks may be required for 
cellular infiltration from the surface of the microsphere volume, to its centre. The 
infiltration of inflammatory cells and in particular, monocytes, macrophages and 
fibroblasts, results in each microsphere having its attendant tissue/material interaction. 
The volume of microspheres also elicits a response, which is generally seen early as a 
granulation tissue response leading to a fibrous site. Given biocompatible 
biodegradable microspheres, the response during the first two weeks is generally 
similar, regardless of the degradation rate of the biodegradable polymer. A minimal 
inflammatory reaction is observed. The second phase of the tissue response is initiated 
by the predominance of monocytes and macrophages. This response occurs after 50-
60 days with poly(DL-lactide-co-glycolide) particles, and after more than 350 days 
with PLLA [58]. The last phase is the breakdown of spheres in particles smaller than 5 
µm, small enough to initiate a tissue response which is predominated by macrophages. 
 
1.3.3 Release 
Improvements in radiolabelling techniques have resulted in increasingly stable 90Y 
microspheres. A new generation of glass (TheraSpheres®, Theragenics, Atlanta, GA, 
USA) and resin microspheres (supplied by the Australian Nuclear Science and 
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Technology Organisation) have overcome the problem of leaching. Routine tests on 
resin and glass microspheres showed that less than 0.1% of the activity leaches from 
the microspheres. Clinical studies on metastatic liver cancer, using these newer glass 
[59] and resin microspheres, have produced good results with very little toxicity [23]. 
Polymeric microspheres loaded with 166Ho showed a high stability. Mumper et al. 
and also our group showed that more than 98% of 166Ho activity was retained in the 
microspheres after 192h incubation at 37°C, in several physiological media [13,29]. 
On the one hand, this is a favourable characteristic of these microspheres for the 
attempted application, but on the other hand this is surprising, since generally low 
molecular weight compounds are released to a high extent and relatively rapidly from 
PLLA microspheres [57,60-62]. We found that HoAcAc can be dispersed in the 
amorphous PLLA phase up to 17% (w/w) indicating the presence of favourable 
PLLA/HoAcAc interactions in the microspheres. Carbonyl groups of PLLA are likely 
to interact with the holmium ion in the HoAcAc complex, by which this complex is 
immobilized in the PLLA matrix. This interaction thus accounts for the high stability 
(= low holmium release) found in HoAcAc loaded microspheres. 
 
1.3.4 Radiotoxicity 
Radiotoxic effects are reported from the old generation of glass and resin 
microspheres, by leaching of the radioisotope from the particles, which can result in 
pancytopenia [63]. The new generation of spheres showed no such leaching. These 
spheres were used for the first time in the well-known dog experiments by Wollner et 
al. [64], showing that the animals survived a liver dose of up to 350 Gy. However, at 
such exceedingly high (and clinically unrealistic) doses, sequelae related to cirrhosis 
would be likely to become a significant problem. Even 800 Gy to the whole liver of 
rabbits was tolerated [65]. These experiments showed that internal radiotherapy using 
non-leaking microspheres can be performed safely with high doses. In patients in 
which doses up to 100 Gy were directed to the liver, the hepatic toxicity of the 
treatment appears to be low, as is shown by the liver enzyme levels [2]. 
Gastroduodenal ulceration has been reported as a complication of intra-hepatic arterial 
glass microsphere therapy, and this may be related to migration of microspheres to 
organs outside the liver, caused by the high density of the spheres [15,29,66,67]. 
Radiation pneumonitis was documented in a patient in which the lung dose was 
greater than 30 Gy, whereas most patients received a lung dose of less than 20 Gy 
[11,68]. 
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1.4 Application in oncology 
Since recent developments, especially the increased skills of interventional 
radiologists, there is an awakened interest in unique selective radionuclide therapy. 
Many kinds of radiolabeled particles and radionuclides have been tested for local 
treatment of a variety of tumours in organs, including liver, lung, tongue, spleen and 
soft tissue of extremities. The purpose of this treatment is the superselective 
application of suitable radioactive (high energetic β-emitters) particles to deliver high 
doses to the tumour, with as little surrounding tissue damage as possible. These new 
embolization methods are extremely important particularly for cancers with an 
extremely poor prognosis and without other adequate therapies, such as primary and 
metastatic malignancies of the liver. 
 
1.4.1 Liver cancer 
Patients with primary or metastatic tumours were treated by radio-embolization via a 
catheter [59,69] or direct injection of beads into the tumour, with a needle [21,70]. 
Most studies describe administration of microspheres to patients via a catheter, 
whereby the tip was placed in the hepatic artery. The spheres eventually lodge in the 
microvasculature of the liver and tumour, remaining until the complete decay of the 
radioisotope. Lung shunting and tumour-to-normal liver ratio was determined after 
infusion of 99mTc-labeled macroaggregated albumin, and microspheres were 
subsequently administered to patients [71,72]. Tumour-to-normal liver ratio was 
approximately 3-5 [12,22,56,73]. In some studies the blood flow within the liver was 
temporarily redirected in favour of the tumour by a bolus infusion of a 
vasoconstrictor, and the spheres were then embolized into the arterial circulation [69]. 
While external beam radiation causes radiation hepatitis at doses above 30-35 Gy [74] 
the liver can tolerate up to 80-150 Gy, using internal radionuclide therapy [12,69,72]. 
Increased longevity, pain relief, tumour response and total clinical improvement are 
frequently reported [12,24,37,70]. 
 
1.4.2 Head-and-neck cancer  
Chemo-embolization with ethylcellulose microspheres of 100-450 µm has been used 
in the treatment of maxillary tumours. The role of intra-arterial radioisotope therapy in 
the treatment of head-and-neck cancer is just beginning in rabbits, in the work of van 
Es et al. [75]. The optimal size of microspheres for treatment of unresectable head-
and-neck cancer is still to be established. Van Es et al. suggest that large microspheres 
of 40-65 µm should be used for the embolization of these tumours. Other 
embolizations in the treatment of head-and-neck cancer have been carried out with 
particles of 100-450 µm [76]. 
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1.4.3 Ovarian cancer 
The overall 5-year survival in patients with epithelial ovarian cancer is as low as 35-
38%. Initially, intraperitoneal 198Au-colloid was used as an adjunct in the treatment of 
ovarian cancer, but this resulted in a significant number of major complications and 
associated deaths [77]. Subsequently 32P became the radioisotope of choice because of 
a higher β energy compared with 198Au. Vergote et al. [45] used 211At-microspheres 
for the treatment of mice with ovarian cancer. This was prepared by copolymerization 
of glycidyl methacrylate and ethylene glycol dimethacrylate with a diameter of 1.8 
µm. The α-emitters such as 211At, 212Bi and 212Pb may be a useful addition to future 
treatment of small clusters of cancer cells. 
 
1.4.4 Other cancers 
Intra-arterial administration of 90Y-microspheres has been carried out in the spleen 
[78]. Of nine patients with lymphosarcoma, five manifested no clinical response after 
splenic irradiation. One patient who complained of weakness, rapid fatigue and 
anorexia, had relief of all symptoms after splenic irradiation. 
 
1.5 Perspectives 
Improvements in radiolabelling techniques have resulted in increasingly stable 
microspheres with a leakage of less than 0.1% of the activity. Three major 
radiolabeled microsphere materials, glass, resin-based and polymer-based are now 
available for therapy or are being tested in animals. The only commercially available 
glass-type 90Y microspheres are very stable and have a proven reputation in the 
treatment of primary or metastatic hepatic cancer, but their high density is a serious 
drawback. Consequently, less dense particles have been developed in the form of resin 
and polymeric spheres. Resin-based spheres also  have a high chemical stability and, 
with half the density of glass, they provide good prospects for the treatment of liver 
cancer. Resin particles are currently being investigated in patients, and these particles 
show results comparable to glass. Polymeric microspheres like poly(L-lactic acid) 
spheres have a near plasma density and additional advantages such as biocompatibility 
and biodegradability. A polymeric sphere appears to be the best particle for this kind 
of therapy, although with the drawback of low resistance to irradiation in a nuclear 
reactor. Recent studies have demonstrated that polymeric microspheres can be 
prepared with sufficient amounts of activity for therapeutic application. These 
microspheres are therefore one of the future materials for use in the battle with liver 
cancer. Other oncological applications such as the treatment of head-and-neck cancer, 
bone metastases and ovarian cancer are in the pipeline. Internal radionuclide therapy 
is likely to play a substantial role in the control of hepatic and other types of cancer in 
the future. 
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1.6 Aims and scope of the thesis 
In this thesis the feasibility of poly(L-lactic acid) microspheres loaded with 166Ho for 
internal radiation therapy of liver malignancies is investigated. Aspects of preparation, 
characterization, biodistribution and therapeutical effect in animals were addressed in 
order to answer the following questions: 
1 Is it possible to prepare holmium containing microspheres in a reproducible way 
to enable routine production and facilitate therapeutic application? 
2 What are the physical characteristics of these microspheres before and after 
neutron activation? 
3 Can selective targeting of liver tumours be accomplished in vivo? 
4 Is there a therapeutic effect of these microspheres on liver tumours? 
 
1.7 Outline of the subsequent chapters 
In Chapter 2 the preparation and neutron activation of holmium containing poly(L-
lactic acid) microspheres is presented. The microspheres were prepared using a 
solvent evaporation technique and the effect of the formulation and processing 
parameters on the holmium loading were evaluated. Further, the effects of neutron 
irradiation conditions were examined and defined in detail. In Chapter 3 the crystal 
structures of two holmium acetylacetonate complexes were elucidated using X-ray 
diffraction. Chapter 4 describes an in depth characterization of PLLA microspheres 
loaded with HoAcAc. PLLA microspheres, and as a control PLLA films, with and 
without HoAcAc were investigated using a variety of advanced techniques. Chapter 
5 deals with the influence of neutron irradiation on the HoAcAc loaded PLLA 
microspheres. Possible radiation damage of both the PLLA matrix and the Ho-
complex was investigated. In Chapter 6 the biodistribution of PLLA microspheres 
loaded with 166Ho is studied in rats with liver tumours. The distribution of the activity, 
especially the tumour-to-normal liver-tissue ratio, after administration of 166Ho-PLLA 
microspheres with sizes between 20 and 50 µm was determined. Also, an extensive 
histological evaluation was performed. Chapter 7 reports on the therapeutic effect of 
166Ho-PLLA microspheres in a rabbit model. Liver function was examined by 
histology and analysis of liver enzyme activity. Chapter 8 summarises this thesis and 
gives suggestions for further research to enable clinical application of Ho-loaded 
PLLA microspheres for the internal radionuclide therapy of tumours. 
Chapter 1  
 
24 
References 
1. Scheele J and Altendorf-Hofmann A. Resection of colorectal liver metastases. 
Langenbeck’s Arch. Surg. 1999;313-327. 
2. Häfeli UO, Casillas S, Dietz DW, Pauer GJ, Rybicki LA, Conzone SD and Day DE. 
Hepatic tumor radioembolization in a rat model using radioactive rhenium 
(186Re/188Re) glass microspheres. Int. J. Radiation Oncology Biol. Phys. 
1999;44:189-199. 
3. Link KH, Kornman M., Formentini A, Leder G, Sunelaitis E, Schatz M, Preßmar J and 
Beger HG. Regional chemotherapy of non-resectable liver metastases from colorectal 
cancer – literature and institutional review. Langenbeck’s Arch. Surg. 1999;384:344-
353. 
4. Bastian P, Bartkowski R, Köhler H and Kissel T. Chemo-embolization of experimental 
liver metastases. Part I: distribution of biodegradable microspheres of different sizes in 
an animal model for the locoregional therapy. Eur. J. Pharm. Biopharm. 1998;46:243-
254. 
5. Ackerman NB, Lien WM, Kondi ES and Silverman NA. The blood supply of 
experimental liver metastases.  The distribution of hepatic artery and portal vein blood 
to “small” and “large” tumors. Surgery 1969;66:1067-1072. 
6. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J. Cont. Release 
1998;53:49-67. 
7. Harbert JC. In Nuclear Medicine: Diagnosis and Therapy; Harbert JC, Eckelman WC 
and Neumann RD. Thieme Medical Publishers, Inc., New York, 1996;1141-1155. 
8. Müller JH and Rossier PH. A new method for treatment of cancer of the lungs by 
means of artificial radioactivity (Zn63 and Au198). Acta Radiol. 1951;35:449. 
9. Grady ED, Sale W, Nicolson WP and Rollins CR. Intra-arterial radioisotopes to treat 
cancer. Am. Surg. 1960;26:678-684. 
10. Ehrhardt GJ and Day DE. Therapeutic use of 90Y Microspheres. Nucl. Med. Biol. 
1987;14:233-242. 
11. Ho S, Lau WY, Leung TWT, Chan M, Ngar YK, Johnson PJ and Li AKC. Clinical 
evaluation of the partition model for estimating radiation doses from yttrium-90 
microspheres in the treatment of hepatic cancer. Eur. J. Nucl. Med. 1997;24:293-298. 
12. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD and Shapiro B. 
Hepatic radioembolization with yttrium-90 containing glass microspheres. Preliminary 
results and clinical follow-up. Eur. J. Nucl. Med. 1994;35:1637-1644. 
13. Mumper RJ, Ryo UY and  Jay M. Neutron activated holmium-166-Poly(L-lactic acid) 
microspheres: A potential agent for the internal radiation therapy of hepatic tumours. J. 
Nucl. Med. 1991;32:2139-2143. 
 
General introduction: Advances in nuclear oncology 
25 
14. Turner JH, Claringbold PG, Klemp PFB, Cameron PJ, Martindale AA, Glancy RJ, 
Norman PE, Hetherington EL, Najdovski L and Lambrecht RM. 166Ho-microsphere 
liver radiotherapy: a preclinical SPECT dosimetry study in the pig. Nucl. Med. Comm. 
1994;15:545-553. 
15. Ho S, Lau WY, Leung TWT and Johnson PJ. Internal radiation therapy for patients 
with primary or metastatic hepatic cancer. Cancer 1998;83:1894-1907. 
16. Conzone SD, Häfeli UO, Day DE and Ehrhardt GJ. Preparation and properties of 
radioactive rhenium glass microspheres intended for in vivo radioembolization therapy. 
J. Biomed. Mater. Res. 1998;42:617-625. 
17. Brown RF, Lindesmith LC and Day DE. 166Holmium-containing glass for internal 
radiotherapy of tumors. Int. J. Rad. Appl. Instrum. B 1991;18:783-790. 
18. Kawashita M, Miyaji F, Kokubo T, Takaoka GH, Yamada I, Suzuki Y and Inoue M. 
Surface structure and chemical durability of P+-implanted Y2O3-Al2O3-SiO2 glass for 
radiotherapy of cancer. J. Non-Cryst. Solids 1999;255:140-148. 
19. Schubiger PA, Beer H-F, Geiger L, Rösler H, Zimmerman A, Triller J, Mettler D and 
Schilt, W. 90Y-resin particles-animal experiments on pigs with regard to the 
introduction of superselective embolization therapy. Nucl. Med. Biol. 1991;18:305-311. 
20. Zimmerman A, Schubiger PA, Mettler D, Geiger L, Triller J and Rösler H. Renal 
pathology after arterial yttrium-90 microsphere administration in pigs. A model for 
superselective radioembolization therapy. Invest. Rad. 1995;30:716-723. 
21. Wang S-J, Lin W-Y, Chen M.-N, Chi C-S, Chen J-T, Ho W-L, Hsieh B-T, Shen L-H, 
Tsai Z-T, Ting G, Mirzadeh S and Knapp FF. Intratumoral injection of rhenium-188 
microspheres into an animal model of hepatoma. J. Nucl. Med. 1998;39:1752-1757. 
22. Burton MA, Gray BN, Klemp PF, Kelleher DK and Hardy N. Selective internal 
radiation therapy: distribution of radiation in the liver. Eur. J. Cancer Clin. Oncol. 
1989;25:1487-91. 
23. Lau WY, Leung WT, Ho S, Leung NWY, Chan M, Lin J, Metreweli C, Johnson P and 
Li AKC. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial 
yttrium-90 microspheres: a phase I and II study. Br. J. Cancer 1994;70:994-999. 
24. Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ and Li AKC. Selective 
internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial 
infusion of 90yttrium microspheres. Int. J. Radiation Oncology Biol. Phys. 1998;40:583-
592. 
25. Wunderlich G, Pinkert J, Andreeff M, Stintz M, Knapp FF, Kropp J and Franke WG. 
Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a 
promising new agent for radiotherapy. Appl. Radiat. Isotopes 2000;52:63-68. 
26. Rhodes BA, Zölle I, Buchanan JW and Wagner HN. Radioactive albumin microspheres 
for studies of the pulmonary circulation. Radiology 1969;92:1453-1460. 
 
Chapter 1  
 
26 
27. Watanabe N, Oriuchi N, Endo K, Inoue T, Tanada S, Murata H and Sasaki Y. Yttrium-
90-labeled human macroaggregated albumin for internal radiotherapy: combined use 
with DTPA. Nucl. Med. Biol. 1999;26:847-851. 
28. Jay M, Khare SS, Mumper RS and Ryo UY. Microencapsulation of activable 
radiotherapeutic agents. Biological and Synthetic Membranes 1989;292:293-300. 
29. Nijsen JFW, Zonnenberg BA, Woittiez JRW, Rook DW, Swildens-van Woudenberg 
IA, van Rijk PP and van het Schip AD. Holmium-166 poly lactic acid microspheres 
applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of 
preparation and neutron activation techniques. Eur. J. Nucl. Med. 1999;26:699-704. 
30. O’ Donnell PB and McGinity JW. Preparation of microspheres by solvent evaporation 
technique. Adv. Drug Del. Rev. 1997;28:25-42. 
31. Mumper RJ and Jay M. Poly(L-lactic acid) microspheres containing neutron-activatable 
holmium-165: A study of the physical characteristics of microspheres before and after 
irradiation in a nuclear reactor. Pharm. Res. 1992;9:149-154.  
32. Kooijman H, Nijsen JFW, Spek AL and van het Schip AD. Diaquatris(pentane-2,4-
dionato-O,O’)holmium(III) monohydrate and diaquatris(pentane-2,4-dionato-O,O’)-
holmium(III) 4-hydroxypentan-2-one solvate dihydrate. Acta. Cryst. 2000;C56:156-
158. 
33. Häfeli UO, Sweeney SM, Beresford BA, Sim EH and Macklis RM. Magnetically 
directed poly(lactic acid) 90Y-microspheres: Novel agents for targeted intracavitary 
radiotherapy. J. Biomed. Res. 1994;28:901-908. 
34. Häfeli UO, Sweeney SM, Beresford BA, Humm JL and Macklis RM. Effective 
targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally 
applied magnetic field. Preliminary in vitro and in vivo results. Nucl. Med. Biol. 
1995;22:147-155. 
35. Mantravedi RVP, Spigos DG, Tan WS and Felix EL. Intraarterial yttrium-90 in the 
treatment of hepatic malignancy. Radiology 1982;142:783-786. 
36. Rösler H, Triller J, Baer HU, Geiger L, Beer HF, Becker C and Blumgart LH. 
Superselective radioembolization of hepatocellular carcinoma: 5-year results of a 
prospective study. Nukl. Med. 1994;33:206-214. 
37. Herba MJ, Illescas FF, Thirlwell MP, Boos GJ, Rosenthall L, Atri M and Bret PM. 
Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 
1988;169:311-314. 
38. Meade VM, Burton MA, Gray BN and Self GW. Distribution of different sized 
microspheres in experimental hepatic tumours. Eur. J. Clin. Oncol. 1987;23:37-41. 
39. Bastian P, Bartkowski R, Köhler H and Kissel T. Chemo-embolization of experimental 
liver metastases. Part I: distribution of biodegradable microspheres of different sizes in 
an animal model for the locoregional therapy. Eur. J. Pharm. Biopharm. 1998;46:243-
254. 
General introduction: Advances in nuclear oncology 
27 
40. Campbell AM, Bailey IH and Burton MA. Analysis of the distribution of intra-arterial 
microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys. 
Med. Biol. 2000;45:1023-1033. 
41. Spencer RP. Applied principles of radiopharmaceutical use in therapy. Nucl. Med. Biol. 
1986;13:461-463. 
42. Spencer RP. Short-lived radionuclides in therapy. Nucl. Med. Biol. 1987;14:537-538. 
43. ICRP Publication 38. Radionuclide transformations energy and intensity of emissions, 
Pergamon Press: Oxford, 1983. 
44. Neves M, Waerenborgh F and Patricio L. Palladium-109 and holmium-166 potential 
radionuclides for synoviotherapy-radiation absorbed dose calculations. Appl. Radiat. 
Isot. 1987;38:745-749. 
45. Vergote I., Larsen R H, de Vos L, Nesland JM, Bruland Ø, Bjørgum J, Alstad J, Tropé 
C and Nustad K. Therapeutic efficacy of the α-emitter 211At bound on microspheres 
compared with 90Y and 32P colloids in a murine intraperitoneal tumor model. Gynecol. 
Oncol. 1992;47:366-372. 
46. Wang SJ, Lin WY, Chen MN, Hsieh BT, Shen LH, Tsai ZT, Ting G, Chen JT, Ho WL, 
Mirzadeh S and Knapp FF. Rhenium-188 microspheres: A new radiation synovectomy 
agent. Nucl. Med. Biol. 1998;19:427-433. 
47. Collet JH. Lim LY and Gould PL. Gamma-irradiation of biodegradable polyesters in 
controlled physical environments. Polymer reprints 1989;30:468-469. 
48. Schakenraad JM, Oosterbaan JA, Nieuwenhuis P, Molenaar I, Olijslager J, Potman W, 
Eenink MJD and Feijen J. Biodegradable hollow fibres for the controlled release of 
drugs. Biomaterials 1988;9:116-120. 
49. Sintzel MB, Merkli A, Tabatabay C and Gurny R. Influence of irradiation sterilization 
on polymers used as drug carriers-A review. Drug Develop. Ind. Pharm. 1997;23:857-
878. 
50. Esselbrugge H, Grootoonk J and Feijen J. γ-irradiation of poly(L-lactide) hollow fibers. 
Thesis, University of Twente, The Netherlands: Biodegradable hollow fibres for 
controlled drug delivery, Appendix A, 1992;245-258. 
51. Henn GG, Birkinshaw C, Buggy M and Jones EA. comparison of the effects of γ-
irradiation and ethylene oxide sterilization on the properties of compression moulded 
poly-d, l-lactide. J. Mater. Sci. Mat. Med. 1996;7:591-595. 
52. Montanari L, Costantini M, Signoretti EC, Valvo L, Santucci M, Bartolomei M, 
Fattibene P, Onori S, Faucitano A, Conti B and Genta I. Gamma irradiation effects on 
poly(DL-lactictide-co-glycolide) microspheres. J. Control. Release 1998;56:219-229. 
53. Mohr D, Wolff M and Kissel T. Gamma irradiation for terminal sterilization of 17β-
estradiol loaded poly(DL-lactide-co-glycolide) microparticles. J. Control. Release 
1999;61:203-217. 
Chapter 1  
 
28 
54. Bittner B, Mäder K, Kroll C, Borchert H-H and Kissel T. Tetracycline-HCl-loaded 
poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: 
influence of γ-irradiation on radical formation and polymer degradation. J. Control. 
Release 1999;59:23-32. 
55. Chu CC and Campbell ND. Scanning electron microscopic study of the hydrolytic 
degradation of poly(glycolic acid) suture. J. Biomed. Mater. Res. 1982;16:417-430. 
56. Ho S, Lau WY, Leung TWT, Chan M, Ngar YK, Johnson PJ and Li AKC. Partition 
model for estimating radiation doses from yttrium-90 microspheres in treating hepatic 
tumours. Eur. J. Nucl. Med. 1996;23:947-952. 
57. Anderson JM and Shive MS. Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Adv. Drug Del. Rev. 1997;28:5-24. 
58. Visscher GE, Robison RL, Maulding JW, Fong JW, Pearson JE and Argentieri GJ. 
Note: Biodegradation of and tissue reaction to poly(DL-lactide) microcapsules. J. 
Biomed. Mater. Res. 1986;20:667-676. 
59. Houle SH, Yip TK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, Cawthorn RH 
and Richmond-Cox K. Hepatocellular carcinoma: Pilot trial of treatment with Y-90 
microspheres. Radiology 1989;172:857-860. 
60. Jalil R and Nixon JR. Microencapsulation using poly(L-lactic acid) IV: Release 
properties of microcapsules containing phenobarbitone. J. Microencapsul. 1990;7:53-
66. 
61. Miyajima M, Koshika A, Okada J, Ikeda M and Nishimura K. Effect of polymer 
crystallinity on papaverine release from poly(L-lactide acid) matrix. J. Control. Release  
1997;49:207-215. 
62. Miyajima M, Koshika A, Okada J and Ikeda M. Mechanism of drug release from 
poly(L-lactic acid) matrix containing acidic or neutral drugs. J. Control. Release 
1999;60:199-209.  
63. Mantravedi RVP, Spigos DG, Tan WS and Felix EL. Intraarterial yttrium 90 in the 
treatment of hepatic malignancy. Radiology 1982;142:783-786. 
64. Wollner I, Knutsen C, Smith P, Prieskorn D, Chrisp C, Andrews J, Juni J, Warber S, 
Klevering J, Crudup J and Ensminger W. Effects of hepatic arterial yttrium 90 glass 
microspheres in dogs. Cancer 1988;61:1336-1344. 
65. Yan Z-P, Lin G, Zhao H-Y and Dong Y-H. An experimental study and clinical pilot 
trials on yttrium-90 glass microspheres through the hepatic artery for treatment of 
primary liver cancer. Cancer 1993;72:3210-3215. 
66. Shepherd FA, Rotstein LE, Houle S, Yip T-CK, Paul K and Sniderman KW. A phase I 
dose escalation trial of yttrium-90 microspheres in the treatment of primary 
hepatocellular carcinoma. Cancer 1992;70:2250-2254. 
General introduction: Advances in nuclear oncology 
29 
67. Anderson JH, Goldberg JA, Bessent RG, Kerr DJ, McKillop JH, Stewart I, Cooke TG 
and McArdle CS. Glass yttrium-90 microspheres for patients with colorectal liver 
metastases. Radiotherapy and Oncology 1992;25:137-139. 
68. Lin M. Radiation pneumonitis caused by yttrium-90 microspheres: radiologic findings. 
Am. J. Rad. 1994;162:1300-1302. 
69. Gray BN, Burton MA, Kelleher D, Klemp P and Matz L. Tolerance of the liver to the 
effects of yttrium-90 radiation. Int. J. Radiation Oncology Biol. Phys. 1990;18:619-623. 
70. Tian J-H, Xu B-X, Zhang J-M, Dong B-W,  Liang P and Wang X-D. Ultrasound-
guided internal radiotherapy using yttrium-90-glass microspheres for liver 
malignancies. J. Nucl. Med. 1996;37:958-963. 
71. Leung W, Lau W, Ho  SKW, Chan M, Leung NWY, Lin J, Metraweli C, Johnson PJ 
and Li AKC. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-
arterial technetium-99m macroaggregated albumin. J. Nucl. Med. 1994;35:70-73. 
72. Ho S, Lau WY, Leung TWT, Chan M, Chan KW, Lee WY, Johnson PJ and Li AKC. 
Tumour-to-normal ratio of 90Y microspheres in hepatic cancer assessed with 99mTc 
macroaggregated albumin. Brit. J. Rad. 1997;70:823-828. 
73. Yorke ED, Jackson A, Fox RA, Wessels BW and Gray N. Can current models explain 
the lack of liver complications in Y-90 microsphere therapy? Clin. Cancer Res. 
1999;5:3024s-3030s. 
74. Ingold J, Reed G, Kaplan H and Bagshaw M. Radiation hepatitis. Am. J. Roentgenol. 
Radium Ther. Nucl. Med. 1965;93:200-208. 
75. Van Es RJJ, Franssen O, Dullens HFJ, Bernsen MR, Bosman F, Hennink WE and 
Slootweg PJ. The VX2 carcinoma in the rabbit auricle as an experimental model for 
intra-arterial embolization of head neck squamous cell carcinoma with hydrogel 
dextran microspheres. Lab. Anim. 1999;33:175-184. 
76. Tomura N, Kato K, Hirano H, Hirano Y and Watarai J. Chemoembolization of 
maxillary tumors via the superficial temporal artery using a coaxial catheter system. 
Radiation Med. 1998;16:157. 
77. Vergote I, Larsen RH, de Vos L, Winderen M, Ellingsen T, Bjørgum J, Hoff P, Aas M, 
Tropé C and Nustad K. Distribution of intraperitoneally injected microspheres labeled 
with the α-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) 
colloids in mice. Gynecol. Oncol. 1992;47:358-365. 
78. Ariel IM and Padula G. Irradiation of the spleen by the intra-arterial administration of 
90yttrium microspheres in patients with malignant lymphoma. Cancer 1972;31:90-96. 
  
Chapter 2 
 
 
 
 
 
Holmium-166 poly (L-lactic acid) microspheres 
applicable for intra-arterial radionuclide 
therapy of hepatic malignancies: effects of 
preparation and neutron activation techniques 
European Journal of Nuclear Medicine 1999;26:699-704 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J.F.W. Nijsen1, B.A. Zonnenberg2, J.R.W. Woittiez3, D.W. Rook1, 
I.A. Swildens-van Woudenberg1, P.P. van Rijk1 and  
A.D. van het Schip1 
1Department of Nuclear Medicine, University Medical Center, Utrecht, The Netherlands 
2Oncology Section, Department of Internal Medicine, University Medical Center, 
Utrecht, The Netherlands 
3Netherlands Energy Research Foundation, Petten, The Netherlands 
Chapter 2 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Since one of the most frequent sites of human metastatic cancer is the liver, 
particularly in colon and rectum carcinoma, there is a special need for the 
development of an effective therapy. This study describes the parameters for 
reproducible production of poly(L-lactic acid) (PLLA) microspheres with an average 
diameter of 37 µm and labelled with neutron-activated 166Ho (Emax =1.84 MeV, t1/2 
=26.8h), suitable for use in internal radionuclide therapy of liver metastases. It is 
demonstrated that holmium loaded PLLA microspheres can be prepared by a 
relatively simple method, with incorporation of 17.0±0.6% holmium (n=5), and that 
20 GBq can be obtained from 400 mg neutron activatable microspheres. In order to 
produce this high amount of activity, the microspheres must be free of water and 
irradiation must be performed in a polyethylene vial, with a relatively low neutron 
flux (5×1013 cm–2.s–1) within 1h. Under these well-defined conditions minor surface 
changes were seen which barely affected total volume and consequently total 
radioactivity of the microspheres with a diameter of 20–50 µm. Overall structural 
integrity was maintained in terms of form and size. In vitro analyses showed that 
>99.3% of 166Ho activity was retained in the microspheres after 192h incubation in 
PBS, plasma and leucocytes, while in liver homogenate retention was still 98.4%. 
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2.1 Introduction 
Liver metastases frequently occur during the progression of various solid tumours, 
especially colorectal cancers, and are the cause of 25–50% of all cancer deaths [1–3]. 
The median survival of patients with liver metastases ranges from 2–12 months 
depending on volume of the metastases and histology of the original tumour [1,4]. 
External beam radiotherapy in the treatment of hepatic malignancies is limited by the 
tolerance of the hepatic parenchyma, which can tolerate doses of only up to 30 Gy for 
whole liver irradiation; this treatment modality is therefore ineffective [3,5,6]. 
A particularly useful alternative mode of therapy is the use of intra-arterially 
injected radioactive particles of a size sufficient to lodge in endarterioles. The basis 
for such therapy is that tumours are usually rich in vasculature and that liver 
metastases are almost exclusively dependent on arterial blood supply. This contrasts 
with normal liver, which receives most of its flow from the portal vein [7–9]. This 
selectivity can also be increased by the use of vasoactive drugs, which cause 
vasoconstriction of the normal liver arterioles, but to which tumour vessels, lacking 
smooth muscle, are insensitive [10–14].  
Treatment with radioactive microspheres is based on this principle. Microspheres 
with a diameter between 20 and 50 µm will lodge in the vascular bed of the liver [3, 
15–17]. The spheres are administered via a catheter through the hepatic artery, after 
administration of a vasoactive drug. Owing to the high selectivity of this technique, 
the radiation is mainly restricted to the tumour, with absorbed radiation doses to the 
tumour varying between 50 and 150 Gy [2,18].  
Studies on selective internal radiation therapy of colorectal liver metastases using 
90Y glass microspheres have shown encouraging results [5]. In this technique the 
microspheres are injected into the hepatic artery and are preferentially directed into 
the vascular network of liver metastases by enhancing the proportion of blood flow to 
the tumour, as opposed to normal liver parenchyma, using vasoactive agents [14]. 
Although the glass spheres have several advantages, their high density (3.29 g/ml), 
their apparent non-biodegradability and the lack of -emission of 90Y (Emax =2.28 
MeV, t1/2 =64.1h) for imaging may be considered disadvantages [19,20]. The high 
density is a particularly serious drawback since this accounts for the considerable 
toxicity caused by backflow to surrounding tissues such as the stomach. 
Neutron-activated 166Ho is a -emitter (Emax =1.84 MeV) with radiotherapeutic 
properties appropriate for therapy, that also emits photons (81 keV, 6.2%) suitable for 
imaging. The use of 166Ho embedded in microspheres of poly(L-lactic acid) (PLLA-
MS) combines the advantages of microspheres with the additional advantages of 
biocompatibility, biodegradability, short physical half-life of 26.8h, natural abundance 
of 165Ho (100%) and near plasma density.  
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PLLA-MS containing 166Ho were first described by Mumper et al. [19]. A sample 
consisting of 50 mg microspheres and 150 mg inositol was irradiated in a reactor for 
up to 3h, in a thermal neutron flux of 8.88×1012 cm–2.s–1, resulting in 1295 MBq of 
activity. Inositol was added to disperse the internal heat produced during neutron 
irradiation. 
This study describes the production of PLLA-MS with an average diameter of 37 
µm and labelled with 166Ho, for the treatment of liver metastases. Effects of 
production together with irradiation parameters were examined. Optimisation of these 
parameters resulted in a reproducible and straightforward method for the production 
of holmium loaded PLLA-MS, of uniform size and high chemical stability, which 
gave therapeutic amounts of activity within 1h irradiation time and precluded the need 
for any additives. 
 
 
2.2 Materials and methods 
2.2.1 Chemicals  
All chemicals were commercially available. Acetylacetone, 2,4-pentanedione (AcAc; 
MW 100.12; >99%) was obtained from Sigma Aldrich (Steinheim, Germany). 
Holmium(III) chloride hexahydrate (HoCl3· 6H2O; MW 379.38; 99.9%) was obtained 
from Phase Separations BV (Waddinxveen, The Netherlands). Ammonium hydroxide 
(NH4OH; MW 35.05; 29.3%) and polyvinyl alcohol (PVA, average MW 30,000–
70,000) were obtained from Sigma Chemical Co. (St. Louis, Mo.). Poly(L-lactic acid) 
(PLLA; MW 26,000, intrinsic viscosity 0.09 l/g in chloroform 25°C) was supplied by 
Purac Biochem BV (Gorinchem, The Netherlands). Hydrochloric acid (HCl; MW 
36.46; 37%) and chloroform (MW 119.39; Lichrosolv) were supplied by Merck 
(Darmstadt, Germany).  
 
2.2.2 Methods 
2.2.2.1 Preparation of Ho-acetylacetonate (Ho-AcAc) 
Acetylacetone (180 g) was dissolved in 1080 g water. The pH of this solution ranged 
between 3.5 and 4.0. Ammonium hydroxide was added to the stirring colourless 
acetylacetone solution until pH 8.5 was reached and the solution became yellow from 
the formation of acetylacetonate. Holmium chloride (10 g in 30 ml water) was then 
stirred into this solution and HoAcAc crystals were allowed to form at room 
temperature for at least 1 day. The crystals were collected by filtration over a 5.0 µm 
Millipore filter, washed 3 times with water and dried under nitrogen. 
The HoAcAc crystals were examined by infrared spectroscopy, nuclear magnetic 
resonance (NMR), elemental analysis, X-ray crystallography and scanning electron 
microscopy (SEM).  
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2.2.2.2 Synthesis of holmium loaded microspheres 
Biodegradable poly(L-lactic acid) microspheres were manufactured in a glass beaker 
with four baffles. HoAcAc complex (10 g) and PLLA (6 g) were added to 
continuously stirred 186 g chloroform. PVA was dissolved in continuously stirred 
water of 40°C and poured into the glass beaker after cooling. The solutions and the 
beaker were kept at 25°C. The chloroform solution was added to the PVA solution 
and continuously stirred (500 rpm) until the chloroform was completely evaporated 
[19,21]. To remove residual PVA and unincorporated HoAcAc, the formed 
microspheres were washed sequentially with water, 0.1 N HCl and water.  
The microspheres were graded and collected according to size on stainless steel 
sieves of 20 and 50 µm (20 µm sieve, S/Steel, NEN 2560, Endecotts, London; 50 µm 
sieve, S/Steel, ASIM E 11 87; B.V. Metaalgaasweverij, Twente, The Netherlands) 
under sprinkled water, and dried under nitrogen.  
Characterisation of non-irradiated and irradiated microspheres was carried out by 
SEM, laser particle size analysis and -spectrometry of 166Ho, after neutron activation 
of the 165Ho incorporated in the PLLA-MS. For determination of PLLA molecular 
weight, microspheres were dissolved in chloroform and analysed by high performance 
liquid chromatography (HPLC) using a gel permeation chromatography column 
(Shodex KD 800) from Showa Benco, Japan. 
 
2.2.2.3 Low and high neutron flux irradiations of 165Ho-PLLA-MS &p.2: 
All irradiations were performed twice in the reactor facilities in Petten, The 
Netherlands. Two high neutron flux facilities were used, the pneumatic rabbit system 
(PRS) and the reloadable isotope production system (HIP). Irradiation in the PRS 
facility (neutron flux 5×1013 cm –2.s –1) was carried out in a polyethylene or quartz vial 
packed in a polyethylene “rabbit”. Irradiation in the HIP facility (neutron flux 2×1014 
cm –2.s –1) was performed in a quartz vial in a sealed aluminium cylinder, which was 
itself then enclosed in a polyethylene cylinder. Amounts of 10, 200 or 400 mg of dried 
165Ho-PLLA-MS were irradiated for 0.5, 1, 2 or 4h. The effect of the presence of 
water during irradiation was studied by spiking some samples of microspheres with 50 
µl of water. The holmium content of the 165Ho-PLLA-MS was determined by neutron 
activation in the low neutron flux facility (neutron flux 3.1×1011 cm–2.s–1). 
 
2.2.2.4 In vitro biodegradability and release studies. 
Irradiated microspheres (100 mg in 0.5 ml saline) were incubated in 2 ml 10 mM 
phosphate-buffered saline pH 7.4 (PBS), a suspension of human leucocytes in saline 
and homogenised pig liver (1.0 g) suspended in PBS. Release of 166Ho was 
determined by incubation at 37°C in a dialysis cassette (Slide-A-Lyzer, Pierce, 
Rockford, Ill.). After incubation for 1, 3, 24, 96, 192 and 288h, release of free 166Ho 
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was assayed in a gamma counter. Samples incubated for 288h were investigated for 
their biodegradability by SEM. 
 
 
2.3 Results 
2.3.1 Preparation and analysis of HoAcAc  
After the addition of holmium chloride to the solution of acetylacetonate, pink crystals 
of HoAcAc appeared within 4h. Infrared spectroscopy and NMR analysis of the 
HoAcAc crystals established the presence of three acetylacetonate molecules and two 
to three molecules of water. Results of elemental analysis indicated the complexation 
of one holmium atom together with three acetylacetonate molecules and the presence 
of three water molecules (Table 1).  
 
Table 1. Elemental analysis of holmium-trisacetylacetonate: 
measured versus theoretical values. 
l.b: 
&Element Mass content (%) Theoretical Ho-complex 
3×H2O 
 C  36.55  34.90 
 H  4.98  5.27 
 O  27.12  27.89 
 Cl  0.00  0.00 
 Ho  31.19  31.94 
/tbl.b: 
 
This was definitively confirmed by X-ray crystallography, which revealed a 
monohydrated crystal structure in which one holmium atom was complexed by three 
acetylacetonate molecules and two water molecules (Fig. 1). From the X-ray 
crystallography and SEM data the HoAcAc crystals appeared to have a flat 
morphological structure with a length of 2–3 mm and a width of 0.1–0.3 mm. The 
density of the crystals appeared to be 1.74 g/ml and the molecular mass 516.30 
including the non-coordinating water molecule. 
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Fig. 1. Unit cell of holmiumtrisacetyl-
acetonate with two coordinated water 
molecules as shown by X-ray 
crystallography (C, carbon atom; O, oxygen 
atom; Ho, holmium atom; hydrogen atoms 
not shown).&/ 
 
 
 
 
 
2.3.2 Synthesis and analysis of holmium loaded microspheres 
Microsphere size and form depend on several parameters. Parameters investigated in 
this study were: PVA concentration, stirring rate, temperature and Ho-acetylacetonate 
concentration. Low concentrations of PVA (<0.2%) gave small and mostly non-
spherical particles. Concentrations of 2%–3% PVA gave smooth microspheres while 
higher concentrations (>4%) resulted in non-spherical particles. Increased stirring rate 
resulted in decreased particle size; 750 rpm gave particles with an average diameter of 
32 µm while 500 rpm resulted in an average diameter of 37 µm. Effects of 
temperature and HoAcAc concentration were minor. Increasing the temperature, from 
18°C to 25°C to 37°C, resulted in a slightly larger particle size. High concentrations of 
HoAcAc, >12 g in 186 g chloroform, resulted in a mixture of microspheres HoAcAc 
crystals; the latter were hard to remove and required washing at least 4 times with 20 
ml 1 N HCl. The parameters examined resulted in a standard method under the 
following conditions: 2% PVA, 10 g HoAcAc in 186 g chloroform, 25°C and 500 
rpm, yielding 3–4.5 g of microspheres with a diameter of 20–50 µm and incorporation 
of 17.0%±0.6% holmium (w/w) according to neutron activation (n=5). 
 
2.3.3 Characterisation of microspheres after reactor irradiation 
Samples were irradiated individually and within 1 day, in order to create reactor 
conditions as closely comparable as possible. It appeared that well-defined irradiation 
conditions were necessary to produce therapeutic dosages of 166Ho-PLLA-MS while 
maintaining their integrity and suitability for therapy. Irradiation parameters affecting 
the integrity to a greater or lesser extent were (1) irradiation time, (2) the facility, (3) 
the amount of microspheres per vial, (4) water content of the microspheres and (5) 
material of the vial. Irradiation conditions and extent of loss of structural integrity 
after irradiation are summarised in Table 2. Non-irradiated 165Ho-PLLA-MS show a 
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smooth, spherical appearance (Fig. 2A). After irradiation in the PRS facility (neutron 
flux 5×1013 cm–2.s–1) for 1h in polyethylene vials, minor surface changes were seen 
with SEM (Fig. 2B), giving rise to small PLLA fragments. These led to a larger 
number of particles <20 µm (Fig. 3A). Nevertheless, the total volume of these small 
particles (Fig. 3B) and hence their total radioactivity hardly increased (the latter is 
likely to be related to the size and thus the volume of the particles). While overall 
structural integrity was maintained in terms of form and size, the microspheres 
showed a minimal tendency towards aggregation; they could, however, be easily 
suspended in PBS and should be suitable for intra-arterial therapy. Similar results 
were obtained when quartz instead of polyethylene vials were used, although some 
aggregation of the microspheres was observed. The presence of water had a more 
destructive effect. The microspheres appeared to have melted and were stacked (Fig. 
2C). Irradiation in the PRS facility of 200 or 400 mg microspheres for 2h instead of 1h 
had a disastrous effect on the integrity of the microspheres in both polyethylene and 
quartz vials. A mixture of small and very large sharply edged particles of 50–400 µm 
was obtained (Fig. 2D). Irradiation of only 10 mg under the same conditions resulted 
in intact microspheres. 
 
Table 2. Summary of irradiation conditions and structural integrity after irradiation of 
microspheres&/ 
: 
Time (h)        PRS (5· 10 13 )     HIP (2· 10 14) 
 Polyethylene   Quartz  Quartz 
 10 mg 200 mg 400 mg  200 mg  200 mg 
0.5       – 
1.0 ++ ++/+a ++  ++  – 
2.0 ++ – –  –  – 
 
Irradiations were done twice in the pneumatic rabbit system (PRS) or reloadable isotope 
production (HIP) facility. ++, Integrity maintained, suitable for radionuclide therapy: 
spherical particles, uniform size, minimal aggregation, easy to suspend; +, integrity affected: 
recognisable but aggregated spheres, no uniform size; –, integrity completely destroyed: large 
aggregated structures, no recognisable spheres. aSpiked with water (50 µl). 
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Fig. 2A–D. Electron micrographs illustrating effect of neutron irradiation. A 165Ho-PLLA-
MS before irradiation (×1000). B Microspheres irradiated for 1h (×1000). C Microspheres 
spiked with 50 µl water irradiated for 1h (×1500). D Microspheres irradiated for 2h (×500). 
Irradiations were performed with 200 mg microspheres in polyethylene vials and neutron flux 
5×1013 cm–2.s–1.&/f  
 
 
The HIP facility (neutron flux 2×1014 cm–2.s –1) in which only quartz vials are used 
appeared to be impractible for our purpose. Irradiation of 200 mg microspheres for 
0.5h gave similar results to those shown in Fig. 2C, while longer irradiation times 
resulted in crispy, yellow material.  
 
Fig. 3A-B. Population distri-
bution of irradiated (1–2h and 
10–400 mg) and non-irradiated 
(ref) microspheres (A). Bars 
represent percentage of total 
number of particles per group:  
 <20 µm;  20–50 µm;  >50 
µm. Volume weight distribution 
of irradiated (1-2h and 10–400 
mg) and non-irradiated (ref) 
microspheres (B). Bars represent 
percentage of total volume of 
particles per group:  <20 µm, 
 20–50 µm;  >50 µm.&/f  
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2.3.4 In vitro biodegradability and release studies 
Analysis of the molecular weight of PLLA of microspheres before and after 
irradiation (1h, neutron flux 5×1013cm–2.s–1) revealed a reduction in polymer 
molecular weight of 93% by gel permeation chromatography. Visible changes were 
also observed following incubation for 288h, 37°C, in PBS and pig liver homogenate 
(Fig. 4A,B). Despite these physical and morphological changes, >99.3% of 166Ho 
activity was retained in the microspheres after 192h (>7 half-lives) incubation in PBS, 
plasma and leucocytes, while in liver homogenate retention was still 98.4% (Fig. 4C). 
 
   
 
Fig. 4A–C. Biodegradability and 166Ho release of 166Ho-PLLA-MS. Microspheres were 
irradiated for 1h, neutron flux 5×1013 cm–2.s–1 and incubated for 288h at 37°C in PBS (A) or 
pig liver homogenate (B) (×1500). C In vitro release of 166Ho after incubation in: PBS (, 
human plasma (), human white blood cells () and pig liver homogenate (×). 
 
 
2.4 Discussion 
The use of radioactive microspheres administered arterially as radionuclide therapy 
for liver metastases has the potential to overcome the disadvantages of external beam 
radiation, which is limited by the radiosensitivity of the healthy tissue. As yet this 
application is restricted to the use of 90Y glass microspheres, which have suboptimal 
properties.  
The potential use of PLLA-MS containing 166Ho, as first suggested by Mumper et 
al. [19], combines the best of two worlds: low density, biocompatible microspheres 
for embolization of tumour and immobilisation of 166Ho, which has favourable 
physical characteristics for image guided radionuclide therapy. 166Ho emits negatrons 
(Emax =1.84 MeV) for therapy as well as photons (81 keV, 6.2%). This allows for 
dosimetric calculations and interaction during administration, and contributes only 
1.1% to the overall absorbed radiation dose [20] that will be delivered at a relatively 
high dose rate, due to the 26.8h half-life as compared to the 64h half-life of 90Y. 
Moreover, 165Ho has a natural abundancy of 100% and a cross-section of 64 barn, 
allowing for short neutron activation times.  
The aim of this study was to develop a well-characterised method for reproducible 
preparation of 165Ho-PLLA-MS, to be dispensed in patient-ready doses, that only 
A      B     C 
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needs to be activated by neutron bombardment to a therapeutic amount of 
radioactivity and is ready for patient administration without any additional handling. 
To attain this goal, the holmium content of the microspheres must be sufficiently high, 
and neutron activation in a high flux reactor is necessary to obtain appropriate 
amounts of activity in workable time. At the same time, activation conditions must be 
such as to maintain the structural integrity of the microspheres and their stability with 
respect to 166Ho release.  
Holmium was complexed with acetylacetonate to enable incorporation into PLLA. 
Under the conditions we used, pH=8.5 and a 70-fold molar excess of AcAc, 80% of 
holmium is complexed as HoAcAc, of which standard 31.2% (w/w) is holmium. 
Subsequently, HoAcAc was embedded in PLLA microspheres prepared by the solvent 
evaporation technique. The form, diameter and stability of the microspheres appeared 
to be affected by several parameters, of which the concentration of PVA, used as an 
emulsifier, was the most prominent. An optimum concentration of 2% PVA resulted 
in spherical particles with a smooth surface and an average diameter of 37 µm (range 
5–100 µm); 74% of the microspheres were between 20 and 50 µm, with a density of 
1.4 g/ml and a reproducible 165Ho content of 17.0±0.6% (w/w). After sieving out and 
drying of the 20 to 50 µm fraction of the microspheres, less than 1% of its total 
volume was <20 µm. The drying phase after sieving proved to be particularly 
important. Residual water caused aggregation of microspheres and rendered them 
useless for therapy, especially after neutron irradiation (Fig. 2C).  
The conditions during neutron activation of the 165Ho-PLLA-MS needed to be 
strictly defined. This study demonstrated that microspheres must be free of water and 
that high neutron flux (>5×1013 cm–2.s –1) and irradiation time of more than 1h must be 
avoided. It should be stressed that the reactor facilities we used differ by a factor of 4 
in neutron flux. However, distance from the core, geometry and neutron flux together 
determine the radiation environment of the microspheres and their condition after 
neutron activation. Therefore, our findings cannot be interpreted solely in terms of 
neutron flux, and they should be extrapolated to other reactors only with prudence. 
 Aggregation of microspheres was slightly greater after neutron bombardment in 
quartz vials than in polyethylene vials; this can be explained by neutron activation of 
the vial material, giving a higher radiation burden to the microspheres in the case of 
the quartz. The amount of microspheres per vial had a more pronounced effect in that 
small amounts (10 mg) were intact after irradiation in the PRS facility for 2h, while 
larger amounts (>200 mg) were completely destroyed under identical conditions; this 
may be explained by the higher total water content of the latter.  
Using the optimised reactor conditions, reduction in the molecular weight of PLLA 
was the only change in microspheres observed after irradiation. However, this 
apparently did not affect stability in terms of 166Ho release even after more than 7 half-
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lives incubation under physiological conditions, thus making 166Ho-PLLA-MS 
applicable for therapy. 
The present study has demonstrated that holmium loaded PLLA-MS can be 
prepared straightforwardly with reproducible incorporation of 17.0±0.6% (w/w) 165Ho, 
which is high enough to produce sufficient amounts of therapeutic 166Ho activity 
provided that the proper irradiation conditions are adhered to. This study explicitly 
shows that production of the desired amount of activity entails more than a simple 
adjustment of irradiation parameters. The effect of changing irradiation parameters 
appeared to be unpredictable and had to be determined experimentally in each case. 
Adjustment of the parameters used by Mumper et al. [19] to produce substantially 
more activity in a shorter time was therefore impracticable. Mumper et al. were able to 
produce up to 1295 MBq of 166Ho within 3h by irradiation (neutron flux 8.88×1012 
cm–2.s–1) of 50 mg microspheres with 150 mg inositol as an additive. In contrast, from 
the present work irradiation conditions could be defined such that 20 GBq of 166Ho is 
obtained within 1h by neutron activation (neutron flux 5×1013 cm–2.s–1) of 400 mg 
microspheres without any additives (n=10 irradiations). This would strongly facilitate 
routine production and transport to the therapy site. Efficacy studies in animals with 
liver tumours are now being undertaken. Other therapeutic applications, such as 
radionuclide synovectomy, are conceivable, by simply adapting the size of the 
microspheres. 
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Abstract 
The structures of the title compounds, [Ho(C5H7O2)3(H2O)2].H2O and 
[Ho(C5H7O2)3(H2O)2].C5H8O2.2H2O, both show an eight-coordinate holmium(III) ion 
in a square antiprismatic configuration. The packing of these structures consists of an 
infinite two-dimensional network of hydrogen-bonded molecules. In both structures, 
the same hydrogen-bonded chain of HoIII complexes is found. 
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3.1 Comment 
Holmium in the trivalent state, like other rare earths, reacts with acetylacetonate 
(pentane-2,4-dione) to form a complex coordinated with three acetylacetonate ligands 
and one or two water molecules [1,2]. The crystal structure of diaquatris(pentane-2,4-
dionato-O,O’)-holmium(III) monohydrate was reported by Aslanov et al. [3] with R = 
0.13, but no further data are available from the Cambridge Structural Database 
(Version of April 1999; [4]). The pentanedione-Ho complex is essential for the 
development of a new intra-arterial radionuclide therapy for the treatment of liver 
metastases [5]. For the preparation of microspheres embedded with holmium we 
needed a stable hydrophobic holmium complex which can be incorporated easily and 
in high concentration into poly(L-lactic acid) (PLLA) microspheres. This study 
reports structural data on the holmium acetylacetonate (HoAcAc) complex, which was 
chosen for further investigation because it has the above-mentioned properties.  
The HoAcAc complex showed a high chemical stability in PLLA microspheres 
before and after irradiation in a nuclear reactor. Release of neutron-activated holmium 
from the microspheres is <1.6% after 192h incubation in liver homogenate. As the 
incorporation of holmium in PLLA microspheres can be as high as 17% w/w, 
holmium-loaded microspheres are therefore suitable for selective internal radionuclide 
therapy. Neutron-activated 166Ho is a -emitter which can be used for treatment of 
 	
	

  	
 
 -photons which can be used for imaging the 
distribution of activity in the patient. Owing to the high selectivity of the technique by 
which it is administered, the radiation is mainly restricted to the tumour. 
Crystals of diaquatris(pentane-2,4-dionato-O,O’)holmium(III) were obtained under 
different experimental conditions, such as pH (see Experimental). The crystal 
structures were determined to identify unambiguously the composition of the 
materials obtained. Two of these structures are presented here, namely, 
diaquatris(pentane-2,4-dionato-O,O’)holmium(III) monohydrate, (I), and diaquatris-
(pentane-2,4-dionato-O,O’)holmium(III) 4-hydroxypentan-2-one solvate dihydrate, 
(II), obtained at pH 8.5 and 9.0, respectively.  
 
 
Chapter 3 
48 
In both structures, HoIII displays square antiprismatic coordination by eight O atoms. 
There are no significant differences between the geometric parameters of these 
complexes. 
In structure (II), hydrogen bonds between the complexes join them into a chain 
running in the [010] direction. A link between two Ho atoms is formed either by a 
hydrogen-bonded motif with graph set R22 (8) or by two symmetry-related motifs, 
each with graph set R22 (6) [6]. Two non-coordinating water molecules and a free 4-
hydroxypentan-2-one molecule also form a hydrogen-bonded chain in the [010] 
direction. This solvent chain donates three hydrogen bonds to the O atoms coordinated 
to Ho and accepts one hydrogen bond from a coordinated water molecule, thus 
forming a two-dimensional network in the (010) plane (see Fig. 3). The hydroxyl atom 
of the 4-hydroxypentan-2-one is disordered over two positions. The minor position 
forms a bifurcated intra/intermolecular hydrogen bond, whereas the major component 
forms only an intermolecular hydrogen bond.  
 
 
Fig. 1. Displacement ellipsoid plot [7] of 
(I) showing the atomic labelling scheme 
and 50% probability displacement 
ellipsoids. H atoms and the non-
coordinating water molecule have been 
omitted for clarity. 
 
 
 
 
 
Fig. 2. Displacement ellipsoid plot [7] of 
(II) showing the atomic labelling scheme 
and 50% probability displacement 
ellipsoids. H atoms and the non-
coordinating water molecule have been 
omitted for clarity. 
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Fig. 3. Crystal packing diagram for (II). The hydrogen-bonded chain of solvent molecules has 
been accentuated using solid bonds. Methyl groups and H atoms not involved in hydrogen 
bonding have been omitted for clarity. 
 
In structure (I), the complexes are joined by hydrogen bonds into an infinite one-
dimensional chain running in the [101] direction. This chain is identical to that found 
in structure (II). The non-coordinating water molecule links these chains in a two-
dimensional network in the (010) plane. One of the H atoms of this water molecule is 
disordered over two positions, in both of which it forms hydrogen bonds.  
 
3.2 Experimental 
Pentane-2,4-dione (180 g, 1.80 mol) was dissolved in water (1080 g, 59.34 mol), 
followed by addition of ammonium hydroxide (28% w/w) until a solution of pH 8.5 
was obtained. Holmium chloride hexahydrate (10 g, 26.4 mmol) in water (30 g, 1.64 
mol) was then added to the solution, yielding yellow crystals (pink under fluorescent 
lighting) of (I) after 24h at room temperature. Satisfactory spectroscopic data (1H 
NMR, 13C NMR and IR) were obtained. At pH 9.0, crystals of (II) were obtained, 
which were also yellow in daylight and pink under fluorescent lighting. 
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Compound (I) 
 
Crystal data  
[Ho(C5H7O2)3.(H2O)2].H2O Dx = 1.744 Mg m-3 
Mr = 516.30 Mo K		 
Monoclinic, P21/c Cell parameters from 447 
a = 8.242 (2) Å reflections 
b = 21.782 (6) Å -25 
c = 12.557 (3) Å -1 
 = 119.292 (14) T = 150 K 
V = 1966.1 (9) Å3 Needle, yellow-pink 
Z = 4 0.35 x 0.08 x 0.03 mm 
 
Data collection 
Nonius KappaCCD diffractometer 
 
Area-	
	
 Rint = 0.086 
Absorption correction: multi-scan max = 25.24 
 (Spek, 1990) h = -9  
Tmin = 0.614,Tmax = 0.855 k = -25  
15 088 measured reflections l = -15   
3548 independent reflections 
 
Refinement 
Refinement on F2 H atoms: see below 
R(F) = 0.042 w!"2(Fo2) + (0.027P)2 + 9.5P] 
wR(F2) = 0.099 where P = (Fo2 + 2Fc2)/3 
S = 1.151 (#!max = 0.002 
3548 reflections #max = 1.19 e Å-3 
254 parameters #min = -1.51 e Å-3 
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Table 1. 
Selected geometric parameters (Å,    
     
Ho1 - O1 2.360 (4)  Ho1 - O5 2.306 (5) 
Ho1 - O2 2.321 (5)  Ho1 - O6 2.401 (4) 
Ho1 - O3 2.374 (5)  Ho1 - O7 2.420 (5) 
Ho1 – O4 2.327 (5)  Ho1 - O8 2.364 (5) 
     
O1 - Ho1 - O2  73.15 (16)  O5 - Ho1 - O6 72.84 (16) 
O3 - Ho1 - O4  71.05 (17)  O7 - Ho1 - O8 71.49 (16) 
     
 
 
Table 2. 
Hydrogen-bonding geometry (Å,    
D-H…A D-H H…A D…A D-H…A 
     
O7-H74…O3i 0.78 (6) 2.00 (6) 2.771 (7) 168 (6) 
O7-H75…O1i 0.79 (5) 2.29 (6) 2.940 (6) 140 (5) 
O8-H84…O9 0.78 (7) 1.98 (7) 2.759 (9) 177 (7) 
O8-H85…O6ii 0.79 (6) 2.06 (6) 2.841 (6) 174 (8) 
O9-H94…O4iii 0.79 (9) 2.01 (9) 2.760 (8) 159 (9) 
O9-H95…O2iii 0.79 (16) 2.39 (16) 2.994 (8) 134 (14) 
O9-H95…O9iv 0.79 (16) 2.35 (15) 2.785 (8) 115 (13) 
O9-H96…O2iii 0.78 (10) 2.42 (15) 2.994 (8) 131 (12) 
     
Symmetry codes: (i) 1 - x, -y, 2 - z; (ii) -x, -y, 1 - z; (iii) 1 + x, y, z; (iv) 1 - x, -y, 1 - z. 
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Compound (II) 
 
Crystal data 
[Ho(C5H7O2)3(H2O)2].C5H8O2.H2O Dx = 1.622 Mg m-3 
Mr = 634.43 Mo K		 
Monoclinic, P21/c Cell parameters from 25 
a = 11.4903 (11) Å reflections 
b = 11.0242 (6) Å -18.35 
c = 20.5442 (15) Å   -1 
  T = 293 K 
V = 2597.7 (3) Å 3 Needle, yellow-pink 
Z = 4 0.70 x 0.20 x 0.05 mm 
 
Data collection 
Enraf-Nonius CAD-4T diffractometer Rint = 0.041 

	
 max = 25.25 
Absorption correction: Gaussian h = -13   
(Spek, 1990) k = 0   
Tmin = 0.517, Tmax = 0.857 l = -24  
9388 measured reflections 3 standard reflections 
4697 independent reflections frequency: 60 min 
3764 reflections with I intensity decay: 1% 
 
 
Refinement 
Refinement on F2 H atoms: see below 
R(F) = 0.032 w!"2(Fo2) + (0.02P)2 + 5P] 
wR(F2) = 0.069 where P = (Fo2 + 2Fc2)/3 
S = 1.173 (#!max = 0.002 
4697 reflections #max = 1.66 e Å-3 
338 parameters #min = -1.96 e Å-3 
 
 
Crystal structure of the holmium complex 
53 
Table 3. 
Selected geometric parameters (Å,    
     
Ho1 - O1 2.387 (3)  Ho1 - O5 2.302 (3) 
Ho1 - O2 2.334 (3)  Ho1 - O6 2.383 (3) 
Ho1 - O3 2.305 (3)  Ho1 - O7 2.356 (3) 
Ho1 – O4 2.342 (3)  Ho1 - O8 2.416 (3) 
     
O1 - Ho1 - O2  71.77 (11)  O5 - Ho1 - O6 71.59 (11) 
O3 - Ho1 - O4  73.59 (11)  O7 - Ho1 - O8 71.29 (11) 
     
 
 
Table 4. 
Hydrogen-bonding geometry (Å,    
D-H…A D-H H…A D…A D-H…A 
     
O7-H74…O10i 0.82 (4) 1.92 (4) 2.721 (5) 165 (5) 
O7-H75…O1ii 0.81 (4) 2.09 (5) 2.854 (5) 159 (5) 
O8-H84…O4i 0.84 (4) 1.99 (3) 2.788 (5) 157 (4) 
O8-H85…O6i 0.82 (4) 1.99 (5) 2.765 (5) 157 (5) 
O9-H94…O12 0.89 (5) 2.01 (5) 2.887 (7) 173 (12) 
O11-H114…O2iii 0.84 (4) 2.07 (4) 2.906 (4) 171 (6) 
O11-H115…O10iv 0.83 (4) 2.13 (4) 2.918 (5) 159 (6) 
O12-H124…O5 0.84 (5) 2.21 (5) 2.879 (5) 136 (5) 
O12-H125…O11 0.85 (6) 1.92 (6) 2.756 (5) 170 (6) 
C10-H101…O11v 0.96 2.58 3.375 (7) 141 
     
Symmetry codes: (i) –x, 1 – y, -z; (ii) –x, -y, -z; (iii) x, ½ - y, ½ + z; (iv) –x, y - ½, ½  -z;  
(v) –x, ½  + y, ½  - z. 
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For both structures, H atoms bonded to O were located on difference Fourier maps 
and their coordinates were included as parameters in the refinement. Distance 
restraints were applied to ensure reasonable intramolecular geometries. Methyl-H 
atoms were located from difference Fourier syntheses and refined as part of a rigid 
group allowed to rotate around the C-C bond but not tip or distort. All other H atoms 
were introduced at calculated positions, riding on their carrier atoms. The high 
uncertainties shown by some of the data given in Tables 2 and 4 are due to H95 and 
H96 being disordered components. The occupation ratio of the disordered H atom of 
(I) was fixed; the occupation ratio of the disordered H atom of (II) was refined. 
Displacement parameters of all H atoms were related to their carrier atom by a fixed 
constant. For (I), the highest peak of 1.66 Å-3 in the difference Fourier synthesis was 
located 1.07 Å from Ho1; the deepest trough of -1.96 Å-3 was 0.92 Å from the same 
position. 
Data collection: COLLECT [8] for (I), locally modified CAD-4 Software [9] for 
(II); cell refinement: DENZO-SMN [10] for (I), SET4 [11] for (II); data reduction: 
DENZO-SMN for (I), HELENA [12] or (II); for both compounds, program(s) used to 
solve structure: SHELXS86 [13]; program(s) used to refine structure: SHELXL97 [14]; 
molecular graphics: PLATON [7]; software used to prepare material for publication: 
PLATON. 
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Abstract: 
Holmium loaded PLLA microspheres are useful systems in radio-embolization therapy of 
liver metastases because of their low density, biodegradability and favourable radiation 
characteristics. Neutron activated Ho loaded microspheres showed a surprisingly low 
release of the relatively small holmiumcomplex. In this paper factors responsible for this 
behavior are investigated, in particular by the use of differential scanning calorimetry, 
scanning electron microscopy, infrared spectroscopy and X-ray diffraction. The holmium 
complex is soluble in PLLA up to 8% in films and 17% in microspheres. Interactions 
between carbonyl groups of PLLA, and the Ho-ion in the holmiumcomplex, explain very 
satisfactory the high stability of holmium loaded microspheres.  
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4.1 Introduction 
Injectable glass microspheres loaded with a radioactive compound have been 
investigated as systems in the treatment of hepatic metastases [1]. After introduction 
into the hepatic artery, these microspheres accumulate in the capillary bed of the liver, 
resulting in a high dose of radioactivity into the area of tumor cells. Studies on 
selective radio-embolization therapy of colorectal liver metastases using yttrium-90 
(90Y) glass beads have shown encouraging results [1,2]. However, their high density 
(3.29 g/ml) and non-biodegradability are obvious disadvantages of this system [3,4]. 
Also, the choice of the radionuclide 90Y which lacks γ-emission for imaging can be 
considered as a disadvantage [4,5]. As an alternative for glass particles, microspheres 
of poly(L-lactic acid) (PLLA) containing holmium-166 (166Ho) were proposed [4]. 
The main advantages of this system are the reduced density when compared with glass 
beads and the well-known biocompatibility and biodegradability of PLLA 
microspheres. Moreover, 166Ho has a distinct advantage over 90Y. It has a relatively 
short physical half-life (26.8h compared with 64.1h for 90Y) and is γ-emitting. 
By increasing the incorporation of holmium acetylacetonate (HoAcAc), combined 
with a higher neutron flux during irradiation, we succeeded in preparing microspheres 
with a substantially higher dose of radioactivity than the preparation described by 
Mumper et al. [6], thus making clinical trials feasible. We were able to show that more 
than 98% of the 166Ho activity was retained in the microspheres (after 192h incubation 
at 37°C, in several physiological media) [7]. This is a favourable characteristic of 
these microspheres for the proposed application, but it is also surprising, since 
generally low molecular weight compounds are released to a great extent, and 
relatively rapidly from PLLA microspheres [8-10]. PLLA, instead of e.g. poly(lactic-
co-glycolic acid) was selected for the preparation of HoAcAc-loaded microspheres 
because the crystalline domains of this polymer guarantee a good dimensional 
stability of the spheres once they are irradiated in a nuclear reactor, which can be 
accompanied with temperatures of 50–60°C. An additional advantage is the lower 
susceptibility of the crystalline state of PLLA to radiation induced degradation 
compared with the amorphous state [11]. The aim of the present study is to obtain 
insight into the factors responsible for the low-release properties of the holmium 
loaded microspheres.  
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4.2 Materials and Methods 
4.2.1 Materials 
All chemicals were commercially available and used as obtained. Acetylacetone, 2,4-
pentanedione, (AcAc; MW 100.12; >99%) was obtained from Sigma Aldrich 
(Steinheim, Germany). Holmium(III) chloride hexahydrate (HoCl3.6H2O; MW 
379.38; 99.9%) was obtained from Phase Separations BV (Waddinxveen, The 
Netherlands). Polyvinyl alcohol (PVA, average MW 30,000-70,000) was obtained 
from Sigma Chemical Co. (St. Louis, Mo). Poly(L-lactic acid) (end-capped, molecular 
weight as indicated by supplier 26,000 g/mol; intrinsic viscosity 0.9 dl/g (chloroform 
25°C)) was obtained using stannous octoate as initiator (residual amount <100 ppm) 
and was supplied by Purac Biochem BV (Gorinchem, The Netherlands). Ethylene 
dinitrilotetraacetic acid disodium salt dihydrate (EDTA, ≥99.0%) and zinc sulfate 
heptahydrate (ZnSO4.7H2O, >99.5%) were obtained from Merck (Darmstadt, 
Germany).  
 
4.2.2 Methods 
4.2.2.1 Preparation of the Ho-acetylacetonate complex  
The complex of holmium with acetylacetone (further abbreviated as HoAcAc) was 
prepared and characterized as described previously [7,12]. In short, acetylacetone (180 
g) was dissolved in 1080 g water. The pH of this solution was brought to 8.5 with an 
aqueous solution of NH3 (28.4% (v/v)). Holmium chloride (10 g in 30 ml water) was 
added to this solution, and HoAcAc crystals were formed at room temperature in 24h. 
The crystals were collected by filtration, washed with water and dried under nitrogen.  
 
4.2.2.2 Preparation of HoAcAc-loaded microspheres  
HoAcAc-loaded poly(L-lactic acid) microspheres with different HoAcAc amounts 
were prepared by solvent evaporation as described previously [7]. As an example: 
HoAcAc (0-10 g) and PLLA (6 g) were dissolved in 186 g chloroform. The resulting 
homogeneous solution was added to an aqueous solution of PVA (1000 g water, 2% 
(w/w)). The mixture was stirred for 48h under nitrogen and the formed microspheres 
were collected by centrifugation and washed with water, 0.1 N HCl and water, 
respectively. The microspheres were suspended in water (around 4 g in 200 ml) and 
fractionated according to size using stainless steel sieves of 20 and 50 µm with a 
sprinkler system (Analysette 3 system, Fritsch GmbH, Idar-Oberstein, Germany) and 
dried under nitrogen.  
 
4.2.2.3 Preparation of holmium loaded poly(L-lactic acid) films 
In order to achieve a standardized and exact loading of poly(L-lactic acid) (PLLA) 
with HoAcAc, films of PLLA loaded with HoAcAc were prepared and obtained by 
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the following method: PLLA (0-2.5 g) and HoAcAC (0-1.6 g) were dissolved in 
chloroform (22.5 g). The resulting homogeneous and viscous solutions were poured 
onto a glass plate and the solvent was evaporated, resulting in films of 1-2 mm 
thickness, and a holmium loading ranging from 0-20% (w/w). All films were 
duplicated. 
 
4.2.2.4 Characterization of the microspheres and films  
4.2.2.4.1 Determination of the holmium and chlorine content  
The holmium content in the PLLA film and microspheres was determined by titration 
based on the method described for aluminum sulphate [13]. About 50 mg 
microspheres (accurately weighed) were dissolved in 10 ml dichloromethane. To this 
solution, 2 ml 1M HCl and 50 ml water were added. The resulting two phase system 
was stirred for two minutes and boiled until the dichloromethane had evaporated. 
After cooling to room temperature, 3 ml 0.04 M EDTA-solution and four droplets of 
methylene-red were added. Thereafter, an aqueous solution of 1 M NH4OH was added 
until the solution changed from reddish to yellow. The solution was then kept at 
100°C for 11 minutes. After cooling to room temperature, 50 mg xylenol-orange and 5 
g hexamethylenetetramine were added. The solution was brought to a pH of 5.0 with 1 
M HCl, and titrated with zinc sulfate heptahydrate (0.01 M).  
Chlorine content was determined by neutron activation (NRG, Petten, The 
Netherlands) [14]. 
 
4.2.2.4.2 Scanning electron microscopy 
Surface morphology of HoAcAc-loaded PLLA microspheres and films was evaluated 
by scanning electron microscopy using a Philips XL30 FEGSEM. A voltage of 5 or 10 
kV was applied. Samples of PLLA microspheres and films, as well as HoAcAc 
crystals, were mounted on aluminum stubs and sputter-coated with a Pt/Pd layer of 
about 10 nm. Holmium distribution on the surface of the microspheres was analyzed 
by an energy dispersive x-ray spectrometer (EDX). 
 
4.2.2.4.3 Differential scanning calorimetry  
The modulated DSC (MDSC) analysis was performed with a DSC 2920 (TA 
Instruments, Inc., New Castle, DE, USA, division of Waters Inc.). Samples of 
approximately 6 mg were transferred into aluminum pans. A small pin hole in the lid 
avoided possible pressure build-up during measurement. The sample compartment 
was purged with helium. Scans were recorded under “heating only” conditions, with a 
heating rate of 2°C/min and cooling rate of 1°C/min. The settings were periods of 60s 
and a temperature modulation amplitude of 0.32°C. The universal analysis software 
version V2.5.M was used in evaluation. The Tg-values were determined by taking the 
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half height between the baseline below and above the temperature range of the glass 
transition.  
 
4.2.2.4.4 Thermo-gravimetric analysis (TGA) 
HoAcAc-loaded microspheres and films, together with HoAAc crystals, were 
analyzed with a TGA51 thermogravimetric analyzer (TA Instruments, Inc., New 
Castle, DE, USA, division of Waters Inc.). Samples of about 15 mg were heated under 
nitrogen at a rate of 2°C/min, up to 1000°C.  
 
4.2.2.4.5 X-ray diffraction studies 
X-ray diffraction experiments were carried out on a Nonius κ-CCD diffractometer 
with sealed tube (powder diffraction experiments) or rotating anode (single-crystal 
diffraction experiments), using MoKα radiation with a graphite monochromator. 
Powder patterns were recorded at a sample-to-detector distance of 75 mm and the 
maximum scattering angle (2 θ) was 22°. Separate blank patterns were recorded in 
order to allow the subtraction of air-scattering. Single-crystal diffraction experiments 
were carried out under temperature control, with an Oxford Cryosystems Cryostream 
Cooler. 
 
4.2.2.4.6 Infrared spectroscopy 
Infrared spectra were recorded on a Bio-Rad FTS 6000 spectrometer (Cambridge, 
MA, USA), in the range of 400-4000 cm-1 (scan number 256, resolution 2 cm-1). 
Samples of microspheres, crushed HoAcAc crystals and films were prepared by 
mixing with spectroscopy grade KBr grain. The KBr mixture was then pressed into a 
pellet. Acetylacetonate was prepared by adding acetylacetone to an aqueous solution 
of NH3 (28.4% (v/v)), resulting in a concentrated acetylacetonate solution. 
Acetylacetone and prepared acetylacetonate were brought to the surface of KBr 
pellets. In addition to solid state IR experiments, samples of HoAcAc, films and 
microspheres were analyzed, in deuterated chloroform using a liquid cell with KBr 
windows.  
 
4.3 Results and Discussion 
4.3.1 Preparation of HoAcAc-loaded microspheres 
As reported previously, X-ray crystallography revealed that per mol HoAcAc, 3 moles 
of water are present (2 moles of water directly coordinated to Ho and 1 mole 
uncoordinated water) [12]. The microspheres prepared by the solvent evaporation 
method, with a size distribution (20-50 µm) suitable for radio-embolization therapy, 
were obtained with a yield of about 30% of the starting materials PLLA and HoAcAc. 
The loading of the microspheres with Ho was 17.0±0.6% holmium (w/w) (average 
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±s.d., n=5). Less than 0.3% (w/w) chloroform, based on chlorine content, was found 
in the holmium loaded microspheres.  
 
4.3.2 Scanning electron microscopy (SEM) 
Fig. 1 shows representative SEM pictures of films with 8 and 20% Ho loading. It is 
obvious that HoAcAc crystals are present in films with 20% Ho (Fig. 1b). In contrast, 
in films containing 8% Ho (w/w), no crystals could be observed. SEM analysis of 
films differing in HoAcAc content revealed that crystals were present at a loading 
≥12%. This indicates that below this concentration HoAcAc molecules are dispersed 
in the PLLA matrix, and it suggests the presence of PLLA/HoAcAc interactions. 
 
       
Fig. 1. Electron micrographs of films illustrating the forming of HoAcAc crystals at high 
loadings of holmium in the PLLA matrix (magnification 500x). (a) film with 8% holmium 
(w/w). (b) film with 20% Ho (w/w) loading resulted in crystals of HoAcAc (white arrows) 
surrounded with PLLA. 
 
 
In Fig. 2 a representative SEM picture of microspheres with a diameter of 20-50 µm is 
shown. It demonstrates that the particles are spherical and smooth. There were no 
HoAcAc crystals present on the surface of the microspheres, even at a Ho loading of 
17%. EDX showed a homogeneous dispersion of Ho on the surface layer of the 
microspheres. 
 
 
 
 
 
 
 
 
a b 
Chapter 4 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Electron micrograph of microspheres with a loading of 17% 
(w/w) Ho demonstrating the spherical structure and the smooth 
surface of the particles. 
 
 
4.3.3 Differential scanning calorimetry and thermo-gravimetric analysis 
4.3.3.1 PLLA films and microspheres without holmium 
Representative MDSC scans of PLLA films and microspheres, with and without 
HoAcAc, are shown in Figs. 3 and 4; Table 1 summarizes the results. MDSC 
thermograms of PLLA (as received), a PLLA film and microspheres without 
holmium, showed a melting temperature (Tm) of about 176°C and melting enthalpy of 
54, 46 and 57 J/g, respectively. The melting enthalpy and Tm for PLLA is in complete 
agreement with data published previously [15-17], and suggests a high degree of 
crystallinity (∆H for fully crystalline monodisperse lactic acid oligomers amounted to 
93 J/g [18]. During the first heating a small Tg was observed at 66°C for PLLA (as 
received), at 49°C for PLLA film and at 58°C for empty microspheres (Table 1). 
During cooling following the first heating, which means that the thermal history of the 
samples was destroyed, a Tg of around 66°C was observed in all three PLLA samples.  
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Table 1. Transition temperatures of PLLA samples with varying HoAcAc loadings (n=2-5) 
 
appearance Tg 
(°C) 
T1 max 
 (°C) 
∆H1 
(J/g) 
T2 max 
 (°C) 
∆H2 
(J/g) 
Tm max 
PLLA 
(°C) 
*enthalpy  
(J/g) 
 
PLLA  
(as recieved ) 
 
66±1 
 
 
--- 
 
--- 
 
--- 
 
--- 
 
176±0 
 
 
54±3 
 
 
PLLA film 
0% Ho 
 
49±2 
 
 
--- 
 
--- 
 
--- 
 
--- 
 
177±0 
 
 
46±1 
 
 
PLLA film 
4% Ho 
 
50±6 
 
 
nd 
 
nd 
 
nd 
 
nd 
 
168±1 
 
 
62±6 
 
 
PLLA film 
8% Ho 
 
52±10 
 
 
54±10 
 
6±2 
 
88±5 
 
 
8.8±2 
 
165±0 
 
 
60±3 
 
 
PLLA film 
12% Ho 
 
nd 
 
44±6 
 
 
18±4 
 
 
84±6 
 
 
29±16 
 
 
164±1 
 
 
64±4 
 
 
PLLA film 
16% Ho 
 
nd 
 
40±5 
 
 
24±2 
 
 
87±2 
 
 
84±7 
 
 
163±1 
 
 
53±9 
 
 
PLLA film 
20% Ho 
 
nd 
 
44±8 
 
 
29±14 
 
 
87±4 
 
 
112±28 
 
 
163±1 
 
 
51±6 
 
 
Microspheres 
without Ho 
 
58±2 
 
--- 
 
--- 
 
--- 
 
--- 
 
176±0 
 
 
57±4 
 
 
Microspheres 
with Ho 7% 
 
56±3 
 
nd 
 
nd 
 
nd 
 
nd 
 
163±0 
 
41±7 
 
Microspheres 
with Ho 17% 
 
59±2  
 
nd 
 
nd 
 
nd 
 
nd 
 
159±1 
 
 
25±12 
 
 
*Corrected for HoAcAc loading. nd = not detectable. Tg in the first heating; Tmax, ∆H: as in 
Fig. 3. 
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Fig. 3. MDSC thermograms of films with 0% (A), 4% (B), 8% (C), 12% 
(D), 16% (E) and 20% (w/w) Ho loading (F). Trace G shows HoAcAc. 
T1max and T2max: peak maximum of first and second endotherm, ∆H1 and 
∆H2: enthalpy of first and second endotherm, Tm: melting temperature, 
∆Hm: enthalpy of melting endotherm. 
 
 
 
Fig. 4. MDSC thermograms of PLLA microspheres with 0% (A) and 17% 
(w/w) Ho loading (B).  
 
 
T2 max 
T1 max Tm û+2 
û+1 
û+m 
A 
B 
Tm 
Tc 
Tg 
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4.3.3.2 Holmiumacetylacetonate 
A weight loss of about 10-14% was observed from TGA analysis of freshly prepared 
HoAcAc crystals beginning at a temperature of 50°C, when this sample was heated 
from room temperature to 120°C. This is most likely ascribed to the loss of the three 
water molecules present in the HoAcAc asymetric unit cell [12]. TGA showed a 
substantial weight loss above 200°C, indicating decomposition of HoAcAc. The 
residual weight is around 40% and indicates the presence of Ho2O3. MDSC 
thermograms (Fig. 5) of freshly prepared HoAcAc crystals showed two endotherms at 
temperatures around 64 and 95°	
 
2). These endotherms were almost totally present in the non-reversing signal and not 
in the reversing signal, and were not detected in the second heating run (Fig. 5).  
 
Table 2. Transition temperatures of HoAcAc crystals (n=3-8) 
 
appearance Tg cooling 
(°C) 
T1 max 
 (°C) 
∆H1 
(J/g) 
T2 max 
 (°C) 
∆H2 
(J/g) 
 
HoAcAc1 
 
 
47±3 
 
 
64±5 
 
 
78±20 
 
 
95±4 
 
 
149±9 
 
 
HoAcAc2 
 
 
60±3 
 
55±6 
 
 
76±9 
 
 
91±1 
 
 
103±11 
 
 
Tg: glass transition temperature observed by cooling down the sample (Fig. 5), Tmax: peak 
maximum of first or second endotherm, ∆H: enthalpy of first or second endotherm (Fig. 3, 
trace f). 1HoAcAc freshly prepared, 2HoAcAc recrystallized in chloroform.  
 
 
Additionally, in the cooling curve and in the second heating a strong Tg was observed 
in the reversing heat flow signal at around 47°C. This indicates that the first 
endotherm is due to the evaporation of the non-coordinating water molecule, whereas 
the second endotherm is due to evaporation of the two coordinating water molecules. 
We have recently deployed X-ray diffraction in the investigation of the effect of 
HoAcAc monohydrate crystals upon heating. The crystallographic unit cell of this 
compound contains 4 non-coordinating water molecules and 4 Ho-complexes, with a 
total of 8 coordinated water molecules [12]. At 40°C the unit cell volume is 
1999.9±1.0 Å3, slightly higher than the value found at -123°C (1966.1±0.9 Å3 [12]). 
When the crystals are heated to 50°C, the diffraction pattern changes dramatically. 
The high resolution reflections all become very weak and most of them can no longer 
be observed. The volume of the unit cell drops to 1873±3 Å3. 
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Fig. 5. MDSC thermograms of holmiumacetylacetonate. Heat flow (curve A). T1max and 
T2max: peak maximum of first and second endotherm of HoAcAc. Reversing heat flow 
(curve B) is given in an enlarged scale, shown on the right y-axis (first heating: dotted line), 
Tg is glass transition temperature. Non-reversing heat flow (curve C). 
 
 
Interestingly, this decrease in volume of 127 Å3 corresponds with the volume of 4 
water molecules in liquid water (119.7 Å3). Unfortunately, the modification of 
HoAcAc obtained at 50°C is unstable. After a few minutes even the low resolution 
reflections can no longer be observed. Collection of a full data set and complete 
structure determination is therefore impossible.  
It is interesting to note that, in the MDSC thermograms of HoAcAc aged at room 
temperature for 4 months, only an endotherm around 95°C (∆H=153 J/g) was 
observed. This means that with ageing the non-coordinating water molecule is 
removed. When HoAcAc crystals (either freshly prepared or aged) were dissolved in 
chloroform, followed by slow evaporation of the solvent, a powder-like material was 
obtained. MDSC analysis showed the same two endotherms as in freshly prepared 
crystals. From the results presented above, it can be concluded that by heating the 
HoAcAc crystals to 50°C, the non-coordinating water is removed, and this is 
associated with a concomitant conversion of the crystalline to the amorphous state, 
which underscores the important role of this water molecule for the crystal structure of 
HoAcAc [12]. We observed that the loss of crystal water occurs at a higher 
cooling 
first heating 
Second heating 
T2max 
T1max 
Tg  
cooling 
first heating 
Second heating 
A 
B 
C 
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temperature (120°C), when the heating rate was increased from the routinely applied 
2°C /min to 10°C /min. Mumper et al. [6] also observed a thermal effect at 121°C, ∆H 
104 J/g, using the latter heating rate, but erroneously ascribed this to a melting 
endotherm.  
Fig. 6 (trace A-C) shows the IR bands of acetylacetone, acetylacetonate and 
HoAcAc in the C=C and C=O region (1700-1500 cm-1) [19-22]. The results are 
summarized in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. IR spectra of acetylacetone (A), acetylacetonate (B), HoAcAc (C) and films with 4% 
(D) and 16% (w/w) Ho loading (E). 
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After addition of an aqueous solution of NH3, by which the acetylacetonate anion is 
formed, as well as a carbonyl band (1620 cm-1), the stretching vibration C=C 
(1537cm-1) band is also observed. In HoAcAc the C=O and C=C stretching vibrations 
are shifted to lower wave numbers (1610 and 1517 cm-1). When HoAcAc crystals 
were heated to 80°C (15 min), by which method amorphous HoAcAc is formed as 
seen by X-ray diffraction and MDSC, no difference in C=O and C=C vibration bands 
was observed (not shown). HoAcAc crystals dissolved in deuterated chloroform gave 
two bands at 1621 and 1603 cm-1 respectively, indicating that in solution one of the 
three acetylacetonate anions (partially) dissociates from the complex, resulting in Ho3+ 
coordinated by two acetylacetonate anions.  
 
 
4.3.3.3 HoAcAc-loaded films  
Ho loaded PLLA microspheres and films were prepared from a solution of PLLA and 
HoAcAc in chloroform. Fig. 3 shows the MDSC thermograms of PLLA films, with 
varying Ho loading. Due to the irreversible changes which HoAcAc undergoes, 
thermograms were recorded over the first run only. It appears that up to 8% Ho 
content no signal due to HoAcAc was observed (Fig. 3 trace B and C). This suggests 
that, in agreement with SEM analysis, HoAcAc is molecularly dispersed in the PLLA 
matrix at concentrations of <8% Ho (w/w). The dispersed HoAcAc in the PLLA 
matrix explains very well the observed decreased Tm of the PLLA phase (from 176°C 
to 163°C, Table 1). At higher loadings of Ho (≥12%) clear endotherms (evaporation 
of crystal water, Fig. 3 trace D-F) were observed. This demonstrates that, in 
agreement with SEM (Fig. 1b), above this loading HoAcAc is also present in its 
crystalline form. The melting enthalpy of PLLA increased from 46 J/g to around 60 
J/g in films with a relatively low HoAcAc loading (Table 1) and this suggests that 
HoAcAc acts as a crystallization nucleus for PLLA. Due to the high crystallinity of 
the PLLA matrix no clear Tg could be detected.  
IR spectra of films with 16% holmium loading showed that the C=O vibration of 
AcAc was detected at the same wave number as for HoAcAc crystals (1610 cm-1, Fig. 
6 trace C, E and Table 3). In contrast, in films with a low loading (4%) the C=O 
vibration was observed at both 1622 and 1606 cm-1, Fig. 6 trace D and Table 3). Since 
the band at 1622 is indicative of the acetylacetonate anion (Fig. 6 trace B, Table 3), 
this suggests that in films with the 4% loading, some of the carbonyl groups of AcAc 
do not interact with the Ho3+ ion. The remaining positive charge is then a candidate 
for interaction with carbonyl oxygens present in PLLA
 
of which only a minor portion 
can interact due to their large molar excess over holmium (seven-fold in case of the 
highest holmium loading of 17%). As expected, no detectable changes in the C=O 
band of PLLA (1760 cm-1) were observed since any shift will be obscured by the 
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strong absorption band of the remaining, non-coordinating C=O bonds. The reactions 
that are supposed to occur are: 
C=O band of A) HoAcAc at 1610 cm-1; B) PLLA at 1760 cm-1; C) acetylacetonate 
anion at 1623 cm-1 
 
 
 
Table 3. Summary of infrared data  
 
appearance 
 
(C=O)  
 
(cm-1) 
(C=C) 
 
(cm-1) 
 
 
Acetylacetone 
 
1626 
 
np 
 
Acetylacetonate 
 
1620 
 
1537 
 
HoAcAc 
 
1610 
 
1517 
 
PLLA film 4% Ho 
 
1622, 1606 db 
 
1525 
 
PLLA film 16% Ho 
 
1610 
 
1522 
 
Microspheres with Ho 17% 
 
1623, 1610 db 
 
1525 
 
(C=O), (C=C): stretching vibrations, np = not present, db = double band. 
 
 
 
4.3.3.4 Microspheres 
Fig. 4 shows the MDSC thermograms of empty as well as HoAcAc-loaded 
microspheres. MDSC thermograms of microspheres with 7% holmium loading 
showed no signals, due to HoAcAc, thus indicating that correspondingly with 
HoAcAc-loaded films, HoAcAc is dissolved in the microspheres. Interestingly, 
microspheres with a high Ho loading, 17%, (Fig. 4 trace B) did not show signals 
ascribable to crystalline HoAcAc. This means that in contrast to films with a 
comparable Ho loading (Fig. 3 trace E), HoAcAc was present in an amorphous state. 
OO
Ho
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SEM analysis also suggested the absence of HoAcAc crystals in PLLA microspheres 
(Fig. 2). Furthermore, a strong decrease in enthalpy of fusion of the PLLA phase was 
observed (∆H=25 J/g, Table 1) and now a strong Tg (59°C, with relaxation peak in the 
first heating run [23], Fig. 4) was present, especially in the reversing heat-flow. These 
factors indicate that the PLLA phase has a low degree of crystallinity, and this accords 
well with powder diffraction, (see section 4.3.4). The apparently better dispersion of 
HoAcAc in PLLA microspheres, when compared with PLLA films, may be ascribed 
to the relatively faster removal of the solvent during microsphere preparation. This 
results in a more rapid solidification of the PLLA matrix, which will impede the 
crystallization of both PLLA and HoAcAc.  
The IR spectrum of HoAcAc loaded microspheres showed, as in the films with a 
low loading, a C=O vibration of HoAcAc at both 1623 and 1610 cm-1. This again 
suggests that carbonyl groups of PLLA can interact with the HoAcAc complex, 
resulting in the immobilization of this complex in the PLLA matrix. This in turn 
explains the low release characteristics of the HoAcAc loaded microspheres. 
 
4.3.4 X-ray powder diffraction 
X-ray diffraction on films with a relatively low HoAcAc loading showed the presence 
of a crystalline PLLA phase, whereas,  as in both MDSC and SEM, no HoAcAc 
crystals were detected (Fig. 7). A broad peak appeared, which we assign to Ho-Ho 
interactions (due to their large scattering power) in the amorphous state. The distance 
associated with the peak maximum is about 16 Å, which does not correspond with 
normal Ho-Ho distances in crystalline HoAcAc. However, at a higher loading (16% 
Ho (w/w)) a crystalline PLLA phase, as well as crystalline and amorphous HoAcAc 
was observed. The crystalline form can be assigned to crystal form I as described in a 
previous paper [12]. In agreement with MDSC data, X-ray diffraction analysis showed 
a strongly reduced crystallinity of the PLLA matrix in HoAcAc loaded microspheres 
compared with unloaded microspheres. Interestingly, microspheres with a high 
HoAcAc loading again showed a large broad peak, which we ascribed to Ho-Ho 
interactions in the amorphous state. This means that in PLLA microspheres, HoAcAc 
is incorporated in an amorphous way. These observations suggest that it is associated 
with amorphous PLLA, and explains the amount of HoAcAc that can be 
accommodated in the PLLA matrix. 
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Fig. 7. X- 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shifted upwards by 55000 units. Lower curves: microspheres of PLLA (thick line) and 
microspheres of PLLA loaded with 17% Ho (thin line). Upper curves: film of PLLA (thick 
line), film of PLLA loaded with 4% Ho (thin line) and film of PLLA loaded with 16% Ho 
(thin dashed line). In the latter curve, peaks either correspond to crystalline PLLA, 
amorphous Ho-Ho or crystalline HoAcAc (crystal form I). 
 
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4.4 Conclusions 
Poly(L-lactic acid) microspheres, films and microspheres with different holmium 
acetylacetonate contents were prepared, in order to get insight into factors responsible 
for the low release properties of the holmium loaded microspheres. MDSC, X-ray 
diffraction and SEM analysis revealed that HoAcAc is molecularly dispersed in PLLA 
up to 8% (w/w) holmium in films. This indicates that interactions are present between 
HoAcAc and PLLA. Above this concentration HoAcAc is also present in a crystalline 
form. In contrast, in PLLA microspheres HoAcAc is present in an amorphous form 
and is molecularly dispersed in the amorphous PLLA phase, even at higher HoAcAc 
loadings. IR spectroscopy produced evidence of the type of interaction between 
HoAcAc and PLLA. Carbonyl groups of PLLA are likely to interact with the Ho-ion 
in the HoAcAc complex, and as a result this complex is immobilized in the PLLA 
matrix. This interaction thus accounts for the  high stability (= low release) found in 
HoAcAc-loaded microspheres.  
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Abstract
Holmium-loaded microspheres are useful systems in radio-embolization therapy of liver
metastases. For administration to a patient, the holmium-loaded microspheres have to be
irradiated in a nuclear reactor to become radioactive. In this paper the influence of neutron
irradiation on poly(L-lactic acid) (PLLA) microspheres and films, with or without
holmium acetylacetonate (HoAcAc), is investigated, in particular using differential
scanning calorimetry (MDSC), scanning electron microscopy, gel permeation
chromatography (GPC), infrared spectroscopy, and X-ray diffraction. After irradiation of
the microspheres, only minor surface changes were seen using scanning electron
microscopy, and the holmium complex remained immobilized in the polymer matrix as
reflected by a relatively small release of this complex. GPC and MDSC measurements
showed a decrease in molecular weight and crystallinity of the PLLA, respectively, which
can be ascribed to radiation induced chain scission. Irradiation of the HoAcAC loaded
PLLA matrices resulted in evaporation of the non-coordinated and one coordinated water
molecule of the HoAcAc complex, as evidenced by MDSC and X-ray diffraction analysis.
Infrared spectroscopy indicated that some degradation of the acetylacetonate anion
occurred after irradiation. Although some radiation induced damage of both the PLLA
matrix and the embedded HoAcAc-complex occurs, the microspheres retain their
favourable properties (no/marginal release of Ho, preservation of the microsphere size),
which make these systems interesting candidates for the treatment of tumours by radio-
embolization.
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5.1 Introduction
Poly(L-lactic acid) (PLLA) is a biodegradable and biocompatible, semi-crystalline
polymer that can be used for the preparation of microspheres loaded with neutron-
activatable Ho-complexes [1,2] or radioactive yttrium and rhenium salts [3-5]. These
systems are presently under investigation in the field of internal radio-embolization.
Especially liver metastases, which cause 25-50% of all cancer deaths [6-8], can
potentially be treated with such radioactive particles through embolization of the
hepatic artery [9-13]. Currently, both glass and resin-based microspheres with
radioactive yttrium are applied for treatment of liver metastases and beneficial effects
are reported [10,11,14]. However, glass has some drawbacks such as its high density
and non-degradability. Therefore, biodegradable and biocompatible materials like
PLLA are in favour over glass. In a previous paper we described the preparation and
characterisation of PLLA microspheres loaded with holmium acetylacetonate
(HoAcAc) [2]. For therapeutic application of these microspheres they have to be
irradiated with neutrons to become radioactive. The radioactive microspheres are
administered into the hepatic artery and will be trapped in the liver especially in and
around tumours [2,5]. Only marginal leakage of radioactive holmium should occur. In
a previous study only small amounts of free holmium (Ho) were found during in vitro
experiments. For example, the retention of Ho in irradiated microspheres is over 98%
after 192h (>7 half-lives) incubation in liver homogenate [2].
The neutron irradiation together with the simultaneously generated gamma rays, as
well as secondary gamma rays caused by the H(n,γ) and Ho(n,γ) reactions [15,16], can
result in damage to both the PLLA matrix and the entrapped HoAcAc complex. γ-
Irradiation is applied as a sterilisation method for PLLA and therefore its effects on
PLLA have been investigated extensively. After γ-irradiation of PLLA a decrease in
molecular weight is observed [17,18], which is caused by chain scission due to radical
formation [19]. Chain scission occurs predominantly in the amorphous phase of the
polymer [1,19,20]. This could imply that after neutron irradiation similar processes in
PLLA matrices would occur. However, irradiation in a nuclear reactor differs from γ-
irradiation by higher linear energy transfer (LET) of nuclear interaction products
leading to high radiation doses. Thus far, no systematic studies of the effect of neutron
irradiation on PLLA have been published. Therefore, we investigated the influence of
neutron irradiation on PLLA films and microspheres with and without HoAcAc using
a variety of techniques: scanning electron microscopy (SEM), gel permeation
chromatography (GPC), differential scanning calorimetry (MDSC), X-ray diffraction
and infrared spectroscopy (IR).
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5.2 Materials and Methods
5.2.1 Materials
All chemicals were commercially available and used as obtained. Acetylacetone, 2,4-
pentanedione, (AcAc; MW 100.12; >99%) was obtained from Sigma Aldrich
(Steinheim, Germany). Holmium(III) chloride hexahydrate (HoCl3.6H2O; MW
379.38; 99.9%) was obtained from Phase Separations BV (Waddinxveen, The
Netherlands). Polyvinyl alcohol (PVA, average MW 30,000-70,000) was obtained
from Sigma Chemical Co. (St. Louis, Mo, USA). Poly(L-lactic acid) (end-capped;
intrinsic viscosity 0.9 dl/g (chloroform 25˚C)) was supplied by Purac Biochem BV
(Gorinchem, The Netherlands). Ethylenedinitrilotetraacetic acid disodium salt
(dihydrate) (EDTA, ≥99.0%) and zinc sulphate heptahydrate (ZnSO4.7H2O, >99.5%)
were obtained from Merck (Darmstadt, Germany).
5.2.2 Methods
5.2.2.1 Preparation of the HoAcAc loaded films and microspheres
Films and microspheres of PLLA loaded with HoAcAc were prepared as described
previously [2,21,22]. Briefly, acetylacetone was dissolved in water. The pH of this
solution was brought to 8.5 with an aqueous solution of NH3. Holmium chloride in
water was added to this solution after which HoAcAc crystals were formed at room
temperature. The crystals were collected by filtration. HoAcAc loaded films were
prepared by dissolving PLLA and HoAcAc in chloroform. The resulting
homogeneous and viscous solutions were poured onto a glass plate and the solvent
was evaporated, resulting in films of 1-2 mm thickness, and a holmium loading range
of 0, 4 and 16% (w/w). HoAcAc-loaded poly(L-lactic acid) microspheres with
different HoAcAc amounts were prepared by solvent evaporation as described
previously [2]. HoAcAc and PLLA were dissolved in chloroform. The resulting
homogeneous solution was added to an aqueous solution of PVA. The mixture was
stirred and the formed microspheres were collected by centrifugation. Microspheres
with a size of 20-50 µm were obtained by sieving.
5.2.2.2 Irradiation
Irradiations were performed in the pneumatic rabbit system (PRS) in the reactor
facilities in Petten, The Netherlands. The PRS (neutronflux 5x1013 cm-2.s-1)
irradiations were carried out on samples of 100-200 mg, which were packed in
polyethylene vials. The irradiation time was 0.5 and 1h. The 1h irradiation resulted in
an estimated radiation dose of 2 MGy (personal communication, NRG, Petten, The
Netherlands) and gives an amount of microsphere associated radioactivity needed for
the treatment of a patient. Analyses were performed after a cooling time of 1 month.
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5.2.2.3 Characterization of microspheres and films
5.2.2.3.1 Determination of holmium content
The holmium content in the PLLA film and microspheres was determined by titration
based on the method described previously [22].
5.2.2.3.2 Scanning electron microscopy
Surface morphology of HoAcAc-loaded PLLA microspheres and films was
investigated by scanning electron microscopy using a Philips XL30 FEGSEM. A
voltage of 5 or 10 kV was applied. Samples of PLLA microspheres and films as well
as HoAcAc crystals were mounted on aluminium stubs and sputter-coated with a
Pt/Pd layer of about 10 nm. Holmium distribution was analysed by an energy
dispersive x-ray spectrometer (EDX) that was integrated in the scanning electron
microscope.
5.2.2.3.3 Differential scanning calorimetry
Modulated DSC (MDSC) analysis was performed with a DSC 2920 (TA Instruments,
Inc., New Castle, DE, USA). Samples of approximately 6 mg were transferred into
pierced aluminium pans. The sample compartment was purged with helium. Scans
were recorded under “heating only” conditions, with a heating rate of 2°C/min and
cooling rate of 1°C/min. The settings were periods of 60 s and temperature
modulation amplitude of 0.32°C. The universal analysis software version V2.5.M was
used for evaluation.
5.2.2.3.4 Infrared spectroscopy
Infrared spectra were recorded on a Bio-Rad FTS 6000 spectrometer (Cambridge,
MA, USA), in the range of 400-4000 cm-1 (scan number 256, resolution 2 cm-1).
Samples of  microspheres, HoAcAc crystals and films (irradiated or non-irradiated)
were prepared by mixing with spectroscopy grade KBr grain and then pressed into a
pellet. Acetylacetonate was prepared by adding acetylacetone to an aqueous solution
of NH3, resulting in a concentrated acetylacetonate solution. Acetylacetone and
prepared acetylacetonate were brought on to the surface of KBr pellets. In addition to
solid-state IR experiments, samples of HoAcAc, films and microspheres were
analysed after dissolution in deuterated chloroform using a liquid cell with CaF2
windows.
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5.2.2.3.5 X-ray diffraction studies
X-ray diffraction experiments were carried out on a Nonius κ-CCD diffractometer
with sealed tube (powder diffraction experiments) or rotating anode (single-crystal
diffraction experiments), using MoKα radiation with a graphite monochromator.
Powder patterns were recorded at a sample-to-detector distance of 75 mm and the
maximum scattering angle (2 θ) was 22˚. Separate blank patterns were recorded in
order to allow the subtraction of air-scattering.
5.2.2.3.6 Molecular weight determinations
The weight-average molecular weight (Mw) and number-average molecular weights
(Mn) of PLLA were determined by gel permeation chromatography (GPC). GPC
measurements were performed with two thermostated (35°C) columns in series (PLgel
Mixed-B, Polymer Laboratories) equipped with an evaporative light scattering
refractive index detector (PL-ELS 1000, Polymer Laboratories). Samples of
approximately 1 mg were dissolved in 2 ml HPLC-grade chloroform and filtered.
Elution was performed with chloroform and the flow-rate was 1 ml/min. The columns
were calibrated using poly(styrene) standards of known molecular weights (Polymer
Laboratories, Shodex and Tosoh).
5.3 Results and Discussion
5.3.1 Scanning electron microscopy
For therapeutic application of the HoAcAc loaded microspheres, the size has to be
preferably between 20 and 50 µm [23,24,25]. Therefore it was investigated whether
the size distribution had altered after neutron irradiation. Since neutron irradiation is
associated with an increase in temperature, fusion of microspheres may occur. SEM
and particle size measurements demonstrated that no substantial particle fusion
occurred. However, surface changes on the microspheres were seen with SEM giving
rise to small PLLA fragments (Fig. 1). Similar fragments were seen on irradiated
films. However, the amount of radioactivity in particles with a size <20 µm is still
marginal (1% and 3% before and after irradiation, respectively) [2].
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Fig. 1. Electron micrographs of microspheres with a loading of 17% (w/w) Ho, magnification
500x. Non-irradiated microspheres have a spherical structure and smooth surface (a). After
irradiation only small surface changes were seen (white arrow; b).
5.3.2 Differential scanning calorimetry
Films and microspheres both with and without Ho loading were analysed with MDSC.
Table 1 (films) and table 2 (microspheres) summarise the results. Irradiation of films
without holmium resulted in a decreasing Tm and slightly decreased enthalpy of fusion
with increasing irradiation time (Table 1 and Fig. 2 trace A) indicating impairment of
the crystalline phase of PLLA after neutron irradiation [1,19]. In contrast to the non-
irradiated films (small Tg observed at 66°C), in the irradiated film (1h) a clear Tg was
seen at 35°C both during cooling and in the second run, indicating a loss in
crystallinity. The PLLA film in which HoAcAc was molecularly dispersed (4% Ho
(w/w) [22]) also showed a decreasing Tm of the PLLA phase with increasing
irradiation dose (Fig. 2 trace B). Again, a Tg was seen during cooling and the second
run for irradiated films (Table 1). In 1h irradiated PLLA films with HoAcAc present
in its crystalline form (16% (w/w) Ho-loading) no Tm was observed, indicating a
complete loss of crystallinity of the PLLA phase (Table 1). The decrease in Tm and
enthalpy of fusion in Ho-loaded films was more extensive in comparison with
unloaded films, which can probably be explained by secondary irradiation damage due
to the radioactive holmium. In the non-irradiated films with 16% Ho (w/w) two other
endotherms were observed besides the PLLA melting endotherm: the first endotherm
(40°C) is due to the evaporation of the non-coordinating water molecule, and the
second endotherm (87°C) is due to evaporation of the two coordinating water
molecules [22]. After irradiation the first endotherm at 40˚C was absent (Fig. 2 trace
C) which can be explained by a rise in temperature up to 50°C (personal
communication, NRG, Petten, The Netherlands) during irradiation resulting in
evaporation of the non-coordinating water molecule. The second endotherm showed a
50-60% reduction in enthalpy which suggests that one of the coordinated water
molecules did evaporate resulting in only one water molecule firmly attached to the
Ho-ion, which in turn can explain the increase in T2 max (Table 1). The loss of this one
a) b)
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coordinated water molecule is most likely caused by irradiation damage and not by
heating, since the reactor temperature does not rise above 50°C.
Table 1. Transition temperatures of PLLA films with varying HoAcAc loadings (n=4-10)
Irradiation
time
(h)
Appearance Tg
(°C)
Tg c/2
(°C)
T1 max
(°C)
∆H1
(J/g)
T2 max
(°C)
∆H2
(J/g)
Tm max
PLLA
(°C)
*enthalpy
(J/g)
0 PLLA film
0% Ho
49±2 66/nd --- --- --- --- 177±0 46±1
0.5 PLLA film
0% Ho
nd nd --- --- --- --- 154±1 47±2
1 PLLA film
0% Ho
nd 35/35 --- --- --- --- 136±2 32±7
0 PLLA film
4% Ho
50±6 nd nd nd nd nd 168±1 62±6
0.5 PLLA film
4% Ho
nd 55/55 nd nd nd nd 149±1 44±3
1 PLLA film
4% Ho
nd 46/46 nd nd 127±7 9±12 133±1 28±3
0 PLLA film
16% Ho
nd nd 40±5 24±2 87±2 84±7 163±1 53±9
0.5 PLLA film
16% Ho
nd 55/57 nd nd 93±3 35±5 138±3 39±8
1 PLLA film
16% Ho
nd 54/54 nd nd 97±2 37±3 nd nd
*Corrected for HoAcAc loading. nd = not detectable. Tg c/2= Tg cooling/ Tg second heating,
Tmax, ∆H: as in Fig. 2.
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Fig. 2. MDSC thermograms of films with 0% (A), 4% (B) and 16% (C) Ho (w/w) loading
irradiated for 0 (1), 0.5 (2) and 1h (3) in a nuclear reactor. For example: thermogravic signals
of HoAcAc and PLLA are both seen in the 16% (w/w) Ho loading marked with T1max and
T2max: peak maximum of first and second endotherm, ∆H1 and ∆H2: enthalpy of first and
second endotherm, the thermogravic signals of PLLA: Tm: melting temperature, ∆Hm:
enthalpy of melting endotherm.
Representative MDSC scans of empty microspheres irradiated for 0, 0.5 and 1h are
shown in Fig. 3 trace A. As observed for PLLA films, irradiated non-loaded
microspheres showed a decreased Tm and enthalpy of fusion with increasing
irradiation time (Table 2, Fig. 3). Further, the relaxation peak (at 58°C) and
recrystallisation exotherm were not observed after irradiation for 0.5h (Fig. 3,
compare trace A1 and A2). When the microspheres were irradiated for 1h a strong Tg
(34°C) in the second heating was observed (Fig. 4). As observed for HoAcAc loaded
films, microspheres with molecularly dispersed HoAcAc (7 and 17% Ho (w/w))
showed a decreased Tm and enthalpy of fusion of the PLLA phase with increasing
irradiation time (Table 2, Fig. 3 trace B). Irradiation of holmium loaded microspheres
for 1h showed no melting endotherm of PLLA indicating a total loss of crystallinity.
T1 max
Tm
∆H2
∆H1
∆Hm
0%
 H
o content
4%
 H
o content
16%
 H
o content
A1
A2
A3
B1
B2
B3
C1
C2
C3
Tm
Tm
Tm
Tm
Tm
T2 max
Tm
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Table 2. Transition temperatures of PLLA microspheres with varying HoAcAc
loadings (n=4-10)
Irradiation
time (h)
appearance Tg
(°C)
Tg second
heating (°C)
Tm max
PLLA (°C)
*enthalpy
(J/g)
0 Microspheres
without Ho
58±2 66±1 176±0 57±4
0.5 Microspheres
without Ho
51±1 46±0 151±1 40±1
1 Microspheres
without Ho
nd 34±2 133±0 30±1
0 Microspheres
with Ho 7%
56±3 nd 163±0 41±7
0.5 Microspheres
with Ho 7%
52±2 60±1 147±4 3±2
1 Microspheres
with Ho 7%
nd 60±3 nd nd
0 Microspheres
with Ho 17%
59±2 nd 159±1 25±12
0.5 Microspheres
with Ho 17%
57±3 57±2 147±2 4±2
1 Microspheres
with Ho 17%
58±4 62±2 nd nd
*Corrected for HoAcAc loading. nd = not detectable. Tg, Tmmax, ∆H: as in Fig. 3.
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Fig. 3. MDSC thermograms of microspheres without (A) and with (B) 17% Ho (w/w)
irradiated for 0 (1), 0.5 (2) and 1h (3). Given is the heat flow for first heating, cooling and
second heating. Tg is glass transition temperature, Tc is recrystallisation temperature and Tm is
melting temperature.
Fig. 4. Enlargement of the MDSC
thermogram of microspheres
without holmium (irradiation 1h).
Given is the heat flow for second
heating. Tg is glass transition
temperature, Tm is melting
temperature, ∆Hm is enthalpy of
melting endotherm. Clearly visible
is the broad peak (80-145°C)
existing of several peaks,
indicating a collection of polymer
chains with their own melting
temperatures.
5.3.3 Infrared spectroscopy
With increasing irradiation time of PLLA and holmium loaded PLLA microspheres
and films the intensity of a broad peak (range 3000-3600 cm-1, corresponding to
stretching vibrations of COOH end groups of PLLA chains) in the IR spectrum
0%
 H
o content
17%
 H
o content
A1
A2
A3
B1
B2
B3
Tc
Tg
first heating
Second heating
cooling
Tm
Tm
∆Hm = 31J/g
Tm = 133˚C
Tg = 34˚C
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increased and can be explained by radiation induced chain scission [26]. Tables 3A
and B summarise the observed frequencies of the C=O and C=C bands of AcAc in
different forms (non-complexed and complexed with Ho, and in PLLA matrices)
before and after neutron irradiation for 1h. Stretching vibrations of the C=O and C=C
bands of acetylacetonate in HoAcAc were observed at 1610 and 1517 cm-1),
respectively [22,27,28]. Remarkable was the additional peak observed around 1622/3
cm-1 of the C=O stretching vibration of acetylacetonate in PLLA films (4% loading)
and microspheres (17% Ho loading) [22]. Likely, some of the carbonyl groups of
acetylacetonate do not interact with the Ho3+ ion leaving the remaining positive charge
available for interaction with carbonyl oxygens present in PLLA [22]. After
irradiation of HoAcAc loaded films and microspheres the 1622/3 cm-1 due to the C=O
stretching vibration band was absent. The C=O band around 1600 and C=C stretching
band (around 1520 cm-1) showed a shift to lower wave number and a decrease in
intensity with increasing irradiation time. In contrast to non-irradiated Ho-loaded
PLLA matrices, in which two C=O bands were observed (1600/1 and 1620/1, Table
3B) after dissolution, irradiated Ho-containing films and microspheres showed only
one C=O band at 1601/2 cm-1. Moreover, the C=C stretching vibration observed in
irradiated films and microspheres after dissolution decreased in intensity (Table 3B).
The IR data indicate that some radiation induced structural changes of the
acetylacetonate anion had occurred.
Table 3A. Summary of solid state infrared data in the C=O and C=C region of AcAc of non
irradiated and irradiated (1h) samples.
Irradiation time
(h)
appearance ν(C=O)
(cm-1)
ν(C=C)
(cm-1)
0 PLLA film 4% Ho 1622, 1606 db 1525
1 PLLA film 4% Ho 1603 b 1521*
0 PLLA film 16% Ho 1610 1522
1 PLLA film 16% Ho 1605b 1520*
0 Microspheres with Ho 17% 1623, 1610 db 1525
1 Microspheres with Ho 17% 1597 1523*
0 Acetylacetonate 1620 1537
0 HoAcAc 1610 1517
ν(C=O), ν(C=C): stretching vibrations, db = double band, b = broad band, *lower intensity than
non-irradiated sample
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Table 3B. Summary of infrared data of samples dissolved in deuterated chloroform in the
C=O and C=C region of AcAc of non-irradiated and irradiated (1h) samples.
Irradiation time
(h)
appearance ν(C=O)
(cm-1)
ν(C=C)
(cm-1)
0 PLLA film 4% Ho 1620, 1601db 1522
1 PLLA film 4% Ho 1602 nd
0 PLLA film 16% Ho 1621, 1600db 1522
1 PLLA film 16% Ho 1601 1520*
0 Microspheres with
Ho 17%
1620, 1601db 1522
1 Microspheres with
Ho 17%
1601 1522*
0 Acetylacetonate 1620 1537
0 HoAcAc 1621, 1603db 1523
ν(C=O), ν(C=C): stretching vibrations, db = double band, *lower intensity as non-irradiated
sample, nd = not detectable
5.3.4 X-ray diffraction studies
X-ray diffraction analysis has been performed on non-irradiated PLLA-films with and
without HoAcAc [22]. X-ray analysis of irradiated (1h) PLLA films without Ho and
4% Ho loading showed only a small change in diffraction pattern indicating a
preserved crystallinity of the PLLA matrix (Fig. 5). This is in agreement with the
MDSC analysis (Table 1, Fig. 2). X-ray analysis also showed that HoAcAc complex
was strongly affected by neutron irradiation. The broad peak (Fig. 5) in films with 4 %
Ho (w/w) loading assigned to amorphous Ho-Ho interactions has disappeared,
indicating an increased disorder of Ho-Ho distances. After irradiation (1h) of the 16%
Ho-loaded (w/w) film the initially low crystallinity of PLLA was not detected
anymore. The amorphous HoAcAc component showed the same transformation as
was observed for films with 4% Ho (w/w). The crystalline form had changed after
irradiation in another unknown form. The diffraction pattern of crystalline HoAcAc in
the PLLA matrix changed after irradiation (Fig. 5). Now, a pattern was detected which
resembles the pattern of HoAcAc heated at 80˚C. It was shown that upon heating 2 to
3 of the (non-)coordinated water molecules were lost. Therefore, it is concluded, and
also evidenced by MDSC (Fig. 2), that similar conversions occur by neutron
irradiation in crystalline HoAcAc within the PLLA matrix.
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Fig. 5. X-ray scattered intensity as a function of the diffraction angle 2θ. Scaling is arbitrarily
applied to the curves so as to match the intensities at 2θ of 22˚. The upper three curves are
shifted upwards by 15000 units. Lower curves: films of PLLA loaded with 16% HoAcAc
(thin line) and loaded with 16% HoAcAc and irradiated (thin dotted line).Upper curves: film
of PLLA (thick line), film of PLLA loaded with 4% Ho (thin line) and film of PLLA loaded
with 4% Ho and subsequently irradiated (thin dotted line).
5.3.5 Molecular weight determinations
Table 4 summarizes the Mw and Mn of PLLA in non-irradiated and irradiated (1h)
films and microspheres. As reported for gamma irradiation of PLLA
[19,26,29,30,31,32] neutron irradiation of films and microspheres resulted in a
substantial decrease of the molecular weights. This indicates that chain scissions are
predominant over cross-linking when PLLA is irradiated with neutrons. In line
herewith, no gel fraction was found after dissolution of the irradiated PLLA films with
or without holmium in CHCl3. Radiation induced chain scission of the polymers can
occur by two mechanisms, namely via unzipping [19,33], and by random chain
cleavage of the polymer chain. Since the polydispersity (Mw/Mn) was hardly affected
after irradiation (1h) this indicates that chain scission occurs randomly [19,34].
2θ
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Table 4. GPC data of films and microspheres with varying HoAcAc loadings
Irradiation
time (h)
appearance Mw
(g/mol)
Mn
(g/mol)
poly
dispersity
0 PLLA film 0% Ho 93,000 45,000 2.1
1 PLLA film 0% Ho 6,500 2,700 2.4
0 PLLA film 4% Ho *50,000 25,000 2.0
1 PLLA film 4% Ho 9,200 4,300 2.1
0 PLLA film 16% Ho *45,000 *24,000 1.9
1 PLLA film 16% Ho 6,000 2,100 2.9
0 microspheres 0% Ho 94,000 *44,000 2.1
1 microspheres 0% Ho 5,200 2,400 2.2
0 microspheres 17%
Ho
*21,000 *10,000 2.1
1 microspheres 17%
Ho
3,400 1,500 2.3
*Apparent decrease in Mw and Mn is probably caused due to interactions of PLLA
and HoAcAc
5.4 Conclusions
This study shows that neutron irradiation of PLLA results in similar processes as
found for gamma-irradiation, namely a decrease in molecular weight and loss in
crystallinity. When the PLLA matrices were loaded with HoAcAc, besides damage to
the PLLA also some damage of the HoAcAc complex occurs. This paper
demonstrates that although some radiation induced damage of both the PLLA matrix
and the loaded HoAcAc-complex occurs, the microspheres retain their favourable
properties (no/marginal release of Ho, preservation of the microsphere size) which
makes these systems interesting candidates for the treatment of tumours by radio-
embolization.
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Abstract
Intra-arterial administration of beta-emitting particles that become trapped in the
vascular bed of a tumour and remain there while delivering high doses, comprises an
unique application in the treatment of both primary and metastatic liver tumours.
Studies on selective internal radiation therapy of colorectal liver metastases using
yttrium-90 glass microspheres have shown encouraging results. This study describes
the biodistribution of 37 µm poly lactic acid microspheres loaded with radioactive
holmium-166, after intra-arterial administration into the hepatic artery of rats with
implanted liver tumours. Radioactivity measurements showed >95% retention of
injected activity in the liver and its resident tumour. The average activity detected in
other tissues was ≤0.1 %ID/g, with incidental exceptions in lungs and stomach. Very
little 166Ho activity was detected in kidneys (<0.1 %ID/g), thereby indicating the
stability of the microspheres in vivo. Tumour targeting was very effective, with a
mean tumour to liver ratio of 6.1±2.9 for rats with tumour (n=15), versus 0.7±0.5 for
control rats (n=6; p<0.001). These ratios were not significantly affected by the use of
adrenaline. Histological analysis showed that 5 times as many large (>10) and
medium-sized (4-9) clusters of microspheres were present within tumour and
peritumoural tissue, compared with normal liver. Single microspheres were equally
dispersed throughout the tumour, as well as normal liver parenchyma.
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6.1 Introduction
The liver is one of the most common sites of metastatic cancer in human beings,
especially for metastases of colon and rectum carcinoma. Despite the advances in
radiotherapy, chemotherapy and immunotherapy, surgical excision of localised disease
is currently the only means of improving the survival in these patients [1]. However,
surgical resection of liver metastases of colorectal carcinomas is possible in only 10-
30% of all cases [2,3]. There is therefore a great need for the development of an
effective therapy. A promising alternative is intra-arterial radionuclide therapy. This
depends upon the arterial blood supply to the liver metastases, and the subsequent
infusion of the metastases with well-defined sized [4,5], radioactive microspheres.
Tumours from 1-2 mm acquire their oxygen and nutrients by diffusion and
transportation, thereafter the growth of the tumour depends mainly on angiogenesis
[6]. Newly formed vessels behave differently from the surrounding, well-established
vascular structures of the host tissue [7]. Tumour vessels are morphologically irregular
and have larger lumen. As the liver tumour grows, the new vessels derive their blood
(mainly) from the hepatic artery [8]. Administration of radioactive microspheres
therefore takes place via this artery. Administration of a vasoconstrictor results in the
constriction of vessels of the normal liver, while tumour vessels may not or may only
partially react to vasoconstrictors [9,10]. This results in an enhancement of the blood
flow to the tumour, since the increased resistance of the liver’s vascularization
enhances the blood flow to the open vascularization of the tumour vessels. The
radiation dose may consequently be maximised to the tumour and minimised to the
normal liver [9-11].
Encouraging results were obtained with yttrium-90 (90Y) glass and resin
microspheres [11-13]. The use of neutron activated holmium-166 (166Ho) for this type
of therapy is particularly suitable because of its favourable radiation characteristics
(Emax=1.84 MeV, Eγ=81 keV, t1/2=26.8h) and the 100% natural abundance of 
165Ho.
This led us to produce therapeutic amounts of 166Ho loaded poly lactic acid
microspheres of uniform size and high chemical stability in vitro illustrated by the fact
that more than 99.3% of 166Ho activity was retained in the microspheres after 192-h
(>7 half-lives) incubation in PBS, plasma and leucocytes suspended in PBS [14].
The purpose of this study was to investigate the biodistribution of 166Ho loaded poly
lactic acid microspheres of 20-50 µm (average diameter 37 µm) under influence of the
vasoconstrictor adrenaline in a tumourous rat model. Biodistribution was examined by
scintigraphic imaging and radioactivity measurements of rat livers, with and without
tumour, and of other organs. Microscopic distribution of the microspheres was
investigated after histological staining of dissected liver and tumour tissue, and this
corroborated the radioactivity data.
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6.2 Materials and methods
6.2.1 Animals
All experiments were performed in agreement with The Netherlands Experiments on
Animals Act (1977) and the European Convention for the Protection of Vertebrate
Animals used for Experimental Purposes (1986). Approval was obtained from the
University Animal Experiments Committee (FDC/DEC-GNK nr. 70044). The
experiments were performed using 21 male pathogen-free, inbred WAG/Rij rats
(WAG/Rij Crl BR; Charles River, Someren, The Netherlands) weighing 225-360 g.
The rats were housed in Macrolon cages with sawdust provided as bedding, 2 or 3
animals/cage. A standard pelleted rat maintenance diet (RMH-TM, Hope Farms,
Woerden, The Netherlands) and water were provided ad libitum.
6.2.2 Tumour cells
The medullary thyroid cell line was derived from the Department of Internal Medicine
(University Medical Center, Utrecht, The Netherlands). The original tumour cells were
obtained from a spontaneous medullary thyroid carcinoma of an aging WAG/Rij-rat.
The medullary thyroid cell line was propagated by subcutaneous passage of the back
of the rat. To facilitate implantation the donor rat was killed and the tumour tissue was
dissected. Small parts of firm tumour tissue were chosen for implantation.
6.2.3 Tumour implantation
The rats were anaesthetised with an intraperitoneal injection of Hypnorm® (0.1 ml/100
g, Janssen Pharmaceutical Beerse, Belgium) and intramuscular injection of
Dormicum® (0.05 ml/100 g, Roche Nederland B.V. Mijdrecht, The Netherlands). A
laparotomy was performed by ventral mid-line incision in order to expose the lobes of
the liver. In fifteen rats an incision was made in the cranial brim of the lobus sinister
lateralus and 0.5-1 mm3 tumour-tissue was implanted, together with a piece of
titanium to serve as localisation marker for ultrasound. Control rats (n=6) were sham
implanted by the injection of 0.5 ml saline. After approximately 20 days an ultrasound
investigation (HDI 3000 ATL, Entos CL10-5 transducer) was performed to check
tumour growth.
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6.2.4 Preparation of microspheres
Radioactive microspheres (Fig. 1) were prepared as previously described [14]. Briefly,
holmiumacetylacetonate is incorporated into poly lactic acid by solvent evaporation,
resulting in microspheres of 20-50 µm after sieving (mean 37 µm). Neutron activation
of the holmium loaded microspheres was performed by irradiation in the high-flux
nuclear reactor in Petten, The Netherlands. A neutron flux was used of 5x1013cm-2.s-1
(PRS-facility) for 1h. Neutron activated microspheres (80 MBq in 25 mg) were
suspended in 0.5 ml Gelofusine® (Vifor Medical SA, Switzerland) prior to
administration.
Fig. 1. Scanning electron micrograph of
166Ho microspheres demonstrating their
spherical shape. Average diameter is 37 µm
(magnification 1000x).
6.2.5 Administration of radioactive microspheres
When the tumour had reached a diameter of ≥5 mm, a second laparotomy was
performed in order to administer the 166Ho microspheres. The hepatic artery and the
gastroduodenal branch were identified and isolated at the three-way junction (Fig. 2).
The gastroduodenal artery and the coeliac artery to the aorta were ligated with two
wires (a1 and a2) and one wire (b), respectively. The gastroduodenal artery was
cannulated with a 27G needle with a blunt tip (Anterior Chamber Cannula 5006;
Visitec, USA). The wires a1 and b were tightened, obstructing the backflow of blood
to the gastroduodenal artery and the blood flow from the aorta. The needle was moved
up into the artery so that its tip layed just in the hepatic artery. In order to check the
flow to the liver, Gelofusine® (Vifor Medical SA, Switzerland) was administered
through the pre-flushed administration system. If backflow occurred, wire a2 (over the
needle) was tightened. The suspended radioactive microspheres were administered
with or without a bolus of 0.3 ml adrenaline (1mg/ml, Kombivet V.P. Etten- Leur, The
Netherlands) and the syringe with needle was measured for activity pre- and post-
injection, in order to calculate the injected dose exactly. The sling around the coeliac
artery was removed and the hepatic arterial circulation was restored.
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Fig. 2. Scheme of the
administration technique.
The gastroduodenal artery
was cannulated with a needle
with blunt tip and moved up
into the hepatic artery.
During administration wires
a1 and b were ligated.
6.2.6 Biodistribution studies
The rats were monitored by planar imaging, using a gamma camera (Elscint, Apex
609, Elscint Ltd., Israel) with pinhole collimator. A whole body scintigram was made
30 min and one day after administration, in order to determine gross distribution and
redistribution of radioactive microspheres. The rats were subsequently killed and the
activity in liver, tumour, heart, lungs, intestine, stomach, spleen, kidneys and the rest
of the rat was determined in a low background γ-counter. The results were expressed
as a percentage of injected dose/gram of tissue (%ID/g). Tumour and 2 mm of its
surrounding liver tissue was dissected to determine radioactivity, and defined as the
target tissue. The target to non-target ratio (T/N ratio) was calculated as the ratio
between activity per gram tumour target tissue, or tissue of the sham implantation site
in the control group, and activity per gram liver tissue.
Autoradiography of tissue samples was carried out using PhosphorImager exposure
cassettes (Molecular Dynamics GmbH, Krefeld, Germany). In order to investigate the
microscopic distribution of the microspheres, organs were fixed in phosphate-buffered
4% formaldehyde. The liver lobe with tumour (lobus sinister lateralus) was embedded
in paraffin wax, sectioned in 6 µm coupes, taken every 60 µm transversal on the
embedded tissue, and stained with haematoxylin-eosin. Spheres were counted in
tumour tissue, peripheral tumour tissue and liver parenchyma.
6.2.7 Statistical analysis
Variables were expressed as mean±SD. Study groups were compared with the
unpaired Student’s t test in the case of independent samples. The non-parametric
Mann-Whitney test for two-group comparisons was used when indicated. Paired
samples were analysed using the paired t test, or the Wilcoxon matched-pairs test
coeliac artery
hepatic artery
portal vein
inferior vena cava
gastroduodenal artery
needle
a1
b
a2
aorta
liver
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when indicated. A P value of less than 0.05 was considered to be indicative of a
significant difference.
6.3 Results
6.3.1 Tumour implantation and administration of 166Ho microspheres
Implantation of the tumour resulted in a 100% "take"-rate. To avoid expulsion of the
tumour, a relatively deep incision (2-6 mm) was made in the liver and closed
afterwards with tissue glue. After 16-27 days the tumour had grown from 1-2 mm into
a well-vascularized tumour of 5-12 mm in diameter, as measured by ultrasound, which
gave accurate information about tumour size and form. The tumour appeared as
deviations of rounded tissue in a relatively flat liver image. As a result of the recovery
from the first laparotomy, the omentum was hypervascularized and merged with the
liver and the stitches in the abdomen. All rats survived the operations and were in
good physical condition after their last intervention.
The microspheres showed a tendency to adhere to the wall of the syringe during
administration. This was overcome by agitation and flushing of the syringe, which
enabled the injection of a fixed amount of microspheres to the individual animals.
6.3.2 Biodistribution
On scintigraphic images no radioactivity was visible in tissues other than the tumour
and the liver (Fig. 3).
Radioactivity measurements showed that the average %ID/g in organs other than
liver (control group) or liver with tumour (experimental group) was very low or
negligible (Fig. 4). The %ID/g was highest in the lungs being 0.4±0.7 and 0.3±0.4 in
the experimental and control group, respectively. For the stomach these values were
0.2±0.1 in the tumour group and 0.1±0.1 in the control group. The %ID/g of other
tissues was ≤0.1% in both study groups.
Fig. 3. Whole body scintigraphic image of a tumour-
bearing rat 1 day after the injection of 166Ho poly lactic acid
microspheres into the hepatic artery. Contour of the rat was
merged with the image to show the imaging set-up.
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Fig. 4. Biodistribution of 166Ho
microspheres in rats with implanted
liver tumour (upper panel) and in
control rats without tumour (lower
panel). Mean uptake values are given
in %ID/g ± sd.
In Table 1 the tumour to liver ratio’s obtained for the different study groups are
given. The use of adrenaline during administration did not show a significant effect on
the tumour targeting of the microspheres. Overall a mean T/N ratio of 6.1±2.9 for the
rats with tumour (n=15) versus 0.7±0.5 for the sham-implanted control rats (n=6) was
found, which proved to be a highly significant difference (p<0.001).
Within the liver itself the distribution of the 166Ho microspheres appeared to be
confined predominantly to the tumour and the liver lobe in which the tumour was
implanted, as is clearly illustrated in Fig. 5. As a result the %ID/g in this liver lobe is
higher than in the liver as a whole. Consequently, the mean T/N ratio significantly
(p=0.003) decreased to 4.0±1.6 (n=13) if just the liver lobe instead of the whole liver
was taken as the non-target region.
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Table 1. Tumour/liver-ratio’s in rats with implanted liver tumour and in sham-implanted rats
after administration of 166Ho loaded microspheres with or without adrenaline
Tumour Sham-implanted
+ adrenaline
(n=9)
- adrenaline
(n=6)
+ adrenaline
(n=3)
- adrenaline
(n=3)
2.1 5.0 0.1 0.5
4.5 2.6 0.6 1.5
5.4 12.8 0.6 0.8
7.1 7.9
2.2 8.1
5.9 9.4
7.5
6.0
4.4
Mean 5.0 7.6 0.4 0.9
SD 1.9 3.5 0.3 0.5
Fig. 5. Autoradiogram on phosphor imaging plate of a rat liver with tumour illustrating
preferential accumulation in the liver lobe with resident tumour (left panel, white arrow) and
photograph of the same liver showing the tumour (right panel, white arrow). Scale bar: 1
mm per division.
Histological analysis showed characteristically small irregular vessels inside the
tumour and a plexus of vessels around the tumour. The microspheres appeared to
accumulate predominantly in medium-sized (4-9 microspheres) or large (>10
microspheres) clusters within these vascular structures, in and around the tumour (Fig.
6B). In the normal liver parenchyma these clusters virtually were absent and mainly
isolated microspheres were observed (Fig. 6A).
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Fig. 6A-B. Single 166Ho microsphere in normal liver parenchyma (A) and cluster of
microspheres in tumour tissue (B), HE stained 6 µm coupes. Microscopic magnification:
200x.
6.4 Discussion
The average life expectation of patients following diagnosis of liver metastases is very
poor. There are no conventional therapies that can be used to treat these metastases
adequately. Because of the tumour and liver biology the administration of radioactive
microspheres into the hepatic artery with a vasoconstrictor has been considered as a
therapy [11]. As an alternative for the 90Y glass microspheres, which are currently
available for this kind of internal radionuclide therapy, we have recently described a
straightforward method for the production of radioactive 166Ho loaded microspheres of
poly lactic acid [14]. These microspheres are advantageous in that they combine
biocompatibility and low density with the favourable physical characteristics of 166Ho,
thus enabling image-guided radionuclide therapy. Moreover, production costs would
be reduced due to the 100% natural abundance of 165Ho and its cross-section of 64
barn, which allows for short neutron activation times.
In this study the biodistribution of 166Ho-PLLA microspheres was investigated,
after intra-arterial administration into the hepatic artery of rats with implanted liver
tumours.
Whole body images showed that virtually all injected activity (>95%) had
accumulated in tumour and liver and that no substantial redistribution or shunting to
other tissues had occurred. The average activity detected in other tissues was generally
very low (≤0.1 %ID/g) with occasional exceptions in lungs and stomach. The
maximum activity measured for stomach was 0.8 %ID/g, and observed in two animals,
which was probably due to retrograde flow within the hepatic artery resulting in spill
over to the stomach. Shunting to the lungs was observed in another two animals, with
values of 1.6 and 2.5 %ID/g respectively. In the therapeutic situation possible
A) B)
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arteriovenous shunts should be assessed with a tracer dose prior to the therapy, and
during administration care must be taken to prevent backflow to the stomach.
No substantial amounts of activity were detected in kidneys (<0.1 %ID/g),
indicating that no release of 166Ho from the microspheres had occurred. This was
confirmed by the absence of activity in urine and faeces.
Within the liver, entrapment of the 166Ho microspheres occurred predominantly in
and around the tumour and was found to be approximately six times that found in the
normal liver tissue. The use of adrenaline during administration showed no significant
effect on the T/N ratio in this study. Conflicting evidence of the effect of
vasoconstrictors on tumour blood flow and its effect on the T/N ratio in rat liver
tumours has been published, varying from increase to no effect, or even decrease of
the T/N ratio [15]. The interaction of adrenaline with both alpha- (vasoconstriction)
and beta-adrenoceptors (vasodilatation) may result in a net effect on tumour blood
flow, and hence the T/N ratio being the same in both groups with and without
adrenaline [15].
There was a 6-fold variation in tumour to liver ratios ranging from 2.1 to 12.8
(Table 1). This variability is in accordance with results in rabbits with implanted liver
tumours, where even substantially larger variations in T/N ratios were reported [15].
Also in patients with hepatic cancer variability in the T/N ratio was observed [16].
These variations may be explained by wide variation in tumour to liver blood flow
ratios caused by variation in blood vessel density in and around the tumour between
individuals, as reported by Dworkin et al. [17].
As visualized by autoradiography on phosphor imaging plates (Fig. 5) the 166Ho
microspheres were not deposited homogeneously throughout the whole liver, but were
restricted mainly to the liver lobe in which the tumour was situated. The activity more
or less fades out when further away from the tumour. As a consequence, the T/N ratio
decreased significantly from 6.1 to 4.0 when the liver lobe (which comprises about
25% of total liver weight [18]) instead of the whole liver, was regarded as the non-
target tissue.
The fading out phenomenon of the microspheres was manifested by their spatial
distribution on the microscopic level, and provided direct histological evidence of
their embolization specific to tumour. About 5 times as many large (>10 microspheres)
and medium-sized (4-9 microspheres) clusters were observed within the tumour and
the 0.5 mm layer of peritumoural tissue than in normal liver tissue, whilst individual
microspheres were equally dispersed throughout tumour tissue as well as liver
parenchyma. This is in agreement with the findings of Pillai et al. in rabbits [19].
In conclusion, this in vivo study has demonstrated the preferential embolization of
liver tumours with 166Ho poly lactic acid microspheres, and their stability with regard
to 166Ho release. The biodistribution of these microspheres which achieve average
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concentrations in the tumour of up to 6 times higher than in the liver, and which are
close enough to allow for the delivery of tumouricidal radiation doses to the target
cells, whilst virtually preserving intact the normal hepatic parenchyma, is similar to
that reported for 90Y carrying particles. Burton et al. [11] measured radioactivity in
biopsy samples of tumour nodules and normal hepatic tissue of nine patients with liver
metastases after injection of 90Y containing microspheres and found a mean T/N ratio
of 6 (range: 0.4-45). In other studies T/N ratios of 90Y microspheres were assessed
with 99mTc macroaggregated albumin. The mean T/N ratios reported varied between
2.8 (range: 1.0-10.0) for ten hepatocellular carcinoma patients [20] and 4.8 (range:
0.2-26.5) for 377 patients with hepatocellular carcinoma and 4.3 (range: 2.3-7.2) for
25 patients with colorectal liver metastases [16].
The biodegradability of the poly lactic acid microspheres and their low density (1.4
g/ml) add extra value since it allows for repeated injections and diminishes the chance
of settling during administration. Combined with the imageable gamma emission and
low production costs of 166Ho these microspheres offer an attractive alternative for 90Y
microspheres and warrant further research in this field.
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Abstract 
In this chapter the therapeutic effect of 166Ho loaded poly(L-lactic acid) microspheres 
in rabbits with liver tumours was investigated. New Zealand White rabbits with an 
implanted VX2 tumour were divided in three groups: sham-treated (n=3), cold 
microspheres (n=3) and microspheres loaded with 166Ho (0.9-1.0 GBq; n=2). After 
administration of the microspheres into the hepatic artery the biodistribution was 
studied with a gamma camera and tumour growth was followed in time with 
ultrasound. The radioactive microspheres were heterogeneously distributed over the 
liver and accumulated preferentially in the tumour area, which was confirmed by 
histological analysis. A transient increase of hepatic enzyme activity was observed 
after (radio)embolization. Sham-treated rabbits and rabbits treated with “cold” 
microspheres showed an exponential tumour growth. Therapeutic doses (100 Gy to the 
whole liver) arrested growth and resulted in necrosis of the tumour. No histological 
signs of pathological radiation effects, such as hepatic fibrosis or necrosis of the 
normal liver, were detected. This feasibility study demonstrates that 166Ho loaded 
poly(L-lactic acid) microspheres are promising systems for the treatment of patients 
with liver tumours.  
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7.1 Introduction 
Malignant neoplasms of the liver, both primary and metastatic, are among the most 
common tumours worldwide. In western countries the majority of liver metastases 
originates from colorectal cancer. Its prognosis is poor, with a median survival of 
approximately 6 to 12 months [1]. Currently, chemotherapy, either systemic or by 
hepatic arterial infusion, is the main approach of treatment. Nevertheless, side effects 
of chemotherapy are commonly reported while life extension is often marginal [1-3]. 
Long-term survivors are frequently documented after partial liver resection, but this is 
only possible in 10% of the patients [2,4].  
In the last decade a new therapy, viz. selective internal administration of radioactive 
yttrium loaded glass or resin based microspheres, resulted in a useful treatment with 
minor side effects [5]. The microspheres are administered into the hepatic artery and 
will lodge in the end arterioles in the liver. Tumours are usually rich in vasculature and 
they derive most of their blood supply from the arterial side. Thus accumulation of 
spheres can be found in and around the tumour when administered by the hepatic 
artery [6]. Estimated tumour doses exceed 300 Gy while the absorbed doses to the 
liver range from 50 to 150 Gy [5,7]. Although increased longevity and long term 
survivors are reported, this treatment modality is certainly far from optimal. Especially 
the high density of glass microspheres, the absence of a gamma component for 
imaging and the non-biodegradability are major drawbacks of both the resin- and 
glass-based 90Y loaded microspheres [5,8]. 
These disadvantages are solved to a large extent by the use of a new type of 
microsphere and isotope, as first described by Mumper et al. [8]. Neutron activated 
Ho-PLLA microspheres have more favourable properties. A disadvantage of these 
organic types of spheres is their high susceptibility to degra-dation induced by neutron 
irradiation needed for the activation of the holmium [9,10]. By carefully defining the 
irradiation conditions and increasing the holmium content we succeeded in the 
preparation of useful microspheres loaded with a therapeutic amount of radioactive 
holmium [11]. Experiments in a rat tumour model showed an average tumour/liver 
ratio of six for these PLLA microspheres [12]. 
In order to use these microspheres for therapy in humans, distribution in the liver 
should be inhomogeneous with preference for the tumour area and the delivered 
radiation dose should be able to induce necrosis of the tumour with acceptable toxicity 
to the normal liver. The objective of the present study was to investigate the effects of 
PLLA microspheres, containing therapeutic amounts of 166Ho, in the treatment of liver 
tumours in rabbits. Rabbits were either sham-treated or received a diagnostic or 
therapeutic (100 Gy) dose of microspheres. The dose of 100 Gy to the whole liver was 
chosen since it is well tolerated and results in effective tumour kill or reduction 
[5,13,14]. Tumour growth was investigated by ultrasound. 
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7.2 Materials and methods 
7.2.1 Animals 
All experiments were performed in agreement with The Netherlands Experiments on 
Animals Act (1977) and the European Convention guidelines (86/609/EC). Approval 
was obtained from the University Animal Experiments Committee (FDC/DEC-GNK 
nr. 99042). Ten adult female or male specific pathogen free New Zealand White 
rabbits of 2000 to 3500 g were used (Harlan, Horst, The Netherlands). The rabbits 
were housed individually in steel or plastic cages and provided daily with 
approximately 100 g “complete diet” pellets for rabbits (LKK-20, Hope Farms BV, 
Woerden, The Netherlands). Water was provided ad libitum. Rabbits were sacrificed 
after three or four weeks or earlier, when clear inconvenience for the animal was 
observed. 
 
7.2.2 Tumour cells 
The VX2 cell line was obtained from the Department of Oral and Maxillofacial 
Surgery of the University Medical Center, Utrecht, The Netherlands [15]. The original 
tumour cells were obtained from a virus induced papilloma rabbit carcinoma [16]. The 
VX2 tumour was propagated by subcutaneous passage in the hip region of the rabbit 
or was derived from a part of the implanted tumour in the liver of a freshly killed 
rabbit. In order to facilitate implantation, the tumour tissue was dissected and small 
parts (2 mm in diameter) were chosen for implantation. 
 
7.2.3 Tumour implantation 
Prior to inhalation-anaestheticum, premedication of 0.5 ml methadon (10 mg/ml; 
Veterinary Pharmacy, University of Utrecht, The Netherlands) and 0.5 ml Vetranquil® 
(acepromazine, 10 mg/ml; Sanofi Sante Animale Benelux BV, Maassluis, The 
Netherlands) was given. Subsequently, the rabbits were anaesthetized by an 
intravenous injection of Hypnomidate® (2 mg/ml; B. Braun Melsungen AG, 
Melsungen, Germany) and N2O and halothane (Albic BV, Maassluis, The 
Netherlands) as inhalation anaestheticum. A laparotomy was performed by ventral 
mid-line incision in order to expose the lobes of the liver. Tumour tissue was 
implanted in the lobus sinister lateralus by injection with an Abbocath-T® 18G 
(Abbott Ltd., Ireland), together with a piece of titanium to serve as a localization 
marker for ultra sound. After approximately 12 days the first ultrasound investigation 
(HDI 3000 ATL, Entos™ CL10-5 transducer) was performed to check tumour growth.  
 
7.2.4 Preparation of microspheres 
Radioactive holmium loaded microspheres were prepared as previously described 
[11]. Briefly, holmium acetylacetonate (HoAcAc) is incorporated into PLLA by 
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solvent evaporation, resulting in microspheres of 20-50 µm after sieving. Neutron 
activation of the microspheres was performed by irradiation for 1h in the PRS facility 
of the high-flux nuclear reactor in Petten, The Netherlands. Neutron activated 
microspheres were used the next day for therapeutic purpose (900-1000 MBq in 35-40 
mg) or as diagnostic, “cold” microspheres after decay for four to five days (40-80 
MBq in 35-40 mg). Microspheres were sonicated for 10 min in an ultrasonic cleaner 
and suspended in Gelofusine® (Vifor Medical SA, Switzerland) prior to 
administration.  
 
7.2.5 Administration of microspheres 
When the tumour had reached a diameter of ≥20 mm, a second laparatomy was 
performed in order to administer the holmium loaded microspheres (or Gelofusine® in 
case of sham-treated rabbits). Administration of microspheres was similar as described 
for rats in chapter 6. The gastroduodenal artery was cannulated with an Abbocath-T® 
24G (Abbott Ltd., Ireland). Back flow was checked with 0.1% methylene blue in 5% 
glucose. A pre-flushed administration system similar as described by Herba et al. [17] 
was connected to the Abbocath®. The suspended microspheres were administered and 
the administration system was measured for activity pre- and post injection, in order to 
calculate the injected dosage. The gastroduodenal artery was sealed with tissue glue 
(Histoacryl, B. Braun Melsungen AG, Melsungen, Germany) and wires were removed 
to restore the arterial hepatic circulation.  
 
7.2.6 Biodistribution and assessment of tumour growth 
Rabbits were divided in three treatment groups which received either Gelofusine® 
(control group, n=3), “cold” microspheres containing 40-100 MBq 166Ho for 
diagnostic imaging (n=3) or microspheres containing therapeutic amounts of activity 
(900-1000 MBq; n=2) resulting in approximately 100 Gy to the whole liver. The 
rabbits were monitored by planar and SPECT imaging, using a triple-head gamma 
camera (Prism 3000, Cleveland, USA). A whole body scintigram was made 5 days 
after administration of therapeutic and 1 day after diagnostic microspheres, in order to 
determine gross distribution. 
Ultrasound studies were performed at approximately 4, 10, and 18 days after 
administration of Gelofusine® or microspheres and before sacrificing, and were 
evaluated by the same observer. Examination of the liver, stomach and part of the 
intestines was established by sagittal and transversal scanning of the abdominal 
region. The tumour was measured in three directions and its volume was calculated by 
applying the equation for the volume of an ellipsoid [18]. Ultrasound measurements 
before treatment and sacrificing were compared with calliper measurements at time of 
treatment and autopsy of the rabbit. 
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7.2.7 Toxicity evaluation 
Blood samples were taken three or four times: prior to tumour implantation, before 
administration of microspheres, after administration and before sacrifice. Blood was 
centrifuged at 2500 g for 10 min and the plasma immediately frozen. The plasma 
samples were analysed for alkaline phosphatase as an indicator of biliary toxicity and 
for alanine aminotransferase (ALAT), gamma glutamyltransferase (γ-GT) and 
bilirubine as indicators of hepatocellular toxicity. At autopsy the thoracic and 
abdominal organs were inspected and fixed in phosphate-buffered 4% formaldehyde. 
In order to verify presence of microspheres, tissue samples from the tumour site, liver, 
lungs, spleen, and stomach were embedded in paraffin and histologically evaluated 
after staining with haematoxylin-eosin.  
 
7.3 Results 
7.3.1 Tumour growth and survival 
Implantation of the tumour resulted in a 100% “take-rate”. In tumours transplanted 
from subcutaneous site to liver a slower tumour growth was observed (approximately 
21 days before reaching a diameter >20 mm) compared with tumour tissue that was 
transplanted from liver to liver (approximately 16 days before reaching >20 mm). 
Tumours >2 mm in diameter were visible with ultrasound and were well vascularized 
as illustrated in Fig. 1. 
 
 
 
Fig. 1a-b. Doppler ultrasound (square) of the vasculature of the VX2 tumour (1.2 x 1.3 cm) 
before treatment. The high blood flow in and around the tumour is indicated in the ultrasound 
graph in the white/light grey regions (a). In the schematic drawing the blood flow is indicated 
as grey regions (b). *Branch of the portal vein. 
a) 
* 
* 
tumour 
liver tissue stomach 
subcutis b) 
*
*
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Tumour growth was exponential in both the control group and the rabbits treated with 
“cold” microspheres (Fig. 2 and Table 1). No primary tumour growth was seen in the 
rabbits treated with 900 MBq of activity. 
After the second operation most rabbits showed a decline in physical condition 
mainly manifested by a decrease in appetite.  
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Fig. 2. Tumour growth in the liver of 
rabbits after treatment (day 0). 
Measurements of tumour sizes in time 
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Table 1. Tumour size at treatment and sacrification. 
Rabbit 166Ho 
(MBq) 
Tumour size  
at treatment 
(cm3) 
Tumour size at  
sacrification 
(cm3) 
Day of 
sacrification 
Increase of  
tumour size 
(%) 
Control 1 ---  4.8  132.8 34  2767 
Control 2 ---  13.6  201.1 29  1479 
Control 3 ---  0.1  25.7 30  25700 
Cold 1 92  0.2  11.7 23  5850 
Cold 2 123  3.2  254.9 28  7966 
Cold 3 46  12.9  37.7 24  292 
Therapeutic 1 900  5.4  5.2 28  -96 
Therapeutic 2 928  14.9  11.8 21  -79 
 
7.3.2 Metastatic disease 
Ultrasound appeared to be a useful modality in predicting the size of the tumours (Fig. 
3). In all treatment groups several massive lung and liver metastases were found with 
ultrasound or subsequently at autopsy. Histology showed high proliferation grade and 
necrotic centre indicative for non-differentiated and aggressive tumours. Also 
metastases on the exterior of the stomach and diaphragm were present in all three 
groups. Metastases on the incision wound were sometimes present and often visible 
before treatment. If possible this tumour tissue was resected during the second 
laparotomy. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Correlation between tumour volume measured with 
ultrasound and calliper measurements during operation 
and autopsy of the rabbits. 
 
 
7.3.3 Biodistribution and histological analysis 
Cannulation of the liver artery resulted in deposition of 80-90% of the initial activity 
of microspheres. Based on SPECT and planar scintigraphic images radioactivity 
remained in the liver and tumour with preferential accumulation of activity in the 
tumour (Fig. 4). Activity in the liver was heterogeneously distributed which was 
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confirmed by microscopic analysis showing that microspheres were distributed 
unequally over liver and tumour. Although single spheres were found in similar 
amounts in tumour and liver tissue, the greater part of clustered microspheres had 
accumulated around the (primary) tumour and in the larger vessels (Figs. 5 and 6). No 
microspheres were found in lungs, stomach or spleen. Particularly in the rabbits that 
were embolized with (radioactive) microspheres cholestasis was noted in the liver and 
this was sometimes visualized as small ridges in the ultrasound image. 
      
Fig. 4a-b. Whole body scintigraphic image of a tumour-bearing rabbit 3 days after injection 
of approximately 1GBq 166Ho poly(L-lactic acid) microspheres into the hepatic artery. 
Contour of the rabbit was obtained by using a “flood source”. 
 
 
In the control group and the rabbits embolized with “cold” microspheres histology 
showed compression of liver parenchyma caused by the rapid expansion of the 
tumour. The tumour tissue appeared to be viable and was unaffected by the treatment. 
In contrast, in the therapeutic treated rabbits the primary tumour and the larger 
metastases were entirely necrotic. Also necrotic liver tissue was seen close to large 
blood vessels containing clusters of microspheres. Compression of normal liver tissue 
was scarcely observed. 
 
  
 
Fig. 5a-b. Typical example of a liver tissue section after embolization with cold microspheres 
in the liver artery (a). A schematic overview of the micrograph shows A) tumour tissue B) 
liver tissue and C) connective tissue with bile ducts and blood vessels (b). The magnification 
of the white square of (a) shows five microspheres in small arteries close to the tumour 
(schematic drawing 5 black circles) (c). Since microspheres were cold no damage is seen in 
liver or tumour tissue.  
a) b)) 
A 
B 
B 
C 
b) a) c) 
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Fig. 6a-b. Typical example of a liver tissue section after embolization with microspheres with 
therapeutic amounts of activity (a). A schematic overview of the micrograph shows A) tumour 
tissue and B) liver tissue (b). A cluster of microspheres is seen in a large blood vessel in the 
tumour. No cell nucleus is seen in cells of both liver tissue and tumour tissue indicating 
necrotic tissue (c).  
 
 
7.3.4 Hepatic toxicity 
At this stage of the study plasma data were too incomplete to allow for statistical 
analysis of hepatic enzyme levels. Therefore only the trends observed in the individual 
animals can be described. Total bilirubin levels remained unchanged in all rabbits. For 
alkaline phosphatase, ALAT and γ-GT a transient elevation in activity was observed 
which is illustrated in Fig. 7 for a rabbit that was treated therapeutically with 928 MBq 
of radioactive microspheres. This phenomenon was not observed in sham-treated 
rabbits, which showed no change in activity of liver enzymes during the follow up 
until sacrificing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Liver enzyme levels in a rabbit treated (at day 0) with 928 MBq 166Ho-microspheres. 
 
a) 
A 
B 
b) c) 
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7.4 Discussion 
Treatment of liver malignancies in humans remains a challenge and prognosis of these 
patients is still poor. Conventional therapies such as systemic chemotherapy and 
external radiotherapy are insufficient [1,2]. New approaches such as regional 
chemotherapy result in increased survival and palliation [1,3,19]. Nevertheless, the 
side effects of regional chemotherapy are a considerable drawback.  
A good alternative with less side effects are radioactive yttrium containing glass or 
resin based microspheres. Although these spheres showed some favourable clinical 
results, they have their own disadvantages such as a relatively high density, lack of γ-
emission and non-biodegradability [5]. This is reflected in the risk that these 
microspheres are deposited into the gastroduodenal vasculature under gravity. The 
microspheres can not be tracked during and after administration and repeated 
administration of spheres is difficult. The use of neutron activated holmium loaded 
poly(L-lactic acid) microspheres may overcome these disadvantages.  
In this study the proof of principle of this radioactive holmium loaded system was 
investigated in a rabbit tumour model. A major difference with human liver metastases 
and transplantable rodent tumours is the relatively slow doubling time in humans [20]. 
In the human situation microspheres can be administered via the femoral artery using 
standard radiological intervention techniques. The present rabbit model has the 
disadvantage of relatively rapid tumour growth, the concomitant spread of metastases 
and the need for two laparotomies. 
The present study shows that holmium loaded microspheres infused into the hepatic 
artery do not give rise to backflow to the gastrointestinal vessels and that virtually all 
injected activity is deposited in the liver and tumour. 
The high dose of activity in the liver and tumour was surprisingly well tolerated. 
This effect (external radiotherapy is limited to 30-35 Gy [5,21]) is similar as described 
for the radioactive yttrium loaded microspheres and is probably caused by the 
inhomogeneous distribution of activity in the liver [22,23]. Fox et al. [23] described 
for a patient that 86% of the normal liver parenchyma received less than the dose that 
would be expected for a uniform distribution, and 34% of the tissue received even less 
than one third of the dose [23]. Thus, approximately one third of the tissue receives 
less or equal to 30 Gy (total dose 90 Gy).  
Histology as well as planar and SPECT imaging of the tumorous rabbit livers 
confirmed the high variability in microsphere and activity distribution for this 
embolization technique. In the rabbits embolized with microspheres at least two times 
more activity was found in and around the tumour compared with normal liver 
parenchyma based on SPECT imaging and histology. These values and variability are 
in accordance with results in other animal studies and clinical trials [13,24,25]. 
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It was shown in this study that radioactive microspheres with therapeutic amounts of 
166Ho, approximately 100 Gy to the whole liver, can arrest tumour growth and induce 
tumour necrosis. Studies, in other animal models, will be needed to further investigate 
the potential survival benefit of this therapy.  
The administration of (radioactive) microspheres often gave rise to cholestasis in 
the liver and was also observed in one sham-treated rabbit. This phenomenon was 
probably caused by repeated halothane exposure during the two laparotomies. 
Impaired bile flow and cholestasis were reported as liver injury induced by halothane 
[26] and these effects may be enhanced by microsphere embolization. 
In conclusion, this study has demonstrated that holmium loaded PLLA 
microspheres with a therapeutic dose of activity can arrest tumour growth and induce 
necrosis of tumour tissue while sparing normal liver tissue. These results warrant 
further studies in other models before this therapy can be tested in the human situation. 
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8.1 Summary and concluding remarks 
Liver metastases frequently occur during the progression of various solid tumours, 
especially colorectal cancers, and are the cause of 25-50% of all cancer deaths [1-3]. 
In particular in patients with colorectal cancer the liver is the main metastatic site. 
Median survival of patients with liver metastases is approximately 6-12 months, and 
in the presence of extensive hepatic metastases survival is reported to be less than 6 
months with no 5-year survivors [1,4,5]. Systemic chemotherapy results in only 
limited increase in life span with a median survival of around 1 year. In addition to 
systemic chemotherapy, local hepatic arterial chemotherapy, chemo-occlusion or 
combination therapies have resulted in some extension of life span of approximately 
12-24 months [5-7]. Although loco-regional chemotherapy showed good palliative 
properties, a number of side effects such as nausea, vomiting and diarrhoea has been 
reported. In addition, hepatic toxicity associated with these therapies is often observed 
[5,8]. Surgery is still the only accepted treatment with curative intention, but only a 
minority of the patients can be subjected to this treatment [9,10]. Other newly 
developed surgical modalities like cryo-ablation and radiofrequency ablation have 
resulted in refinement of the surgical techniques which can be applied to a greater 
number of patients. Nevertheless, surgical therapies are only possible in 
approximately 10% of the patients [11,12].  
External beam radiotherapy in the treatment of hepatic malignancies is limited by 
the radiosensitivity of normal liver tissue, which can tolerate doses of only up to 30 
Gy for whole liver irradiation [3,13,14]. Therefore, investigators have searched for 
ways to utilise the arterial vascularization of hepatic metastases in order to inject local 
radioactive deposits. Yttrium-90 (90Y) labelled microspheres which can be 
administered intra-arterially, became available in the late 1980s and resulted in the 
start of a new safe therapy for treatment of liver cancer [2,15]. Livers of patients can 
receive up to 150 Gy without developing radiation hepatitis; a safety limit of 80 to 100 
Gy is used in most studies [16,17]. The median survival in a study of 17 patients with 
liver metastases from colorectal cancer treated with 90Y microspheres was 14 months 
and there were 3 long-term survivors of 4 years [18]. As important as longevity, the 
treatment has very little morbidity [8].  
Although studies with 90Y labelled microspheres, either based on glass or resin, 
showed promising results, their high density (3.3 g/ml for glass and 1.6 g/ml for 
resin), apparent non-	
  
 	  -emission of 90Y (Emax=2.28 
MeV, t1/2=64.1h) for imaging can be considered as disadvantages. Therefore, Mumper 
et al. [19] proposed the use of poly(L-lactic acid) (PLLA) microspheres loaded with 
the β-emitter holmium-166 (166Ho) as alternative for the glass or resin based systems. 
166Ho-loaded microspheres have favourable characteristics above the 90Y glass and 
resin based systems because of their relatively low density and biodegradability. 
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Moreover, 166Ho also emits γ-photons, which makes image-guided radionuclide 
therapy possible. However, because of the relatively low contents of holmium, 10% 
(w/w), Mumper et al. were not able to produce a patient dose with sufficient activity.  
In chapter 2 of this thesis it was shown that adjustment of the irradiation parameters 
used by Mumper et al. to increase the radioactivity was not successful. However, 
optimisation of the formulation and process parameters resulted in PLLA 
microspheres with a substantially higher loading (16-17% (w/w) Ho) than obtained by 
Mumper et al. Further, the irradiation parameters were studied to result in 
microspheres with high activity and acceptable irradiation damage. Thus, we were 
able to produce stable radioactive holmium loaded PLLA microspheres with 
therapeutic amounts of activity (chapters 2-5). This thesis concludes with two animal 
studies that show the successful targeting of the Ho-loaded microspheres to liver 
tumours in rats (chapter 6) and, importantly, in a feasibility study a good therapeutic 
effect of these microspheres in rabbits with liver tumours was demonstrated (chapter 
7). 
 
 
Chapter 1 reviews the current literature on radioactive microspheres used for the 
treatment of liver malignancies. The first usable microspheres for clinical application 
were 90Y-glass microspheres which now have a proven efficacy in the treatment of 
especially liver tumours. Resins with 90Y bound to the carboxylate anions of an acrylic 
copolymer also showed good clinical results. PLLA microspheres with 165Ho-
acetylacetonate (HoAcAc) which can be activated by neutron irradiation (by which 
165Ho is converted into radioactive 166Ho) were introduced as an improved system as 
compared with glass and resin based particles. The size, stability, toxicity, density, 
radio-isotope and other requirements which the optimal microsphere formulation for 
radio-embolization of liver malignancies should meet, are discussed in this chapter. 
This chapter concludes with the scope, aims and outline of the thesis. 
 
In Chapter 2 the preparation of 165Ho-loaded PLLA microspheres with a solvent 
evaporation technique is described. The optimisation of the formulation and process 
parameters resulted in a standard method which yielded PLLA microspheres with a 
diameter of 20-50 µm and a loading of 17% holmium (w/w). Furthermore, the effect 
of the neutron irradiation parameters on the microsphere integrity and Ho-release has 
been evaluated. In order to produce an amount of activity which is sufficient for a 
patient dose (estimated activity of 20 GBq per 400 mg microspheres) the microspheres 
have to be free of water and irradiation with a relatively low neutron flux (5x1013 cm-
2
.s-1) for 1h has to be performed. Irradiation has to be performed preferably in a 
container (e.g. made of polyethylene) which by itself is not activated by the 
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irradiation. The structural integrity of the microspheres was maintained in terms of 
form and size. In vitro analyses showed that >98% of 166Ho activity was retained in 
the microspheres after 192h incubation in PBS, plasma, a leucocyte suspension, and 
liver homogenate.  
 
In Chapter 3 the crystal structures of two HoAcAc complexes were identified with X-
ray diffraction. The structures of the two complexes, [Ho(C5H7O2)3(H2O)2]· H2O 
(complex I; prepared at pH 8.5) and [Ho(C5H7O2)3(H2O)2]· C5H8O2· 2H2O (complex II; 
prepared at pH 9.0), both show an eight-coordinate holmium(III) ion. In both 
structures (I and II), hydrogen bonds between the complexes join them into a chain. In 
complex I the non-coordinating water molecule links these chains in a two-
dimensional network. In complex II two non-coordinating water molecules and a free 
4-hydroxypentan-2-one molecule also form a hydrogen-bonded chain. Diaquatris-
(pentane-2,4-dionato-O,O’)holmium(III) monohydrate (complex I) is the HoAcAc 
complex that is used for the preparation of holmium loaded microspheres.  
 
In Chapter 4 the preparation and characterisation of poly(L-lactic acid) microspheres 
and films loaded with HoAcAc are described. The factors responsible for the low 
release described in chapter 2 are investigated by modulated differential scanning 
calorimetry (MDSC), scanning electron microscopy (SEM), infrared spectroscopy 
(IR) and X-ray diffraction. MDSC analysis of HoAcAc crystals shows two 
endotherms which were ascribed to evaporation of the non-coordinated water 
molecule (first endotherm), and the second endotherm is due to evaporation of the two 
coordinated water molecules. Both MDSC and X-ray diffraction revealed that 
HoAcAc is molecularly dispersed in the PLLA matrix up to a loading of 8% in films 
and 17% Ho (w/w) in microspheres. Crystalline HoAcAc was present in films with 
high loading of holmium >12% (w/w). IR suggested that interactions between 
carbonyl groups of PLLA and the Ho-ion in the HoAcAc complex occurs, which 
might explain the high stability (=low release) of holmium loaded microspheres. 
 
Chapter 5 describes the influence of neutron irradiation on HoAcAc loaded PLLA 
microspheres. The PLLA matrices before and after irradiation, with and without 
HoAcAc, were analysed by MDSC, SEM, gel permeation chromatography (GPC), IR-
spectroscopy and X-ray diffraction. GPC and MDSC measurements showed a 
decrease in molecular weight and crystallinity of the PLLA, respectively, which can 
be ascribed to radiation induced chain scission. Irradiation of HoAcAc loaded PLLA 
matrices resulted in evaporation of the non-coordinated and one coordinated water 
molecule of the HoAcAc complex, as shown by DSC and X-ray diffraction analysis. 
IR spectroscopy indicated that radiation caused some degradation of the 
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acetylacetonate anion. This chapter shows that although radiation-induced damage of 
both the PLLA matrix and the loaded HoAcAc-complex occurs, the microspheres 
retain their favourable properties (size and low Ho release) which makes these 
systems interesting candidates for the treatment of tumours by radio-embolization.  
 
The selective delivery of the 166Ho-loaded PLLA microspheres to liver tumours was 
studied in rats (Chapter 6). The biodistribution of microspheres (20-50 m; 17% Ho 
(w/w), activity of 15-20 MBq for imaging) after administration into the hepatic artery 
of WAG/Rij rats, with implanted liver tumours, was investigated. More than 95% 
retention of the injected activity was found in the liver and its tumour. A marginal 
amount of radioactivity was detected in the kidneys, indicating no leakage of 166Ho. 
Histological analysis showed that many large (>10) and medium sized (4-9) clusters 
of microspheres were present within the tumour and the peritumoural tissue, as 
compared with normal liver tissue. However, individual microspheres were equally 
dispersed through liver and tumour. The mean tumour-to-liver activity ratio was 6 
(sham operated rats 0.7) which demonstrates a successful targeting of microspheres to 
the tumour. The use of the vasoactive agent adrenaline, which has been reported to 
enhance the blood flow to the tumour [20,21], did not result in an increased tumour-
to-liver activity ratio. 
 
Chapter 7 shows the therapeutic effect of 166Ho-loaded PLLA microspheres in rabbits 
with hepatic malignancies. New Zealand White rabbits with an implanted VX2 (virus 
induced papilloma rabbit carcinoma) tumour were treated with cold microspheres or 
microspheres with a therapeutic amount of activity. The control group of sham-treated 
animals served as reference. The activity, and thus the microspheres, was 
heterogeneously distributed over the liver, as was confirmed by a gamma camera and 
histological analysis. Interestingly, a “hot spot” of activity corresponding with the 
location of the implanted tumour was observed, again indicating a successful targeting 
of microspheres to the tumour. Microscopic analysis also showed a high accumulation 
of microspheres within the tumour and peritumoural tissue. A transient increase of the 
liver enzymes was detected after administration of microspheres, indicating some liver 
toxicity. A normal exponential growth of the tumours was observed in the two control 
groups (sham-treated and rabbits which received cold microspheres). In animals 
which received a therapeutic dose of Ho-loaded microspheres growth of the tumour 
was arrested. Moreover, the therapeutic dose of activity induced necrosis of tumour 
tissue while sparing normal liver tissue. This is a very promising result for the further 
development and application of Ho-PLLA systems.  
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8.2 Prospects 
This thesis has demonstrated that 166Ho-loaded poly(L-lactic acid) microspheres are 
very attractive systems for the therapeutic treatment of patients with liver 
malignancies. Before these systems can be fully exploited in clinical practice, a 
number of items deserves further attention. As mentioned in chapter 1, the preferred 
diameter of the microspheres for internal radiotherapy is approximately 30 µm. 
Although the in vivo experiments in this thesis were done with a sub-optimal size of 
spheres (20-50 µm), both the retention in liver and tumour, and the tumour-to-liver 
ratio were quite high (chapters 6 and 7). Probably, microspheres with a narrower size 
distribution (25-35 µm) will show an even higher tumour-to-liver ratio. The solvent 
evaporation production process applied in this thesis results in microspheres with a 
relatively large size distribution of 5-100 µm. This means that the yield of particles 
with the preferred size (~25-35 µm) is rather low. It is therefore recommended to 
investigate whether particles with the right average size and distribution can be 
obtained in a single step by adjustment of the process conditions. Also, other 
preparation methods like spray drying are recommended for further investigation. It is 
likely that the encapsulation efficiency will be improved by using this technique. In 
addition, for large scale production of Ho-loaded microspheres spray drying is 
preferred above the solvent evaporation technique, because spray drying is a 
continuous process, whereas solvent evaporation is a batch process. Moreover, spray 
drying results in less waste production as compared to solvent evaporation. A 
preliminary investigation revealed that the microspheres produced by spray drying 
could not easily be resuspended in saline, most likely because of the hydrophobic 
character of the surface of the microspheres. Probably, the wettability of the 
microspheres can be improved by resuspending the particles in saline in which a 
surface active agent (e.g. Pluronic®) is dissolved. However, the production of 
relatively large microspheres (20-50 µm) with spray drying, is another difficulty.  
In present clinical practice, patients with liver tumours receive 2-4 GBq 90Y- 
particles. When an equivalent dose of 166Ho-loaded PLLA micropsheres has to be 
administered to patients, the total radioactivity should be a factor 2.4 higher [22], 
because of its shorter half-life (3 days for 90Y and 1 day for 166Ho). Moreover, for 
logistic reasons, the time between neutron irradiation and administration of the 
microspheres to the patient is about 1 day. This implies that one patient dosage should 
have an activity of 10-20 GBq off reactor preferably with the highest specific activity 
attainable. From the data described in chapter 7, it can be calculated that 100 mg 
PLLA microspheres with 17% 165Ho loading, yielded an activity of 3.5 GBq directly 
after irradiation. This means that with the current batches of microspheres in 
combination with the irradiation schedule, patient dosages with the required activity 
can be prepared. However, when clinical data would reveal that higher amounts of 
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activity are required, it can be evaluated whether greater amounts of microspheres can 
be administered to patients. If this is not possible, further investigation into the 
development of microspheres with higher specific activity is recommended. It should 
be noted that a ‘simple’ increase of the irradiation time can be associated with 
unacceptable aggregation and fragmentation of the microspheres (chapter 2). This 
means that higher radioactivity has to be achieved by an increase of 165Ho-loading. As 
described in chapter 4, HoAcAc is molecularly dispersed in the amorphous phase of 
the PLLA matrix. Thus, the use of for example fully amorphous poly(dl-lactic acid) 
(PDLA) will probably result in microspheres with a higher holmium loading. 
However, experimental evidence should demonstrate whether microspheres based on 
this polymer remain their structural integrity after neutron irradiation. 
In chapter 5, it is demonstrated that neutron irradiation of Ho-loaded PLLA 
microspheres resulted in a radiation-induced chain scission of PLLA chains. This 
radiation damage was associated with a decrease of polymer molecular weight and of 
crystallinity. However, this does not need to be a disadvantage. It has been reported 
that the degradation time of PLLA matrices strongly depends on the molecular weight 
and the presence of a crystalline phase [23]. For highly crystalline PLLA a 
degradation time of 1-2 years has been reported [23]. Therefore, it can be expected 
that irradiated microspheres will degrade faster compared with non-irradiated spheres. 
PLLA is a biodegradable polymer which finally yields lactic acid as the sole 
degradation product. Although neutron irradiation causes chain scission in PLLA, it 
can not be excluded that also some recombination of radicals formed during 
irradiation occurs. It can be expected that upon degradation of irradiated PLLA 
microspheres under physiological conditions, also other degradation products 
(originating from recombination reactions) will be formed besides lactic acid. It is 
therefore recommended to perform in vitro degradation studies on (non-)irradiated 
PLLA microspheres with and without HoAcAc to gain more insight into the 
degradation kinetics as well as the nature of the degradation products. The amount and 
identity of degradation products other than lactic acid can probably be established by a 
combination of HPLC and mass spectroscopy. Furthermore, it is necessary to perform 
in vivo biocompatibility/degradation studies to establish the in vivo degradation 
behaviour as well as to investigate whether radiation-induced damage of PLLA 
adversely affects its favourable biocompatibility.  
Acute toxicity caused by holmium ions is probably negligible since the holmium 
complex is immobilized in the polymeric matrix, possibly because of interactions with 
PLLA (chapters 4 and 5). Release of holmium will therefore occur upon microsphere 
degradation. Since the degradation/dissolution phase of PLLA matrices is extended 
over time (a few days to weeks), the release of Ho will be gradual and therefore only 
small amounts of holmium ions will enter the circulation. Furthermore, data 
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concerning holmium chloride show a low toxicity (LD50 in mice ip 312 mg/kg) and 
holmium is not noticed as carcinogenic (material safety data sheet; 91/155EEG). 
For the preparation of Ho-loaded microspheres organic solvents are required. In 
this thesis the commonly used volatile solvent chloroform was applied. It was 
demonstrated that its residual content in the microsphere batches was 0.3% (w/w) 
(chapter 4). Lowering the residual solvent by heating for 24 hours at 80ºC resulted in a 
substantial reduction in residual chloroform (~0.01% (w/w)). Although this method 
appeared to be highly efficient, the effects of heating of the PLLA microspheres have 
to be further investigated.  
Since the microspheres are administered into the blood stream, they must be sterile. 
However, it is highly unlikely that non-sterile microspheres receiving a dose of 2 
MGy during neutron irradiation still contain living microbes. The sterilising effect of 
neutron irradiation was evaluated by contaminating holmium loaded microspheres 
with a suspension of Bacillus subtilis bacteria [24]. After neutron irradiation, no living 
bacteria could be detected and it can be concluded that the neutron irradiation for the 
production of radioactive 166Ho-PLLA microspheres is a very effective sterilisation 
method as well.  
In vivo studies were performed in relatively small animals like rats (chapter 6) and 
rabbits (chapter 7). However, administration by catheterisation of the hepatic artery 
via the femoral artery similar to the method used in humans was impossible. 
Nevertheless, the direct administration into the liver artery of rats and rabbits was a 
useful model for studying the biodistribution and efficacy of the 166Ho-loaded PLLA 
microspheres. A major problem was the obstruction of the microspheres in the needle 
of the administration system used in rats. It can be expected that these problems do not 
occur in humans or larger animals because then a relatively large volume of 
suspended PLLA-microspheres can be administered in a relatively short time. 
Moreover, the lumen of the catheters used in human embolizations have a three to 
four fold larger diameter. Obstruction by the microspheres is therefore hardly 
imaginable, as was indeed observed in a recent pilot study in pigs.  
Minimal radiation exposure to personnel who administer the 166Ho-PLLA 
microspheres is also important. We designed and patented a new vial (polyethylene 
based) in which irradiation of the microspheres in a nuclear reactor is performed. 
Subsequently, the microspheres are suspended in saline after which the vial is 
connected to the administration system, and the spheres can be introduced into the 
hepatic artery of the patient via a catheter [25]. With this combined 
irradiation/administration system it is possible to customize the amount of 
radioactivity for the individual radiotherapeutic indication.  
In chapter 7 it was shown that the 166Ho-loaded PLLA microspheres are very 
suitable for treatment of liver malignancies. No back flow of the microspheres, as 
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frequently encountered with the currently used 90Y-systems, occurred and the growth 
of primary tumours was inhibited, which is a very encouraging result for future 
clinical application of these systems. Currently, an efficacy study in dogs with 
spontaneous tumours is being planned in co-operation with the Faculty of Veterinary 
Medicine, Utrecht. 
In conclusion, this pre-clinical study of the preparation and application of 166Ho-
loaded microspheres for the treatment of liver metastases showed encouraging results. 
Human phase-I studies have to answer the questions about dosimetry, efficacy and 
administration technique in more detail. Other applications of holmium loaded 
microspheres such as the treatment of head-and-neck cancer [26,27], bone metastases 
and ovarian cancer are subject of recent and future studies. It is expected that internal 
radionuclide therapy using Ho-loaded PLLA microspheres will play a substantial role 
in the treatment of hepatic and other types of cancer in the near future. 
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Samenvatting
Levermetastasen komen frequent voor bij patiënten met kanker en zijn de oorzaak van
25 tot 50% van alle sterftegevallen gerelateerd aan kanker. Met name bij darmkanker
worden regelmatig deze uitzaaiingen gevonden. De gemiddelde levensverwachting
van patiënten met levermetastasen is slechts 6 maanden wanneer er sprake is van een
uitgebreide metastasering. Zelfs wanneer patiënten met systemische chemotherapie
worden behandeld, is de levensverwachting beperkt tot ongeveer 12 maanden. Naast
systemische chemotherapie worden locale chemotherapie via de leverarterie of
combinatietherapieën gegeven. Deze therapieën verlengen de levensverwachting tot
ongeveer 12-24 maanden. Hoewel deze locale therapieën goede palliatieve resultaten
laten zien, ondervinden deze patiënten een aantal bijwerkingen zoals misselijkheid,
overgeven en diarree. Vaak wordt daarbij ook leverbeschadiging waargenomen.
Chirurgie biedt de enige mogelijkheid tot curatief behandelen, maar is slechts bij een
minderheid van de patiënten toepasbaar. Nieuwe ontwikkelingen zoals cryo- en
radiofrequentie-ablatie resulteren in een verfijning van de chirurgische technieken
waardoor meer patiënten kunnen worden behandeld. Desalniettemin zijn de huidige
chirurgische therapieën toepasbaar bij slechts 10% van de patiënten.
De toepasbaarheid van uitwendige radiotherapie wordt beperkt door de
stralingsgevoeligheid van het normale leverweefsel, dat maximaal 30 Gy kan
verdragen. Om deze reden hebben onderzoekers gezocht naar methodes om ter plekke
van de metastasen een hoge dosis radioactiviteit te introduceren via de arteriële
vascularisatie van de levermetastasen. Zo kwamen aan het eind van de jaren tachtig
radioactief yttrium (90Y) gelabelde microsferen die arterieel toegediend kunnen
worden, beschikbaar voor de behandeling van maligniteiten in de lever. Patiënten
konden met deze therapie worden behandeld met een dosis tot 150 Gy zonder dat er
radiatie hepatitis ontstond; een veiligheidslimiet van 80-100 Gy wordt meestal
gehanteerd. In een studie met 90Y microsferen bij 17 patiënten met uitzaaiingen van
darmkanker in de lever werd een gemiddelde overlevingsduur van 14 maanden
gevonden met daarbij 3 personen die zelfs langer dan 4 jaar overleefden. Naast
verlenging van de levensduur geldt de geringe morbiditeit die bij deze therapie wordt
gezien als een belangrijk voordeel. Ondanks veelbelovende resultaten met de 90Y
gelabelde microsferen van glas of kunsthars, worden hun hoge dichtheid (3,3 g/ml
voor glas en 1,6 g/ml voor kunsthars), niet-degradeerbaarheid en het ontbreken van
gammastraling van 90Y (Emax=2,28 MeV, halfwaardetijd =64,1h), ten behoeve van
beeldvorming, als nadelen gezien.
Daarom heeft Mumper polymelkzuur (PLLA) microsferen beladen met radioactief
holmium (166Ho) onderzocht als alternatief voor de glas- en kunsthars-systemen. Deze
microsferen bezitten een relatieve lage dichtheid (1,4 g/ml) en zijn bovendien
biologische afbreekbaar. Een belangrijk extra voordeel is dat 166Ho wel gammastraling
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(81 keV; 6,2%) uitzendt, die gebruikt kan worden voor beeldvorming. Mumper is er
echter niet in geslaagd een therapeutische dosis te produceren met voldoende
specifieke activiteit. Dit kan waarschijnlijk worden toegeschreven aan de lage
holmiumbelading (10% (w/w)) van de microsferen. In Hoofdstuk 2 van dit
proefschrift wordt beschreven dat een aanpassing van de bestralingsparameters, die
Mumper gebruikte, niet zondermeer leidt tot een toepasbaar systeem met genoeg
activiteit. Optimalisatie van de productie-parameters leidde tot PLLA microsferen met
een hogere holmiumbelading (16-17% (w/w)). Daarnaast werden de
bestralingsparameters bestudeerd en geoptimaliseerd, hetgeen resulteerde in een
hogere activiteit met een acceptabele stralingsschade aan de microsferen. In dit
proefschrift wordt beschreven hoe PLLA microsferen, beladen met therapeutische
hoeveelheden radioactief holmium, geproduceerd kunnen worden en tevens weinig
lekkage van het holmium vertonen. Het proefschrift eindigt met twee dierstudies
waarin de succesvolle “targeting” van de holmium beladen microsferen naar
levertumoren in ratten (Hoofdstuk 6), en de haalbaarheid en effectiviteit van deze
systemen voor de behandeling van tumoren in de lever van konijnen worden
beschreven (Hoofdstuk 7).
Hoofdstuk 1 geeft een overzicht van de huidige literatuur op het gebied van
radioactieve microsferen voor de behandeling van levermetastasen. De eerste klinisch
bruikbare microsferen waren 90Y-glas microsferen. Kunsthars (acrylaat co-polymeren)
microsferen met aan de carboxylaat anionen het 90Y-ion gebonden, worden eveneeens
klinisch toegepast met vergelijkbare resultaten. Polymelkzuur microsferen beladen
165Ho-acetylacetonaat (HoAcAc), kunnen worden geactiveerd d.m.v. neutronen
bestraling (waarbij 165Ho wordt omgezet in het radioactieve 166Ho). Deze microsferen
worden beschreven als een nieuwe generatie systemen met superieure eigenschappen
ten opzichte van de bekende op glas en kunsthars gebaseerde systemen. De grootte,
stabiliteit, toxiciteit, dichtheid, keuze van het gebruikte radio-isotoop en andere
vereisten waaraan een optimaal deeltje moet voldoen om bruikbaar te zijn voor radio-
embolisatie van levermetastasen worden bediscussieerd.
In Hoofdstuk 2 wordt de bereiding, via de “solvent evaporation” techniek, van 165Ho
beladen PLLA microsferen beschreven. De optimalisatie van de productieparameters
resulteerde in een standaardmethode, waarbij vanuit 10 gram HoAcAc en 6 gram
PLLA een opbrengst werd verkregen van ongeveer 4 gram microsferen met een
gewenste diameter van 20-50 µm en een holmiumgehalte van 17%. Tevens is de
invloed van de bestralingscondities op de integriteit van de microsferen en de
holmiumafgifte bestudeerd. Om microsferen te produceren met een therapeutische
dosis (ongeveer 20 GBq per 400 mg microsferen) moeten ze watervrij zijn en
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gedurende maximaal 1 uur met een relatief lage neutronen flux (5x1013 cm-2.s-1)
worden bestraald. Bij voorkeur kan de bestraling worden uitgevoerd in een
bestralingsvat (bijvoorbeeld gemaakt van polyethyleen) dat zelf niet radioactief wordt
tijdens de bestraling. Onder deze omstandigheden bleef de integriteit van de
microsferen wat betreft de vorm en grootte gewaarborgd. Afgifte-experimenten,
waarbij de 166Ho afgifte werd gemeten tijdens 192 uur incubatie in PBS, plasma,
leucocyten suspensie en lever-homogenaat toonden aan dat minder dan 2% holmium
uit de microsferen weglekte.
In Hoofdstuk 3 wordt de kristalstructuur van twee holmium-acetylacetonaat
(HoAcAc) complexen geïdentificeerd met behulp van röntgendiffractie. De twee
structuren, [Ho(C5H7O2)3(H2O)2]·H2O (complex I; bereid bij een pH van 8,5) en
[Ho(C5H7O2)3(H2O)2]·C5H8O2·2H2O (complex II; bereid bij een pH van 9,0), laten
beiden een achtvoudig gecoördineerd holmium(III) ion zien. In beide structuren (I en
II) verbinden waterstofbruggen de complexen tot een keten in de [010] richting. In
complex I worden deze ketens door de niet-gecoördineerde watermoleculen
verbonden tot een twee dimensionaal netwerk. In complex II wordt het netwerk
gevormd door twee niet-gecoördineerde watermoleculen tezamen met een vrij 4-
hydroxypentaan-2-on molecuul. Het diaquatris(pentaan-2,4-dionato-O,O’)-
holmium(III) monohydraat (complex I) is het complex dat in dit proefschrift wordt
gebruikt voor de bereiding van holmium beladen microsferen.
In Hoofdstuk 4 wordt de karakterisering van polymelkzuur microsferen en films
beladen met holmium-acetylacetonaat (HoAcAc) beschreven. De factoren die
verantwoordelijk zijn voor de lage holmiumafgifte, zoals aangetoond in hoofdstuk 2 is
beschreven, worden met behulp van gemoduleerde “differential scanning calorimetry”
(MDSC), scanning elektronen microscopie (SEM), infrarood spectroscopie (IR) en
röntgendiffractie bestudeerd. MDSC analyse van HoAcAc kristallen liet twee
endothermen zien, die kunnen worden toegeschreven aan de verdamping van het niet-
gecoördineerd watermolecuul (eerste endotherm) en de twee gecoördineerde
watermoleculen (tweede endotherm). Zowel MDSC als röntgendiffractie toonden aan
dat HoAcAc moleculair gedispergeerd was in de PLLA matrix bij holmiumbeladingen
tot 8% in films en 17% in microsferen. Kristallijn HoAcAc werd aangetroffen in films
met beladingen van 12% Ho (w/w) of hoger. Door middel van IR metingen werden
aanwijzingen gevonden voor interacties tussen de carbonyl groepen van PLLA en het
Ho-ion in HoAcAc. Deze interacties zijn een mogelijke verklaring voor de geringe
afgifte van het holmium uit de microsferen.
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Hoofdstuk 5 beschrijft de invloed van neutronenbestralingen op holmium-
acetylacetonaat beladen polymelkzuur microsferen. De PLLA matrices met en zonder
HoAcAc werden voor en na bestralen geanalyseerd met behulp van MDSC, SEM, gel
permeatie chromatografie (GPC), IR-spectroscopie en röntgendiffractie. GPC en
MDSC metingen lieten een afname in molecuulgewicht en kristalliniteit zien, welke is
toe te schrijven aan ketenbreuk (chain-scission) door bestraling. Bestraling van
HoAcAc beladen PLLA matrices resulteerde in verdamping van het niet-
gecoördineerde watermolecuul van het HoAcAc complex en werd aangetoond met
MDSC en röntgendiffractie. IR spectroscopie gaf aan dat bestraling degradatie van het
HoAcAc ion induceerde. Dit hoofdstuk laat zien dat de microsferen hun gunstige
eigenschappen (grootte en geringe holmiumafgifte) behouden ondanks de gevonden
stralingsschade aan zowel de PLLA matrix als het HoAcAc complex. Dit maakt deze
systemen geschikt voor de behandeling van tumoren door middel van radio-
embolisatie.
In Hoofdstuk 6 wordt de biodistributie van de microsferen (20-50 µm; 17% Ho
(w/w), activiteit van 15-20 MBq voor beeldverwerking) onderzocht ná intra-arteriële
toediening in de leverarterie van WAG/Rij ratten met geïmplanteerde tumoren. Meer
dan 95% van de totale toegediende activiteit werd in de lever met zijn tumor
teruggevonden. In de nieren werd slechts een marginale hoeveelheid radioactiviteit
teruggevonden, hetgeen duidt op geringe afgifte van 166Ho uit de microsferen.
Histologisch onderzoek gaf aan dat clusters met meer dan 10 microsferen en clusters
van gemiddelde grootte (4 tot 9 microsferen) met name werden gevonden in de tumor
en zijn directe omgeving. Echter, individuele microsferen waren nagenoeg homogeen
verspreid over zowel lever- als tumorweefsel. De gemiddelde tumor-tot-lever ratio op
basis van activiteitsmetingen was 6 (bij controle ratten 0,7). Hiermee is aangetoond
dat “targeting” naar de tumor met deze microsferen succesvol is.
Hoofdstuk 7 laat het therapeutisch effect van de 166Ho beladen PLLA microsferen op
levertumoren in het konijn zien. Konijnen (New Zealand White) met geïmplanteerde
VX2 (virus geïnduceerd papilloma konijnen carcinoom) tumoren werden behandeld
met microsferen met een diagnostische dan wel een therapeutische hoeveelheid
activiteit. De referentiegroep bestond uit een groep “sham”-behandelde dieren.
Histologie en opnamen met een gammacamera toonden een heterogene
activiteitsverdeling en daarmee ook een heterogene verdeling van de microsferen aan.
Een “hot spot” was zichtbaar die correspondeerde met de locatie van de
geïmplanteerde tumor, waarmee de succesvolle “targeting” naar de tumor werd
bewezen. Histologie liet eveneens een ophoping van microsferen zien in en om de
tumor. Er werd een tijdelijke stijging van de leverenzymen gemeten ná toediening van
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de microsferen, wat wijst op enige levertoxiciteit. In beide controle groepen (“sham”-
behandelde en konijnen die diagnostische microsferen kregen ingespoten) werd een
normale exponentiële groei van de tumoren gezien. Bij dieren die een therapeutische
dosis microsferen kregen toegediend, stopte de tumorgroei en leidde zelfs tot necrose
van het tumorweefsel terwijl het gezonde leverweefsel gespaard bleef. Dit is een
veelbelovend resultaat voor de verdere ontwikkeling en toepassing van de gebruikte
holmium-166 beladen polymelkzuur systemen.
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Dit veelomvattende proefschrift was niet tot stand gekomen zonder de hulp en expertise van
anderen. Het leek er op dat alle β-disciplines van de Universiteit van Utrecht met dit
onderzoek te maken kregen. Iedereen die mij heeft geholpen wil ik bedanken voor hun
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speciaal betrokken waren bij het holmiumonderzoek.
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the point. Je inspirerende aanpak heeft erin geresulteerd dat ik het schrijven van artikelen
werkelijk leuk ben gaan vinden. Enorm bedankt voor je enthousiasme.
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- Dr. van het Schip, beste Fred, onze samenwerking werd getekend door Mac en Windows.
Mijn drafts van artikelen werden zelden “geslikt” door jouw Mac. Na een hoop
zweetdruppels maakte jij er telkens weer een stuk ware proza van. Je hebt je altijd hard
gemaakt om anderen ervan te overtuigen dat het holmiumonderzoek iets anders was dan het
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- Dr. van Rijk, beste Peter, bedankt voor de mogelijkheid om dit onderzoek te mogen doen.
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en ideeën. Het is goed te weten dat ik als postdoc de ingezette weg mag voortzetten.
- Don Rook, de laatste jaren raakte je als researchanalist steeds meer betrokken bij het
holmiumproject. Jij hebt met name veel geholpen bij de echt biologische kant van dit
onderzoek. Turen door de microscoop en tot laat in de avond dierexperimenten verrichten
(Zie je hoe leuk biologie is?!). Veel van je werk is terug te vinden in verscheidende
gepubliceerde artikelen en abstracts. Hartelijk dank voor al je inspanning en werk.
- Mies van Steenbergen, zoals vaker door anderen geschreven, je bent de smeerolie in die
goed lopende machine “Biofarmacie”. Je hebt mij kennis laten maken met een groot aantal
technieken en sprong bij wanneer ik in de stress dreigde te raken. Mies, je rol als paranimf
zat in ons “pact” wanneer ik Wim zou strikken als promotor. Ik ben blij dat dit gelukt is
(p.s. De groeten aan je kids!).
- Dr. Zonnenberg, beste Bernard, het was een groot genoegen om met jou samen te werken.
Je hebt de kennis en het charisma van een prof. Je weet de promovendus te motiveren en te
belagen met tal van nieuwe ideeën, maar ik had slechts vijf jaar!
- Dr. de Klerk, beste John, het begon allemaal met Jan Puijk en de Boegem®-zalf. Het was
plezierig om met je samen te werken en mee te rijden op de fiets, maar vooral in de auto.
Het eindigt ermee dat jij nu veel meer huisdieren hebt dan ik.
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- Studenten zaten niet echt te springen om een stageplek in Nederland aangezien het
buitenland immers spannender is. Toch trok het holmiumproject veel goede stagiaires aan.
Ir. Patrick van Veenendaal, je was hier op geheel vrijwillige basis, geen studiepunten, geen
salaris (hoe herkenbaar). Ook na je vertrek bleef je een vraagbaak. Rogier Lange (10 voor
stralingshygiëne, maar minder opruimend op het lab) en Sander Zielhuis (holmiumbepaling
op de labtafel, maar de scriptie kwam iets later), jullie waren een team apart en onmisbaar
voor de farmaceutische aspecten van het onderzoek. Adrien de Witte, (DSC-films en
microspheres) je werk staat in hoofdstuk 4. Was ik echt zo streng? Jan Peter Hoven (bollen
tellen), tja dat verslag… Bart Westendorp (nog meer bollen tellen), laat maar gaan dat gaat
meestal wel goed (hoe zat het ook alweer; is 60 mg nu 0,006 of 0,06 gram?).
- Dr. Marco van de(r) Weert, bedankt voor alle deskundige hulp en uitleg bij IR.
- Overige collega’s Biofarmacie bedankt voor jullie gastvrijheid en gezelligheid (wanneer is
er weer taart?). Jullie zijn het bewijs dat hard werken samen kan gaan met een hoop lol.
Speciaal dank ik Herre Talsma, Sylvia de Jong, Okke Franssen en Jenny Cadee.
- Overige collega’s Nucleaire Geneeskunde. Voor sommigen was ik vreemde eend in de bijt,
maar ik werd als bioloog, “bollenman”, “konijnenboer” en wetenschapper toch
geaccepteerd. Het was leuk veel technieken van de afdeling te kunnen gebruiken. Dank voor
alle uitleg en hulp bij mijn onderzoek. Een aantal mensen wil ik in het bijzonder danken:
alle analisten waren gezien hun geografische ligging achter de “rode deur” nauw betrokken
bij het holmiumproject. Bert & Stephan, bedankt voor jullie technische uitleg en
gezelligheid, tweemaal een trap tegen de printplaat en hij doet het weer! Wim, jouw steun
aan dit project was voor mij van onschatbare waarde. Maarten Gerrits, bedankt voor al je
hulp en steun. John Buijs, die fles wijn staat nog steeds te wachten! Leo, ik ga echt mijn
kamer opruimen .
- Beste Huub Kooijman en Loes Kroon-Batenburg jullie röntgendiffractie-metingen in de
hoofdstukken 2 t/m 5 waren zeer belangrijk voor de karakterisering van de holmium-
microsferen. Loes je had gelijk het was kristallijn!
- Kenmerkend voor dit proefschrift zijn de vele SEM-opnamen. Pim van Maurik hartelijk
dank dat je mij deze techniek leerde. In de toekomst zul je me zeker weer tegenkomen.
- Het dierexperimenteel onderzoek werd verricht in het Gemeenschappelijke Dieren
Laboratorium te Utrecht. Mijn dank gaat uit naar Kees Brandt, Hans Vosmeer, Nico van
Attevelt, Jannico den Breejen, Ate van den Molen, Adrie Versluis en Jeroen van Ark.
- NRG te Petten; Dr. Woittiez, beste Joost, via jou wil ik het NRG hartelijk danken voor alles
wat mogelijk was en is. Zonder jouw expertise en inzet was het niet denkbaar om deze
therapie zo ver te ontwikkelen. Daarnaast wil ik Piet Snip en alle medewerkers, die
geholpen hebben om de bestralingen op tijd en vlekkeloos uit te voeren hartelijk danken.
- Hub Dullens, dank voor het samen uitsnijden van stukjes lever en tumor.
- David Grove jij hebt geholpen met de eerste karakterisering van het holmiumcomplex.
(onder TL roze en bij daglicht geel; it’s amazing!).
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- Rob van der Camp: de “Holmium-man” heeft het geklaard.
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- Zeergeleerde Robert van Es, het was erg prettig om met jou samen te werken. Graag deel ik
die bruine boterham met kaas!
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Beste Mark Konijnenberg, bedankt voor je supersnelle dosimetrie-berekeningen.
- Veel dank gaat naar de fotografie en ICT van RRN: Jan, Roy, Karin en Eugène, dank voor
alle spoed-glossy’s, -dia’s en het verder opmaken van de omslag van dit proefschrift. Sven,
Harm en Karel, bedankt voor jullie assistentie bij mijn computer-vraagstukken.
- Bart van Rijn, met veel enthousiasme heb je meegedacht aan het holmiumproject. Bedankt
voor je bemoeienis rond het octrooi en je inzet voor het toedieningsvat.
- Rudy Meijer en Mourat El Ouamari, bedankt voor jullie hulp bij echografie.
- Experimentele cardiologie: Arjan bedankt voor alle uitleg en hulp bij jullie microscoop.
- Vera Baumans, bedankt voor het meedenken bij het opzetten van de dierexperimenten.
- Lidy Weijers, bedankt voor al je hulp bij het catheteriseren.
- Fred de Coo, ik ben blij dat je mijn paranimf wil zijn. Jij maakte me wegwijs in het AZU en
gaf me goede raad (pak die telefoon en bel!, met een grap bereik je meer). Primus was de
uitvalsbasis als ik het even niet meer zag zitten, daar was een “peptalk” van jou genoeg om
weer met frisse moed verder te gaan. Het proefschrift is geschreven dus … bierûh!
- Mijn ouders, jullie hebben me de opleiding meegegeven en belangrijker het
doorzettingsvermogen. Zonder deze essentiële aspecten had ik het niet tot hier gebracht. Pa,
geen enkel ander moment was goed geweest voor jouw ongeluk. Sorry dat ik niet altijd
paraat kon staan. Mamma, jouw “klus” is waarschijnlijk zwaarder dan mijn promotie, maar
je doet het goed. Mijn broer Peter, daar waar de druk te hoog werd, sprong jij bij. Bedankt
voor al die extra uurtjes die je voor mij “thuis” en in ons winkeltje hebt opgevangen, terwijl
ik werkte aan dit proefschrift.
- Lieve Gabriëlle, zoals je al schreef, zouden de rollen omgekeerd zijn: nu bedank ik jou voor
al je hulp en geduld gedurende de afronding van dit proefschrift. Het is goed dat jij het
allemaal al eens hebt beleefd. Jij hebt gezorgd dat ik volhield en prioriteiten stelde. Onze
samenwerking is bruisend en motiverend. Het is geweldig te weten, dat we blijven
“samenwerken”. Straks zijn er weer twee Dr(’)s in ons huisje, zo zijn we ook begonnen!
145 
Curriculum vitae 
 
De schrijver van dit proefschrift is geboren op 22 november 1970 te Hilversum. Na in 
1990 het diploma VWO te hebben behaald aan de scholengemeenschap Laar & Berg 
te Laren, startte hij met de studie Biologie aan de Universiteit van Amsterdam. In 
1991 startte hij daarnaast de studie Medische Biologie aan dezelfde universiteit. In 
1994 werd in het kader van een wetenschappelijke stage bij de afdeling Nucleaire 
Geneeskunde van het Academisch Ziekenhuis Utrecht, gedurende een jaar, onderzoek 
verricht aan het bereiden van holmiumacetylacetonaat en polymelkzuur microsferen 
die in combinatie gebruikt zouden worden als een mogelijke therapie voor de 
behandeling van levermetastasen. Hij haalde de doctoralen Biologie en Medische 
Biologie in 1995. Na zijn afstuderen werd hij gevraagd om het eerdere 
wetenschappelijke werk voort te zetten in de vorm van een promotieonderzoek, op 
dezelfde afdeling Nucleaire Geneeskunde. Het resultaat van dit onderzoek heeft tot dit 
proefschrift geleid. Na zijn promotie zal hij zijn werk aan het holmiumproject 
voortzetten in een postdoc aanstelling bij Nucleaire Geneeskunde. 
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Lou Reed,  
Magic and Loss 
